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ABTSTRACT
Objective: Colorectal cancer survival varies at individual level and also geographically. 
This study used secondary data to investigate whether hospital organisational factors may 
explain colorectal cancer survival.
Methods: For 28 acute hospitals treating colorectal cancer in London, data on 15 468 
patients first treated between 1996 and 2001 were drawn from the Thames Cancer Registry 
and their 5-year relative survival was calculated, with standard errors adjusted for 
clustering. The literature was examined to identify potential hospital organisational 
predictors of survival. Four English national data sets including measures of hospital 
organisation were identified and assessed for quality using a standardised method 
(Directory of Clinical Databases, DoCDat). Variables were assembled relating to the years 
2000-2001. A multivariate relative survival model was used to investigate cross-sectional 
associations between the organisational measures and survival. Effects of missing data were 
also examined statistically.
Results: The data sets were assessed as of sufficient quality for the study. Most data by 
hospital were over 80% complete. Missing values for tumour stage and lack of detailed 
treatment information were the main limitations of the cancer registry data. Hospital 
organisational variables examined included hospital volume, staffing, waiting times, cancer 
services standards, and type (teaching/non-teaching). Individual factors in the model 
included age, sex, deprivation index and stage, but comorbidity could not be tested. There 
was a significant survival gradient across the hospitals, both before and after adjustment for 
individual factors. No relationship was found between survival and hospital volume, 
medical or nurse staffing, or waiting times for referral assessment. However, significant 
associations were found for teaching status, and for four of the cancer standards.
Discussion: Interpretation is limited by the cross-sectional design, temporal relationships, 
missing data and the limited number of hospitals. However, the study shows the potential 
of using hospital datasets to investigate organisational factors in cancer survival, and 
indicates the possible impact of teaching hospital status and some measures of cancer 
standards on survival. Further research is indicated to confirm these associations and 
investigate pathways for the effects.
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CHAPTER 1
INTRODUCTION
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1 INTRODUCTION
Cancer is a major cause of death and disability in England, and improvement of 
cancer services has been identified as a high priority for the National Health Service 
(NHS). Survival for many cancers is considered to be lower in the UK than comparable 
European countries % and there are also differences between NHS regions and local areas^ ’^ .
Individual factors, both socio-demographic (age, ethnicity and socio-economic 
status) and clinical (tumour stage, co-morbidity), have an impact on survival at population 
level, as well as treatment through surgery, drugs and radiotherapy. But patient outcomes 
have also been shown to vary through organisational factors including access, staffing, 
hospital size and clinical specialisation. The present study investigates the use of existing 
datasets to assess organisational determinants of population survival for colorectal cancer in 
London. Particularly, the feasibility of getting and analysing the data from routine national 
sources, and feasibility in terms of limitations of inferences for these purposes were 
assessed.
1.1 Cancer policy in England
To reduce regional variations in treatment and outcome for cancer patients and to 
achieve more coordinated care, the chief medical officers Dr. Caiman and Dr. Hine in the 
Departments of Health for England and Wales undertook a review of the current state of the 
field and in 1995 they published report which proposed new policy framework designed to 
reorganise cancer services'^. The main recommendations from the Calman-Hine report came 
from the assumption that improved outcomes are associated with specialised care.
The new Labour government responded with the cancer summit in 1999^, appointed 
a Director of Cancer Services (cancer ‘tsar’) as both the Government’s senior civil servant 
for cancer policy and also to head a Cancer Action Team responsible for NHS 
implementation, and published a national Cancer Plan^.
The Cancer Plan for England (2000) set out the government's programme for reform 
of cancer services, to reduce death rates and improve survival and quality of life. Among 
organisational objectives, the Plan sought to develop a service with active patient
16
involvement, multidisciplinary teams and across service collaborations in managing cancer 
patients. Its main commitment was to improve waiting times for diagnosis, referral and 
treatment.
The Cancer Plan developed the earlier designation by Caiman and Hine of cancer 
centres and units, creating 34 defined cancer networks across England. These roughly 
corresponded with NHS decentralised boundaries at the time (regions and special health 
authorities), and reflect patient referral patterns for specialist facilities, and transportation 
links. The cancer networks were required to have a Board representing the collaborating 
hospitals, but were each established by local arrangements without central direction on their 
structures. Likewise, there were developments of cancer specific multidisciplinary teams 
(MDTs) at each acute hospital trust. The MDTs have been created so that each cancer 
patient will be reviewed and managed by the multidisciplinary team of specialists, 
including surgeons, oncologists, radiotherapists, pathologists and specialist nurses.
To set up and develop good local practice, the Cancer Services Collaborative was 
launched by government in England in 1999^’^ . These were a series of projects at local 
level, intended to improve patients’ experience of care by reducing delays and creating a 
more patient-centred approach.
The ‘Improving Outcomes Guidance’ has been developed by the Department of 
Health, and subsequently the National Institute for Health and Clinical Excellence (NICE), 
for a range of tumours -  colorectal (1997; update 2004), breast (1996; update 2002), 
urological (2002) and other tumour types^'^^. These systematic reviews mainly focus on the 
effectiveness of specific diagnostic and treatment procedures, and acknowledge that 
organisational and service level determinants of outcomes are not sufficiently scrutinised in 
the literature. However, they served as a source material for the development of the Manual 
of Cancer Services Standards (2000; update 2004)
The Manual of Cancer Services Standards, published by the Department o f Health 
in December 2000, set out how the MDTs for particular cancers should be organised''^. In 
2001, cancer units and centres were assessed against these standards by peer-review teams 
of health care professionals and managers to identify whether standards were or were not 
being met'^.
The review was undertaken by the Commission for Healthcare Improvement and 
the Audit Commission to assess the progress in implementation of the Calman-Hine 
report'^. They showed marked variation in agreed treatment policies between hospital trusts
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and by tumour type. However, they visited only limited number of hospitals and did not 
specifically assess the impact of reforms on the outcomes of care. The focus of this review 
was the range of services received by cancer patients from their initial point of contact with 
the NHS. Recent assessments by Department of Health and the National Audit Office of the 
progress in the implementation of the Cancer Plan indicated that although substantial 
progress has been achieved in reorganisation of cancer services and improvements in 
outcomes, progress varied by cancer and locality'
National Audit Office identified the following national and local stakeholders 
involved in cancer services in England (see Table 1.1).
Table 1.1 Key stakeholders involved in cancer services*
Stakeholder Role
N ational
D epartm ent o f  H ealth Setting overall policy d irection , securing  resources and setting 
national standards.
N ational C ancer D irector Takes the lead in developing and im plem enting the 
D epartm ent's strategy for cancer. He is supported  by the C ancer  
Action Team , the D epartm ent's cancer policy  team  and  the 
C ancer Services C ollaborative Im provem ent Partnership .
NH S C ancer Screening Program m e O versees the delivery o f  screening  program m es for breast (in 
over 90 units) and cervical cancer, and the developm ent o f  
screening program m es for o ther cancers.
C are G roup W orkforce Team : 
Cancer
D raw s up national w orkforce strategies for cancer. It is 
supported by the lead W orkforce D evelopm ent 
C onfederation .
N H S Inform ation  A uthority D evelops inform ation services to support the  key  c linical 
priorities o f  the D epartm ent o f  H ealth, including  developm ent 
o f  the national cancer dataset to provide data on the w hole 
cancer care pathw ay, w aiting tim es and support for the  N ational 
C linical A udit Support Program m e.
M odernisation A gency Supporting the N H S and its partner o rganisations in im proving  
cancer services. It aim s to ach ieve this th rough the individual 
projects w ithin the C ancer Services C ollaborative  
Im provem ent Partnership.
C ancer registries 9 regional cancer registries collect and collate data from  their 
area and report the results to the O ffice for N ational Statistics.
O ffice for  N ational S tatistics The N ational C ancer Intelligence C entre at the  O N S collates 
national caneer data and carries out a range o f  research . It 
publishes definitive data on cancer outcom es in England.
Com m ission for H ealthcare  
A udit and Inspection
Succeeded the Com m ission for H ealth Im provem ent from  1 
A pril 2004. Independently  inspecting serv ice  standards for 
cancer patients, am ong others, and com m issions national 
clinical audits o f  cancer-rela ted  subjects.
National Institute for  
C linical E xcellence
Providing patients, health  professionals and the public w ith 
authoritative, robust and reliable guidance on curren t "best 
practice". It is responsible for producing  cancer Im proving 
O utcom es G uidance and assessing  the c lin ical- and  cost- 
effectiveness o f  new  treatm ents and prom oting  the ir adoption by 
the NH S.
L oca l
C ancer N etw orks The organisational m odel to deliver the C ancer Plan at a local 
level. There are 34, bringing together com m issioners and 
providers o f  cancer services from  the N H S, local au thorities and 
the voluntary  sector.
Strategic H ealth A uthority 28 SHAs m anage the  perform ance o f  N H S serv ices locally  and 
develop local plans to m eet national priorities.
Prim ary C are T rusts C om m issioning the m ajority  o f  N H S serv ices and m anag ing  the 
provision o f  com m unity services.
C ancer units** N orm ally  a d istrict hospital, o ffering  a range o f  d iagnostic  and 
treatm ent services and care for patients w ith the  com m oner 
cancers. C ancer units are  not separated from  other hospital 
services but are an integrated part o f  the hospital.
Cancer centres** N orm ally part o f  a large general hospital, p rov id ing  serv ices for 
patients w ith com m oner cancers, as well as an additional range 
o f  specialised services w hich it w ill norm ally  p rov ide in support 
o f  cancer units.
Service users Service users (patients and carers) are increasingly  seen as 
stakeholders in cancer services w ho can contribute  to the 
planning, developm ent and  im plem entation o f  cancer services.
*Source: National Audit Office. Tackling Cancer in England: Saving more lives. 2004 
**Reference: Caiman K., Hine D. A Policy Framework fo r  Commissioning Cancer Services: A Report by the Expert A d v iso ij Group on 
Cancer to the C hief M edical Officers o f  England and Wales. 1995
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Fuller information on time-line of key policy developments in England are specified in 
Table 1.2,
Table 1.2 Time-line of the main developments in cancer policy/services in England
Key events Year (one-off or first start)
Calman-Hine report 1995
Organisational changes in local cancer services - 
multidisciplinary teams; cancer centres and units
1996
Cancer Networks 1996
Improving Outcome Guidance for various tumour types Breast cancer (1996; update 2002); 
colorectal cancer (1997; update 
2004); lung cancer (1998); 
gynaecological cancers (1999); 
upper gastrointestinal cancer 
(2001); urological cancers (2002); 
other tumour types (2003-ongoing)
The New NHS white paper (waiting times policy) 1997
Dedicated funding (£10m per annum) for selected cancer 
types
breast cancer (1997); colorectal 
cancer (1998); lung cancer (1999)
Downing Street summit on cancer 1999
Appointed Director o f Cancer Services (cancer ‘tsar’) 1999
Cancer Action Team 1999
Cancer Services Collaborative 1999
NHS Cancer Plan 2000
Cancer Information Strategy 2000
The National Cancer Research Institute 2001
Monitoring Cancer Waiting Times 2001/2002
Manual o f  Cancer Services Standards 2000 (update 2004)
Cancer Services Peer Review using published standards 2001 (2"*^  round 2005-in process)
National Cancer Patient Survey 2000/2001
Key follow-up/progress reports
Commission for Health Improvement/Audit Commission: 
NHS Cancer Care in England and Wales
2001
Department o f  Health:
NHS Cancer Plan. Three-year Progress Report: 
Maintaining the Momentum
2003
National Audit Office reports:
Tackling Cancer in England: Saving more lives 
Tackling Cancer: Improving the patient journey 
The NHS Cancer Plan: A progress report
2004
2005 
2005
1.2 The use of routinely collected data to assess organisational predictors of cancer 
survival
A growing body of evidence suggests that hospital characteristics can influence the 
outcome of care*^’^ .^ Organisational level indicators, including hospital staffing levels and 
volume of activities, are predictors of hospital mortality in cardiology and other
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specialties^ However, this association has been less explored in relation to cancer care.
Studies on cancer outcomes have mainly used in-hospital or 30-day mortality, but 
not long-term survival. This may be because most of the studies have been in the USA, 
where cancer registration is not routine and has developed only recently. In comparison, 
the UK has a long history of national cancer registration, and the capability of measuring 
survival through linkage to death certification. The National Health Service also has 
systematic data sets for management use and performance assessment.
It is difficult, however, to compare outcomes across hospitals when assessing 
provider performance, because different hospitals treat different types of patients. Hospitals 
with sicker patients may have higher rates of complications and death than other 
hospitals^^. Therefore, crude hospital statistics can be misleading and need adjustment for 
case-mix to make meaningful comparisons of performance between hospitals.
In the past, an important limitation was the feasibility of voluntary, standardised 
data collection by health care institutions and agencies^^. Now many of them have begun to 
report standardised quality data routinely, either voluntarily or in response to requirements 
from state, governmental bodies or accreditation agencies. Moreover, there is also a trend to 
report outcome data both on organizational (hospital) and individual (doctor) levels.
However, the quality of administrative databases remains a problem. The literature 
particularly points out variations in coding accuracy, and the lack of comprehensive clinical 
data on disease severity^^’^ .^ In addition, the accuracy of cancer statistics depends on 
completeness and retrieval of case notes, as well as completeness of case ascertainment by 
cancer registries and accuracy of primary data sources from which registrations are 
made^*’^ .^
The literature on cancer outcomes has primarily focused on the role of patient risk 
factors^^, including age, stage of disease and social deprivation, influencing the outcome of 
cancer care^ '^^ .^ However, hospital activities are complex and their outcomes are also 
substantially affected by non-medical factors related to the structure and process of 
care^ '^^ .^ The ‘Improving Outcome’ reviews accompanying the Cancer Plan for England 
indicated that this field was under-researched and suggest areas for further 
investigation^^^^. There is general consensus that the use of clinical guidelines or 
compliance with standards of patients’ management can improve the process and outcome 
of care^^"^ .^ However, there is inconsistent or lack of evidence in the literature that meeting 
proposed treatment or service targets is associated with better survival from cancer"^ "^ . And
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data are especially sparse for specific cancer sites, including colorectal.
Two studies were of particular relevance in the development and conceptualisation of this 
study.
In a national study of England, Jarman et al linked different sources of routinely 
collected data (HES; census; patient surveys; other data on hospital characteristics such as 
staffing levels and GP distribution) to investigate variations in in-hospital mortality over a 
four year period (1991/1992 -  1994/1995 financial years)^^. They made a regression 
analysis, with hospital standardised mortality ratios as the dependent variable. In the study, 
the four year crude death rates varied across 183 acute hospital trusts from 3.4% to 13.6%, 
and the standardised hospital mortality ratios ranged from 53 to 137. Adjustment for age, 
sex, and selected indicators of comorbidity left a large amount of unexplained variation.
The percentage of emergency admissions and the ratios of doctors to head of population 
served, both in hospitals and in general practices, were found to be significant determinants 
of variation in mortality. The numbers of hospital doctors of different grades were also 
considered as explanatory variables, but total number of doctors per bed was found to be 
the best predictor. However, along with the presence of co-existing diseases (comorbidity), 
other important indicators of patient case-mix, like stage or social status, and the severity of 
illness, were not assessed or taken into account in this study. Besides, the validity of the 
indicators of co-morbidity employed remained unclear"^ .^
In a study specific to cancer services, Morris studied adherence to cancer standards 
for colorectal cancer patients in 14 hospital teams in Yorkshire (UK) She concluded that 
a 25% increase in adherence was related to around 8% reduction in the risk of death after 
one and two-year follow-up^^. The effect remained after adjustment for age, stage, socio­
economic status and year of diagnosis. However, this association was not sustained in 
relation to breast and lung cancers. Adherence to the standards was assessed by 
questionnaire and based on score determined by the number (and then percentage) of 
standards that had been met. Each standard was given an equal weight. However, individual 
standards differ in their clinical significance, and it is difficult to interpret the meaning of 
the composite team score. Also, no evidence was required by the questionnaire to prove the 
actual compliance with the standard, as it was done in a national peer review process.
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However, no other study on the relationship between compliance with published Manual of 
Cancer Services Standards as assessed by national peer-review in England, and 
outcomes, was identified.
These two studies indicate the potential for using existing data sets in analyses to explain 
clinical outcomes, and the potential for assessing organisational determinants within cancer 
services. These studies, and further selected key literature, are presented in Table 2.2, 
Literature Review chapter.
1.3 Choice of tumour type for the study
Colorectal cancer is one of the four most common cancers in the UK, contributing 
significantly to cancer mortality. It is the second common cause of death from cancer for 
both men (after lung cancer) and women (after breast cancer). Five-year survival remains 
around 40-45%, and rates are below those in comparable countries elsewhere in Europe and 
in the USA . According to ‘Improving Outcomes’ guidance’ ,^ colorectal cancer accounts 
for more hospital in-patient expenditure than cancer of any other site, and for between 10% 
and 20% of palliative care provision.
Previous studies and published data have demonstrated wide variations in the 
presentation, management and survival for colon cancer between health districts, and by 
social group. Regional cancer survival statistics issued by the Office o f National Statistics 
(ONS) in England show that, for patients diagnosed in 1994-1996 and followed up to the 
end of 2001, there was more regional variation in five-year survival for colon cancer than 
for either breast or lung cancer These results are similar to those in a previous report on 
cancer survival in the health authorities of England for patients diagnosed in 1993-1995, 
and followed up to the end of 2000, which showed inter- and intra-regional variations in 
colorectal cancer survival by health authorities and regions However, the reasons of 
observed differences in survival remain unclear and insufficiently studied, and differences 
in data quality between regional registries may partly contribute to observed variations.
In summary, colorectal cancer is a common, medium-survival cancer. This 
potentially allows sufficient number of patients and ‘events’ (deaths) for survival 
estimations and statistical modelling on hospital level. Local variations on hospital level
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may be expected because of observed regional variations.
1.4 Aims and objectives of the study
The aim of this study is to investigate the association between organisational 
determinants of structure and process of care at hospital level and five-year relative 
survival, for colorectal cancer in London. It was also aimed to investigate the feasibility of 
using routine data for these purposes.
This is justified for at least four reasons: (1) the renewed interest in improving 
outcomes through organisational means, demonstrated within the Cancer Plan for England; 
(2) the evidence that organisational level indicators are associated with the outcome of 
health care for other diseases; (3) the fact that the relationship between organisational 
determinants and outcome has not been fully explored in relation to cancer care, 
particularly colorectal cancer; and (4) the existence of routinely collected data which reflect 
various aspects of cancer care.
It was hypothesised that the characteristics of structure and process of care at 
hospital trusts in London predict colorectal cancer survival, independently of known 
individual level associations. Two main study objectives were:
Obiective 1: To draw available national datasets together; review their properties, assess the 
feasibility of using the datasets in terms of coverage and accuracy, and identify hospital 
level indicators for further investigation, in relation to the evidence from the literature.
Obiective 2: To explore the relationship between hospital level indicators and five-year 
relative survival, after adjustment for patient case-mix, for colorectal cancer in London.
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1.5 An overview of the thesis
Following the Introduction, the thesis is divided into five main chapters: literature review; 
materials and methods; results; discussion; and conclusion. The literature chapter provides 
a review of the use of routine data for outcome research, their advantages and 
disadvantages, with a special consideration of cancer related data quality issues; then 
discusses patient factors that affect outcomes; clinical treatment and organisational 
determinants of cancer outcomes. The next chapter provides with a description of the 
materials and methods used in the research. An account is given of the geographical 
location of the study; study population; research design; sources of data used and data 
analysis. A detailed description of the proposed model for assessment is provided. The next 
chapter describes the main results. The results of assessments of properties of available 
datasets are presented, taking into consideration the feasibility of using the datasets for the 
purposes of the study. Descriptive analysis of the data, as well as univariate and 
multivariate associations are presented too. This follows by discussion of the findings in the 
light of present knowledge. The associations between each predictor and outcomes and the 
main strength and limitations of the study are discussed. The thesis ends with concluding 
overview and suggestions for future research.
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CHAPTER 2
LITERATURE REVIEW
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2 REVIEW OF THE LITERATURE
2.1 Review strategy and selection criteria
The literature review was aimed to describe the opportunities and limitations of 
using routine, administrative data for healthcare research, and to identify potential 
predictors of cancer outcomes, both on individual and organisational level.
The review of the literature was conducted using MEDLINE and EMBASE 
databases for articles published from 1985 onwards. Searches used combinations of key 
words and Medical Subject Headings (MeSH) to identify the majority of included studies; 
outcome, performance, evaluation, health care institution, hospital, quality, routine, data, 
database, dataset, cancer, service, healthcare, mortality, survival, risk, factor, predictor, 
colon, rectal, colorectal, NHS. The words ‘colorectal’ or ‘cancer’ were not required to be in 
the abstract or title, nor to appear in the keyword or indexed terms, because many 
publications dealt with more than one anatomic site or nosology and thus using ‘colorectal 
cancer’ more specifically would have omitted these multiple-site analyses.
As a second stage, the abstracts and titles were screened by the researcher to 
identify relevant studies for inclusion in the review and full text of those articles were 
obtained.
In addition, review of citations and expert advice was carried out to detect 
studies/publications not found in the electronic databases. ‘Grey literature’ (papers, 
documents, reports and web sites prepared by a range of governmental, public and private 
organizations) was also searched through Department of Health and key government 
agency websites, and hand searching of bibliographies in official publications (where these 
are supplied).
Improving Outcome Guidance^ '  ^was published with accompanying systematic 
reviews of the relevant literature. They covered material specific to the cancers they 
concerned, including colorectal, and main themes identified there were used for subsequent 
searches. However, while relevant, their main focus was on clinical aspects as relatively 
little direct research has been carried out on the organizational predictor of cancer
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outcomes^^.
The literature search was not restricted by nationality or language. Studies were 
included in the literature review based on their relevance to the topic under investigation, 
regardless of design employed and the type of publication. Descriptive, observational 
studies, review and discussion papers were the most commonly found and used.
Quality o f routine data
For papers on quality of routine data, the main sources for identifying the ‘concept’ 
key words were papers by lezzoni et al within the supplement to Annals of Internal 
Medicine"^^ which contains articles developed from the Regenstrief Conference entitled 
“Measuring Quality, Outcomes, and Cost of Care Using Large Databases” that was held in 
1996 in USA. Experts from relevant fields were invited to the conference, and they have 
incorporated comments from the discussions and the audience into their papers for this 
supplement. In addition, Donabedian’s key studies^^’^ ’^^ * on the topic were used. Thus, key 
issues related to the quality of routine data were identified and used to conduct subsequent 
searches of the literature.
Predictors
Using a combination of keywords ‘outcome’ + ‘healthcare’, or synonyms of these 
words, allowed distinguishing potential predictors which may affect outcomes. A 
subsequent searches of the literature on key identified predictors were conducted by 
applying a combination of key words ‘volume’ and ‘outcome’; ‘specialisation’ and 
‘outcome’; ‘guidelines’ and ‘outcome’ and so on. This review included not only predictors 
which were available for the study through consequently gained access to a number of 
national datasets, but also important factors which were not available for the study but were 
shown in the literature to have an impact on outcomes of care, for example ‘comorbidity’ 
and ‘specialist surgeon’.
Disease group
Studies which have a focus on cancer patients were the main ones included in this 
review. However, key studies examining organisational determinants in relation to other 
pathologies have also been considered, especially in case of insufficient or lack of evidence 
from cancer literature.
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An overview of the chapter
Review of the literature is presented as a synopsis of identified studies with 
comments/critique on methods and results, as appropriate. A more detailed description of 
selected key references is presented in Table 2.2.
The literature review is divided into several sections which reflect three main 
themes: datasets (sections 2.2); patient factors to affect outcomes (section 2.3); and 
organisational determinants of outcomes (section 2.4).
First theme (‘datasets’) discusses the use of routine data to assess outcomes in 
health care settings. It considers strength and weaknesses of routine observational data, 
with specific emphasis on data quality issues (2.2.1). Particularly, the issues with clinical 
content, completeness of diagnosis and procedures, coding accuracy and differences in data 
quality across hospitals have been reviewed. A special consideration of cancer related data 
quality issues have been provided: death certificate only (DCO) registrations, 
incompleteness and retrieval of case notes, and case ascertainment and registration bias. 
Then the problem of temporality while using routine data in health care research (2.2.2) and 
the use of linkage across data sets (2.2.3) to draw more complete health care experience of 
patients have been discussed. It is followed by examples of risk adjusted models (2.2.4) and 
performance management initiatives (2.2.5), and a brief summary on advantages and 
disadvantages of using secondary data (2.2.6).
Then the review shifts its focus to the individual and organisational determinants of 
outcomes in cancer care.
Firstly, it details patient factors to affect outcomes (2.3) with reviews of the main 
indicators which literature emphasised: age (2.3.1), tumour stage (2.3.2), the effect of social 
deprivation (2.3.3), the presence of comorbidity (2.3.4), and the influence of various types 
of clinical treatment (2.3.5).
Secondly, the review of organisational predictors of outcomes in cancer care has 
been presented (2.4). Particularly, the impact of staffing level (2.4.1); hospital and 
physician volume of cases or operations (2.4.2); specialist care (2.4.3), including multi­
disciplinary management of cancer patients; teaching status of hospitals (2.4.4); compliance 
with clinical guidelines and standards of care (2.4.5), and delays in referral and treatment
29
(2.4.6) have been reviewed
The literature review ends with a summary of literature findings (2.5) presented in 
above mentioned sections of the chapter, and a commentary on selected key references (see 
Table 2.2).
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2.2 Using routine data to assess outcomes
Routine observational data can be accessed as a by-product of administering health 
services, and are held in databases by governmental bodies, service providers or regulatory 
agencies^®. Routine data are attractive to researchers, healthcare professionals, managers 
and policy-makers, since the data are readily available, and include large numbers of 
patients across diverse geographical and healthcare settings^^’^ .^ Adequate data are needed 
to identify the population potentially affected by the change, define an appropriate 
comparison group(s), measure important baseline variables, and ascertain study outcomes^"^.
Routine data may be used to investigate measures of structure, process and outcome 
that form the basis of health care evaluation^^’^ ’^^ ^ Observational studies often show 
variations between geographical regions, healthcare providers and also individual 
practitioners^^. The research challenge is to determine how far these variations are real 
differences rather than artefact, and how far they reflect differences in quality. Artefactual 
issues include both the accuracy (reliability and completeness) of the data, and the temporal 
relationships connecting actions with effects, while differences in quality are related to the 
validity of the data. Researchers may also link data sets to achieve greater depth of analysis: 
but the data sets were usually not originally prepared for this purpose.
Observational studies are not as strong in scientific terms as randomised 
intervention studies, because interpreting results must recognise the possibility of unknown 
confounders. However, by no means all clinical policies are based on randomised 
studies^^’^ ,^ and in many fields randomisation “may prove unnecessary, inappropriate, 
impossible or inadequate”^^ . Statistical models can be made in observational studies to 
attempt to exclude the effects of confounders, but these presume understanding of the 
confounding variables and their accurate measurement^^, neither of which are entirely 
possible, so that at least a moderate bias will remain.
Routine data sets can be used for comparisons between services and geographical 
regions, assessing the effectiveness of health care interventions in practice, and providing 
insights into quality, performance and outcomes of health services^^.
In relation to the design of the study of this thesis, the following sections discuss 
literature relevant to these themes: quality of routine data (2.2.1); temporal relationships 
(2.2.2); data linkages (2.2.3); risk-adjusted models (2.2.4); performance management
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initiatives (2.2.5); and a summary of using secondary data for outcome research (2.2.6).
2.2.1 Data quality
The first and most obvious problem of routine, administrative data is the accuracy 
of the data themselves. According to A. Donabedian, a major aspect of validity “has to do 
with the accuracy of the data”
The accuracy of cancer statistics depends on the completeness of case ascertainment 
by the registries and on the completeness and accuracy of the data sources from which 
registrations are made ^^.The main data sources for cancer registration are hospital notes 
and data on death certificates forwarded by the Office of National Statistics (ONS) to each 
registry on every person dying for whom cancer is mentioned. Death certificates also 
enable registries to identify cases not registered in life. For instance, at Thames Cancer 
Registry (TCR), approximately 50% of the cases identified by death certificate notifications 
will already be known For the remainder, the death certificate is used to initiate a new 
registration. Those cases not traced by following up case notes at hospitals and treatment 
centres defined as death certificate only (DCO) registrations. According to a study on 
completeness of TCR data, improvements in computerised matching of records along with 
active tracing of unmatched deaths have reduced the DCO rate at TCR to 10.5% at the end 
of 1998, and TCR attains 92.1% overall completeness five years after diagnosis for all 
cancers^\
• Clinical content
Administrative databases always contain routine demographic data. Additional 
clinical information includes diagnosis codes (e.g. based on International Classification of 
Diseases (ICD), Ninth Revision, Clinical Modification [ICD-9-CM] or Tenth Revision 
[ICD-10]) and procedure codes. In the United Kingdom, diagnoses are usually reported as 
ICD codes, and surgical procedures categorised according to the classification of operative 
procedures known as OPCS-4. In the United States, discharge diagnoses are reported as 
ICD codes, procedures as Current Procedural Terminology (CPT95) codes, and drugs as the 
Food and Drug Administration’s NDC directory
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ICD codes can be used to make risk-adjustment of patients across hospitals For 
instance, patients with pneumonia can be classified as having more severe disease if the 
discharge abstract also contains codes for sepsis Some ICD codes may also be used to 
indicate technical quality of care but the specificity of the codes is uncertain
Standard code systems are less available for such clinical data as test results, clinical 
observations, units of measure, symptoms, problems, and infectious organisms^^’^ .^
In addition, many of the proposed indicators for performance evaluation/outcome 
management depend on accurate coding of secondary diagnoses, although this is known to 
vary widely The coding, recoding, and measurement of routine patient data in 
hospitals may be adequate for internal management but not for outcomes evaluation
• Completeness and accuracy
Administrative data are typically submitted in formats that limit the number of 
coding slots. In the UK, Hospital Episode Statistics (RES) data system contains up to 7-12 
diagnosis fields (one main diagnosis, one subsidiary diagnosis and six further diagnoses) 
and up to 4 operative procedures fields (one main and three secondary procedures) This 
may be sufficient for uncomplicated cases, but is often inadequate for complicated 
admissions or patients with multiple or chronic diagnoses. A study of US Medicare data 
suggested that chronic conditions were less likely to be coded when patients died because 
all the coding slots were consumed by acute diagnoses On the other hand, risk- 
adjustment for co-morbidity becomes more difficult if many accessory diagnoses are 
recorded.
Administrative databases can be more complete than clinical ones. For example, 
Barrie & Marsh, who compared the Manchester orthopaedic database with the (routine) 
Hospital Activity Analysis dataset, found that overall completeness of the data in the 
orthopaedic database was 62% and the accuracy was 96% On the other hand. Fine et al 
concluded that a specialist database of clinical outcomes after cardiac surgery in the UK 
had a mean of 25% of essential data elements missing, whereas only 1% were missing in 
the patient records
The completeness of cancer registry’s data depends on completeness of primary 
source data (case notes). To assess biases connected with using hospital case notes by 
Thames Cancer Registry (TCR) in relation to colorectal cancer, Vickers & Pollock
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conducted a retrospective case note study^^. Case note retrieval rate for all districts 
combined was 80%. Incompleteness of case notes ranged from 38% to 62% for staging, 8% 
to 40% for treatment, and 70% to 25% for diagnostic tests. Information about treatment was 
missing in 3% to 20%; survival data were omitted in less than 5%. In all districts 
completeness of case notes was inadequate and in some non-retrieval compounded the 
problem. Missing data reduce the quality of cancer registry data and potentially undermine 
interpretation of epidemiological studies and evaluation of care.
The accuracy depends on the correct abstracting of data by the registration clerk and 
coding differences between clinical and registry’s practices. Pollock & Vickers assessed the 
reliability of data collected by the TCR by comparing the registry’s data with those within 
case notes, for colorectal cancer cases diagnosed in 1983 or 1988^\ Among the 416 case 
notes retrieved, including 66 DCO registrations, full or high agreement between registry 
data and hospital notes were recorded for sex, district of residence, and dates of birth and 
death. Only 12% of cases had the same date of diagnosis. Lower agreement rates occurred 
for tumour site (87%), whether treatment occurred (84%), and treatments administered 
(80%, 1983; 72%, 1988). 20% of surgical treatments and 37% of adjuvant therapy, 
radiotherapy, and chemotherapy were not recorded by the registry. Disagreements were 
common among DCO registrations. In 36% of DCO registrations the patients survived 
more than 1 year from diagnosis which may indicate a failure of registry ability to identify 
incident cases. DCO registrations were a good proxy for under-ascertainment of incidence 
in rectal but not colon cancer, and a good proxy for under-ascertainment of treatment in 
both colon and rectal cancers
Coding error is frequently listed as a limitation of studies using hospital discharge 
summary databases. Green et al showed that substantial inter-hospital variations exists, 
particularly in the underreporting of comorbidities and distinction between urgent and 
emergent admissions^"^. They also reported a 9% error rate in the coding of the principal 
diagnosis.
A systematic review of the literature on discharge coding accuracy in the UK 
hospital statistics reported median coding accuracy rates 91% for diagnostic codes and 
69.5% for operation or procedure codes in studies in England or Wales There was a 
trend towards more accurate coding of more frequent conditions. However, reported studies 
were small, from a limited number of centres and of variable quality. Also, accuracy varied 
depending on coding system used.
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There are also fears about manipulation of data, which are supported by evidence of 
a dramatic increase over two years of almost threefold in recorded rates of COPD and over 
fourfold rises in congestive heart failure This was likely to be due to external 
incentives, including changing reimbursement rules.
• DCO registrations
A high proportion of DCOs may bias the calculation of incidence, survival and 
treatment rates through inadequate coding of tumour site or cause of death, and lack of 
information on the date of diagnosis. For the latter reason, they are excluded from the 
survival analysis.
DCO cases typically have very short, poor survival times since there would be less 
time to register them in life^^. A study of the TCR data showed that the following factors 
were associated with DCO registrations: increasing age, decreasing survival, district of 
residence and place of death Higher proportions of DCOs might be expected among 
patients diagnosed post mortem, patients dying at home, patients not receiving active 
treatment, patients with short survival and patients treated at centres which do not liaise 
with cancer registries (e.g. some private institutions).
The percentage of DCOs varies from 1% to 25% of all registrations For instance, 
DCO registrations accounted for 22% and 15% of all colon and rectal cancer cases, 
respectively
Pollock & Vickers investigated variations in five-year relative survival rates for 
colorectal cancer and DCO proportions across four districts in south-east England by 
conducting retrospective case note studies in four of districts (2 with the worst survival and 
2 with the best survival)^^. In all 4 district health authorities, five-year survival decreased 
with the inclusion of DCO registrations. The overall reduction was 8.6% (with variation 
from 4.5% to 9.1% across districts). The authors pointed out the need to assess the impact 
of DCO registrations on national survival rates for all cancers.
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2.2.2 Temporal relationships
A set of guidelines for assessing causal associations in epidemiologic studies was 
defined by Bradford Hill^ ’^’^ .^ In modem epidemiology, the notion of ‘cause’ has become 
more complex to encompass the domains of social and population-level relationships^^. It 
evolves health consequences of complex environmental, social and system interventions 
and processes.
One of the principal factors forjudging whether association is causal is 
‘temporality’: what is the evidence that the exposure precedes the outcome?
Differentiating the timing of each diagnosis is also important for risk adjustment, 
since it allows separating prior risk factors from the possible problems of contemporaneous 
medical care However, discharge diagnoses record conditions that were diagnosed or 
treated at any time during the entire admission, regardless of when they occurred.
One way to address this problem is to carry out risk-adjustment by using only codes 
for diagnoses that are unlikely to arise “de novo” during hospitalization, such as diabetes 
and chronic renal failure In addition, longitudinal data could identify conditions that
had been treated previously and would thus be considered chronic or pre-existing
Differences in time periods covered by various administrative or clinical datasets 
may complicate interpretations of observational studies which incorporate data from several 
sources^^.The situation is particularly complicated with the inclusion of cancer registry 
data, with cancer survival as the outcome measure. In its essence, survival data reflect back 
in time^ '^^^. To assess survival of recently diagnosed patients, we normally need to wait 
several years^ "^ . Thus, survival data usually preceded the organisational data in time.
Overall, with observational, cross-sectional studies there is inherent weakness to ascertain 
the temporal relationship between the exposure and outcome^^. This should be taken into 
account while interpreting the results of such studies.
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2.2.3 Using datasets together
From the perspective o f researchers studying health care services, the ability to 
track services used by patients across care settings and capture the complete health care 
experience of large, representative populations enhances the power of administrative data 
^^ ’^ ^For instance, when databases on utilization and accounting are linked, cost can be 
calculated for a unit of health care service and across categories of service at the patient, 
provider, or medical facility level Geocoding has been suggested for linking individual 
addresses to census data on racial or socioeconomic characteristics to obtain proxy 
measurements of these variables
In an Australian study, a population-linked database was used to relate the cancer 
registry, hospitalization and mortality records of all patients with a diagnosis of colorectal 
cancer to assess the trends in colorectal cancer incidence and mortality in Western Australia 
during 1982-1995 Another study assessed some differentials in survival from 12 
common cancers, including colorectal cancer, by linking the census data with the data from 
Norwegian Cancer Registry
In the UK, cancer survival statistics are routinely produced by linking data from 
cancer registries with the data of death from the National Health Service records and death 
certificates^. Adjustment using census data also allows analysis to take into account 
differential background mortality by age and social deprivation However, linking data 
sets at individual level requires comparable identifiers, and there have been fears about 
confidentiality and privacy In some cases it may be necessary to obtain consent, e.g. 
from survey respondents Nevertheless, even without these identities, records can still be 
linked with reasonable success if sufficient demographic and administrative data are 
available
2.2.4 Risk adjusted models
Pioneering work in data collection and risk analyses has been carried out by cardiac 
surgeons, and substantial information exists in this sphere^"  ^ '^'. Similar projects had been 
developed in other fields and on multinational level. The International Quality Indicator 
project was initiated by the Maryland Hospital Association (USA) in 1985 to assist
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hospitals in identifying opportunities for improvement in patient care^^’*^  ^All individual 
hospitals are anonymous and able to identify themselves only by means of a unique 
identification number that is allocated to the hospital on joining the project.
Another similar development on a national level is ICNARC -  UK Intensive Care 
National Audit & Research Centre, which was established as a result of the success of the 
ICU UK APACHE II study, a large study conducted in the late 80s/early 90s on patient 
outcomes from intensive care units (ICU)*^^.
Databases in cardiac care initially began using only volume and unadjusted 30-day 
operative mortality as outcome criteria In time, along with the progress with the 
building of risk models based on preoperative predictive variables, other outcome measures 
have been added including risk-adjusted mortality and morbidity; length of stay; quality of 
life; functional status; neuropsychological outcomes and long-term outcomes
However, differences in the definition or coding of risk factors, or lack of data on 
some risk factors, may affect the validity of comparisons. Although validated indexes of 
disease-specific severity and functional status now exit for many acute and chronic 
conditions, few of these indexes are routinely measured and incorporated into clinical 
databases^^’*®^’’^ .^ Some researchers proposed to use various factors such as the history of 
medical care encounters, hospitalisation, nursing home residence, and use of medications in 
the past year as a surrogate for case Whether these factors adequately capture
case-mix remains unclear.
2.2.5 Comparing performance
In the UK, an example of comparing performance was the ‘star’ system used by 
Department of Health to rank NHS Trusts based on monitoring specific targets, such as 
‘waiting times’'H o w e v e r ,  it was recognised that “there is a need to ensure that like is 
compared with like and over time figures will need to be ‘risk adjusted’ to standardise for 
factors such as age, severity, case-mix and concurrent illnesses”. The Royal Statistical 
Society called for revision of the system of performance indicators to take into account 
statistical standards Analysis needs to examine not just overall average values of 
performance indicators but to look at variability through the use of plausible ranges of rank 
for each institution. Adjustment for context to achieve comparability also could be 
considered
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A recent study on the association between ‘star’ rating and outcome of adult 
patients admitted to critical care units within acute NHS Trusts showed that, though crude 
mortality for critical care admissions was significantly associated with the rating, the 
association was no longer significant when case-mix differences were taken into account 
* As the authors pointed out, they did not expect to find association between the rating of 
the whole Trust and the outcomes of critical care units because hospitals are complex 
organisations containing many services: poorly rated hospital may have some excellent 
services and vice versa. Besides, ratings have been determined by a small number of 
process measures without adequate account for outcome measures. For this reason, they 
suggested wider use of data from specialised clinical databases such as those presented at 
www.docdat.org
The list entitled “America’s Best Hospitals”, published annually by US News & 
World Report since 1990, is one of the most influential ‘report cards’ on the quality of 
hospitals National data sources are used to evaluate measures of Donabedian’s three- 
element model of structure, process and outcome. Data on staffing level, teaching status, 
equipment and volume of patients are obtained from the American Hospital Association 
(AHA). Outcomes are assessed on the basis of in-hospital mortality rates adjusted for case- 
mix that were derived from Medicare discharge claims Data describing process, are not 
available nationwide. Instead, board-certified physicians are asked to nominate the five 
‘best’ hospitals in their specialties by means of questionnaires. The percentages of these 
physicians who nominated particular hospitals generated ‘reputation’ scores served as a 
proxy measure of high quality in the process of care. A study by Chen et al showed that the 
admission to a hospital ranked high on the list of “America’s Best Hospitals” was 
associated with lower 30-day mortality among elderly patients with acute myocardial 
infarction A substantial portion of the survival advantage may be associated with the 
processes of care, namely higher rates of use of aspirin and beta-blocker therapy. Further 
analyses taking into account nursing home admissions; the distance from home to the 
hospital; deaths occurring after the first hospital day; and the census region did not affect 
the results substantially
However, recent studies have identified a number of methodological weaknesses in 
the selection of top-ranked hospitals relating to all three elements of quality ' The use 
of hospitals’ reputations as a measure of the quality of care was particularly questioned.
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Since the majority o f hospitals would have ‘reputation’ scores near zero (i.e. they were not 
nominated by any of the surveyed physicians), hospitals with high name recognition would 
dominate the rankings. Also, even good risk-adjustment procedures may not take into 
account systematic differences in risk among hospitals '
2.2.6 Using secondary data
Routine observational data / administrative databases are increasingly used to 
compare outcomes between health care institutions, particularly in US, and for performance 
management activities, in general. They can be used as an indicator of the level of 
performance or quality, for clinical decision making, in the evaluation and development of 
treatment algorithms and as measurement of cost-effectiveness The reason is that they 
are readily available, relatively inexpensive to acquire, usually computerized, fairly easy to 
use and normally include entire regional populations or well-defined subpopulations * 
However, administrative databases have well-recognized limitations in 
characterizing patients, clinicians, and institutions Administrative data may not contain 
information sufficiently deep or accurate enough to adjust for systematic differences in 
severity of illness Further major problems may include poor data quality; 
completeness and accuracy of coding of diagnosis and procedures; missing data; lack of 
concurrent controls, inability to ascertain important study outcomes, and incomplete data 
on case mix
While the total size of the databases allows the calculation of statistically significant 
but small effect sizes, the quality of the information in the databases may not allow 
sufficient adjustment for potential confounding factors The effect of random variations, 
which may affect the validity of comparisons between providers’ results, should also be 
taken into consideration In addition, inconsistent interpretation of the data
requirements for the indicators and inconsistent data collection methods may reduce their 
validity and reliability
Many indicators for performance management are based on admission whereas 
hospital discharge summaries reflect conditions that were diagnosed or treated at any time 
during the entire admission, regardless of when they occurred^®. Moreover, the data reflect 
an historic the time period, since when matters may have changed Despite all these
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difficulties and problems with data quality, cancer registries remain an important source of 
data for information on performance of cancer services and have been maintained or used 
by researchers for several decades. The large size of these registries, along with availability 
of clinical data and the possibility of long term follow-up, offers unprecedented 
opportunities for describing the natural history of diseases, understanding the predictors of 
outcomes, particularly survival, and studying the effectiveness of new therapies or disease 
management strategies.
However, as indicated above, completeness of cancer registries relies heavily on 
completeness of clinical case notes. In this context, incompleteness of case notes for 
tumour stage, treatment and diagnostic procedures may cause particular concerns. In 
addition, observed discrepancies in important clinical indicators between cancer registry 
data and clinical notes require cautious interpretation of results in studies which use the 
registry data. Also, a high proportion of cases with DCO registrations may bias survival 
estimates. Thus, while cancer registries have a huge potential to serve as invaluable source 
of information for outcomes and management of cancer services, assessment of quality of 
registry data is essential for any meaningful interpretations of research studies which used 
cancer registry data.
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2.3 Patient factors to affect outcomes
Research into outcomes has primarily focused on the role of patient risk factors. 
With regard to cancer care, the literature notes the importance of age, stage of disease and 
the effect of social deprivation as the main individual level factors influencing the outcome 
of care. The presence of coexisting conditions or diseases (comorbidity) and the type of 
clinical treatment provided have been shown to have significant impact on outcome too. As 
indicated by the authors of the UK National Audit of Malignant Bowel Obstruction due to 
Colorectal Cancer (2000), patient factors such as age, urgency of operation and Dukes’ 
stage have a major effect on mortality, and risk models to adjust for such factors should be 
taken into account when assessing outcomes
2.3.1 Age
The literature shows that survival decreases with increasing age. In the Eurocare 
study, the relative risk of dying for the oldest patients (75+) was 1.39 for rectal cancer and 
1.54 for colon cancer compared with the youngest patients (15-44 years) There were 
similar findings in the study of cancer survival in England and Wales
In colorectal cancer surgery, older patients have higher frequency of comorbidity, 
are more likely to present with advanced stage, undergo emergency surgery and have 
generally worse clinical outcomes^^ '^^^^. Also, a study of colorectal cancer patients in 
England showed that age was a strong predictor of non-treatment and the relative risk of 
not receiving treatment increased for all ages over 65 years^^.
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2.3.2 Stage of disease
Differences in survival for colorectal cancer are clearly related to stage recorded at 
presentation Five-year relative survival rates by Dukes’ stage may vary from 83% to 
3% for colorectal cancer patients with the least and the most advanced stage, respectively 
However, these are unadjusted estimates and other factors play a role too. Also, studies 
by the Association of Coloproctology of Great Britain and Ireland showed that in 
univariate and multivariate models, Dukes’ D stage (the most advanced) was found to be an 
independent predictor of postoperative mortality in colorectal cancer surgery*
However, survival is a complex indicator of cancer care. Longer survival may be 
due to better treatment, or more effective treatment because of earlier diagnosis, or may be 
simply due to earlier diagnosis of the cancer (lead-time bias). Particularly, early diagnosis 
through screening programmes is considered to be an effective method of improving the 
prognosis*^^ However, the increase in the length of survival for patients diagnosed in an 
earlier stage of disease may reflect only the fact that the time of diagnosis was advanced, 
not that death was d e l a y e d * T h e r e f o r e ,  it is necessary to consider the potential 
confounding effect of what is often referred to as “lead time” bias^^.
Adjustments for tumour stage at diagnosis requires careful evaluation of the 
investigations used to determine the stage of disease*^^’*^ .^ Stage-specific comparisons 
maybe biased by so-called “stage migration”, or the Will Rogers phenomenon*where  
extensive diagnostic procedures are common practice, many cancers that would otherwise 
be classified as localised are then accurately classified to a more advanced stage category; 
this shift leads to an increase in the survival of both localised and advanced groups without 
any change in individual outcomes.
2.3.3 The effect of social deprivation
Several studies have reported that the survival of cancer patients, including 
colorectal cancer, shows a negative socio-economic gradient *^’"*'***'*'**. According to 
Auvinen, stage of disease at diagnosis accounted for a substantial proportion of differences 
in survival, and treatment accounted for the rest of them’"**. Monnet et al. recommended
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earlier access to care for people in lower social classes
In the UK, Pollock et al have shown that emergency admissions are more frequent 
in socially deprived areas No association was found between deprivation and the 
incidence of colorectal cancer, but significantly lower 5-year relative survival rates were 
found for breast and colorectal cancer patients in the most deprived areas Colorectal 
cancer patients in the most affluent tenth of enumeration districts had a 40% relative 
survival ratio compared with 32% in the most deprived tenth. However, these findings were 
not adjusted for measures of comorbidity or stage.
Wrigley et al showed similar results but pointed out the need to consider the effect 
of possible confounders Significant prognostic factors for outcomes were age, 
specialisation of surgeon, Dukes’s stage, and emergency compared with elective surgery. 
After adjustment for prognostic factors, the effect of deprivation on both cause spécifié and 
all cause mortality was reduced, and it was non-significant for colorectal cancer. However, 
the most deprived group had consistently worse survival than the most affluent.
In addition, according to the recent study on trends and socio-economic inequalities 
in cancer survival in England and Wales, improvements in survival were greater for those 
living in affluent areas than those in deprived ones This trend persisted even after 
correction for the differences in overall mortality between these two groups.
2.3.4 Comorbidity
Comorbid diseases are assessed by different methods, including medical records in 
electronic databases, medical charts, physical examination, personal interviews, and self- 
reports using written questionnaires'^^. Comorbidity may be estimated in several ways: by 
the co-occurrence of specific diseases in individuals with an index-disease by a simple 
summing up the number of diseases present in one individual; or by a comorbidity index 
that combines the number and severity of the diseases''^^"'^'.,
A number of studies show that cancer patients with comorbid conditions have worse 
survival than patients without comorbidity’ This relationship has been described for a 
number of tumour sites, such as head and neck’^ "’"'^ ;^ lung’^^ ; breast’ prostate’ ’^’ 
and colon’ However, its impact varied between cancer sites and even within the site if 
considered by stage of disease or type of treatment r e c e i v e d A l s o ,  the definition of
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comorbidity used by different studies varied substantially which may affect the 
comparability of the results. In fact, at present, no established way to assess the impact of 
comorbidity in cancer patients exist'
A review of the literature by Piccirillo and Feinstein (1996) indicated that the 
presence of comorbidity had a significant impact on five-year survival for rectal, laryngeal, 
and prostate cancers: the observed five-year survival rates decreased when prognostic 
comorbidity was present, and increased when it was absent (e.g. overall five-year survival 
rate for rectal cancer was 29%; in absence of comorbidity -  32%, and in presence -  
11%)'^^. However, the rates presented were for impact of comorbidity alone, regardless of 
the stage. In fact, it was not clear to what extent these differences were due to stage of 
disease versus comorbidity. In addition, these results were not based on systematic review 
of the literature.
There is general agreement that tumour stage is the most important single factor for 
survival or mortality from colorectal cancer'^"'. Although tumour stage is a crucial 
determinant of patient outcome, comorbidity increases the complexity of cancer 
management and, whilst unrelated to the cancer itself, may affect the choice of treatment 
and prognosis'^'' '^^’'^' '^^’'^^’'^ .^ However, a study of colorectal cancer patients in the 
Netherlands showed that after adjustment for age and Dukes’ stage, comorbidity was not 
associated with the resection rate'^^ (see also Table 2.2). Only few studies have assessed the 
impact of comorbidity on observed variation in cancer survival, or proportion of variation 
explained by comorbidity.
In a study o f lung cancer survival, Tammemagi et al showed that stage was the most 
significant predictor of survival and explained around 25% of the survival variation, while 
comorbidity, though significant, explained only 2.5% of the survival v a r i a t i o n A n o t h e r  
study of elderly women with non-metastatic breast cancer showed that additional 
adjustment for aggregate comorbidity did not change odds ratio estimates of the effect of 
age on the initial treatment for breast cancer'^^.
Read et al using cancer registry data of more than 11 000 patients with breast, lung, 
colon and prostate cancer, studied differential impact of comorbidity on one-year survival 
in these four different cancers'^^. Comorbidity was classified into four groups: none, mild, 
moderate or severe, based on the Adult Comorbidity Index ACE-27, a validated chart-based 
comorbidity i n d e x T h e y  assessed relative prognostic impact of comorbidity by tumour 
site and stage, using hazard ratio adjusted for age, race, and sex. To measure the proportion
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of explained variation by comorbidity within each cancer site/stage group, the authors used 
the method of Heinze and Schemper developed for Cox proportional hazards model'^'. The 
correlation between overall survival rate and severity of comorbidity was statistically 
significant (p<0.001), but fairly strong (r  ^= 0.56). As shown in Table 2.1, the proportion of 
variance in outcome explained by comorbidity ranged from less than 1 % to almost 9% 
depending on tumour site and stage, (see also Table 2.2)
Table 2.1 Relationship between cancer site, lethality, and prognostic importance of
comorbidity 153
A colorectal cancer study in Wessex region in England found that comorbidity was 
associated with all-cause, but not cancer-specific, surv iva lComorb id i ty  was simply 
scored as the number of co-existing conditions recorded in hospital notes. The authors 
rightly pointed out that there is little agreement about measuring comorbidity in cancer 
research and only few studies of colorectal cancer survival contain any health status 
measurementSimi lar ly ,  a study of breast cancer, using US data from the SEER 
programme, found that comorbidity was associated only with all-cause or non-cancer 
specific three-year survival No studies were identified as to the impact of comorbidity 
on relative survival estimates, which take into account background (non-cancer specific) 
mortality, and thus, to some extent, indirectly reflect the presence or absence of co-existing 
diseases or pathological conditions on population level.
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2.3.5 Clinical treatment
Surgery is the principle treatment for colorectal cancer patients Surgery with 
curative intent aims to remove the whole tumour: if it succeeds, the patient may be 
considered free from cancer. When curative surgery is not possible, patients may benefit 
from palliative interventions.
Current clinical guidelines suggest that radical, or curative, surgery is associated 
with better ou tc om e s C ur a t i v e  resection can be defined as “removal o f all macroscopic 
disease at the time of operation, backed up by histological evidence that the resection 
margins of the specimen submitted to the pathologist are clear of tumour” However, the 
term is imprecise, and it is not clear whether the observed differences in outcome were due 
to confounding effect of patient factors, which could also have influenced choice of 
surgery.
In addition, the rate of curative resection depends on the stage of the tumour'^^. The 
Trent/Wales and Wessex audits have shown variability in stage distribution across districts, 
with the percentage of tumours presenting at Dukes’ stage A varying from 6% to 18%, and 
the percentage with distant métastasés varying from 19% to 39%. The rate of curative 
resection varied from 31% to 72%, and this was inversely correlated with the percentage of 
cases with distant métastasés
Another factor which may influence the outcome of surgical treatment is emergency 
surgery. Overall, it was estimated that around a third of colon cancer patients and a tenth of 
rectal cancer patients are admitted as emergencies, and over 20% of patients who undergo 
emergency surgery for intestinal obstruction die within a m o n t h T h i s  is mainly due to 
poor physical status at admission.
Although lacking evidence from the randomised trials, it is widely accepted that 
extended resection of colon -  hemicolectomy, is safer than segmental resections for tumour 
in surgical treatment for colon cancer*^^. In rectal cancer, however, resection technique is of 
greater i m p o r t a n c e ' A  number of studies showed that total mesorectal resection for rectal
cancer was associated with improved long-term survival and reduced local recurrence, as 
compared to other types of s u r g e r y ' H o w e v e r ,  the adequacy of local resection and 
pathology reports may play a role in observed relationships. An audit of pathology
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reporting in Wales showed marked variations in adequacy of reporting between laboratories 
and hospitals'
Systematic reviews of clinical trials show that provision of radiotherapy in 
combination with surgery significantly reduces local recurrence rates for rectal cancer' 
However, the evidence is equivocal as to whether preoperative radiotherapy also leads 
to a reduction in mortality rates and s u r v i v a l E v e n  with modem treatment methods, 
radiotherapy is likely to cause long-term problems with bowel function'^''. There is no 
evidence to support the use of adjuvant radiotherapy for colon cancer.
A systematic review of the literature for ‘Improving Outcomes’ guidance suggested 
that chemotherapy may improve survival for Dukes’ stage C colorectal cancer patients, but 
no clear evidence was identified on the effectiveness of chemotherapy for patients with 
Dukes’ stage B colorectal cancer^
However, as indicated in a previous section (see 2.2.1), the use of cancer registry 
dataset to study the impact of clinical treatment is limited due to the lack of data and its 
poor quality. In fact, current use of cancer treatment information is mainly limited to 
audit studies of specialised site-specific datasets. Particularly, recent audit by the 
Association of Coloproctology of Great Britain and Ireland indicated poor data quality and 
discrepancies between various sources of national data'^'.
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2.4 Organisational determinants of outcomes
Along with patient factors, the outcome of care is also dependent on the quality of 
care received throughout the patient’s stay in hospital and the performance of considerable 
number of health care professionals, all of whom are influenced by the environment in 
which they work such as team coordination, communication, equipment and so on
2.4.1 Staffing level
There is a general belief that increased staffing level may at least partly facilitate 
improvement of outcomes of care in clinical settings. The main reason for that is the 
speculation that it may affect the occurrence of errors, complications and other adverse 
events Also, staffing deficiencies may deprive patients of sufficient nursing or medical 
care and increase stress level among health care workers and lead to higher possibilities of 
mistakes. However, there is insufficient or equivocal evidence in the literature to support 
this notion. The literature is especially scarce on the influence of medical staffing level, 
while the effect of nurse staffing was explored in numerous studies.
Increase nurse staffing has been associated with lower postoperative 
c o m p l i c a t i o n s a  lower incidence of adverse e v e n t s l o w e r  nosocomial infection 
r a t e s a n d  higher patient satisfaction'^^. Studies in the US and the UK, and a number of 
reviews of the l i t e r a t u r e h a v e  demonstrated that the level of nurse staffing may affect 
patient and organisational outcomes, but the results were equivocal and vary by 
institution^ '^ '^^ '^ .^
In a US study of bladder carcinoma patients, hospitals with a high registered nurse- 
to-patient ratios had a lower in-patient mortality risk among patients who underwent 
cystectomy (OR=0.46; p=0.04), after adjustment for age, indicators of social status and 
comorbidity^"^. However, the authors did not account for tumour stage, which is the major 
indicator of disease severity for cancer patients and may affect the observed relationships.
A recent large study of around 13 million patients in approximately 1500 US 
hospitals, commissioned by the American Nurses Association, showed the positive 
association between low level of nurse staffing and a number of in-hospital clinical
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complications, such as pneumonia, postoperative infections, adverse drug reactions and so 
on'^^. Similar results have been presented by Blegen et al (1998) in an example of large 
university hospital in However, both studies did not comprehensively account for
patient case-mix.
Another study in one Thai hospital found that among four different nurse staffing 
variables, after adjustment for patient characteristics, ‘total nurse staff to patients’ was 
significantly associated with in-hospital mortality for one of four common groups of 
principal diagnoses, including cancer^ They did not specify diagnose-specific effect of 
observed relationship.
As detailed in Introduction chapter (see 1.2), a study by Jarman et al linked 
routinely collected national datasets to investigate determinants of in-hospital mortality in 
England^^ A total number of doctors per bed was found to be the best predictor to explain 
variations in in-hospital mortality between NHS hospital trusts. However, the severity of 
illness was not taken into account for, and the validity of applied measures of comorbidity, 
which were adjusted for in the analyses, remained unclear, (see also Introduction chapter, 
1.2.; and Table 2.2)
The literature also indicates an association between doctor and nurse staffing and 
the outcome of intensive care units, particularly mortality and complications 
However, no study was identified that examined the relationship between staffing level and 
longer-term cancer survival.
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2.4.2 Volume effect
Literature data provide similar evidence on association between volume and 
outcome of care in both cancer and non-cancer settings, such as transplantation programme, 
paediatric cancer care '^"^’^ *^ ; breast cancer surgery prostate cancer surgery^'^; trauma 
centres The “higher procedural volume, better outcome” relationship has an extensive 
literature in cardiovascular disease^' ,2 3 ,2 4 ,2 6 ,2 14 , 219 ,2 2 0 ^
However, studies use various definitions of ‘volume’ (quartiles; quintiles; some 
specific cut-off points; other approaches) and consider different aspects of it: volume of 
hospitals; volume of doctors; volume for specific conditions/diseases; volume for specific 
procedures or surgery. Usually the studies have combined hospitals with similar volumes 
into a small number of groups and then compared the rates of outcomes among the groups. 
Most studies considered in-hospital or 30-day mortality as the only measures of adverse 
outcome Longer-term outcomes and survival were investigated to lesser extent. Studies 
normally controlled for differences among ‘volume’ groups by adjusting for the severity of 
patients’ conditions at admission. The level and methods of adjustments differ from study 
to study, which make comparisons between results difficult.
Publications mainly report that high-volume hospitals have better outcomes than 
low-volume hospitals, at least for certain conditions and procedures. Dudley et al, in a 
systematic review, suggested that many deaths could be avoided if patients with specific 
conditions had been treated at high-volume vs. low-volume hospitals However, studies 
used different definitions of ‘volume’ and there were differences in methodology, with 
various degree of case-mix adjustments, which did not allow the authors performing a 
meta-analysis. Excluded were also studies that used other than in-hospital mortality 
outcome measures (e.g. 5-year survival), since they were not available from the California 
database of hospital discharges.
Most studies found positive associations between volume and outcomes only for 
high-risk conditions and complex surgical procedures^M;223-226 ^  systematic review (1980 
-  2000) on the relationship between hospital or physician volume and clinical outcomes by 
Halm et al showed that the strongest associations with high volumes were found for more 
complex surgical procedures, like pancreatic resection and esophagectomy (a median of 3.3 
to 13 excess deaths per 100 cases were attributed to low volume) Overall, 71% of all
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studies of hospital volume and 69% of studies of physician volume reported statistically 
significant associations between higher volume and better outcomes (see also Table 2.2). 
This was confirmed by Hillner & Smith, who analysed the findings of five large studies in 
the US These studies used hospital discharge summaries that included the ICD-9-CM 
coding but not the cancer staging. In addition, they showed that studies that performed 
more complete case-mix adjustment were less likely to report a positive effect of high 
volume on outcomes.
Similar conclusions were provided by other major US studies with the focus on 
cancer-related surgical procedures, based on the analysis of the Nationwide Inpatient 
Sample^^" ’^^ ^^  and Surveillance, Epidemiology, and End Results (SEER) -  Medicare linked 
databases (see also Table 2.2). Adjustments for case-mix and other patient factors did 
not change the findings that low volume was strongly associated with excess mortality for 
specific high-risk surgeries. However, the Nationwide Inpatient Sample-related studies 
were lacking adjustments for tumour stage; and in SEER studies, around 16% of otherwise 
eligible patients were excluded from the cohort due to the lack of detailed data. On the 
other hand, a study in Canada, using electronic hospital records linked with the database of 
vital statistics, showed that, with the exception of colorectal resection, for some major 
surgical operations the inverse association between high volume of procedure and risk of 
30-day postoperative mortality was not specific to the volume of the procedure being 
studied Shared structures and processes in hospitals that do a high volume of any 
complex surgical procedures may account for improved surgical outcome.
To a lesser extent, this tendency was confirmed in relation to in-hospital 
mortality^^^’^ ^^ ’^ ^^  or survival for colorectal cancer. For instance, a study by Schrag et al, 
using SEER database, examined 27 986 colon cancer patients aged 65 years and older who 
had surgical resection for primary adenocarcinoma diagnosed between 1991 and 1996 
The authors found a small difference in 30-day postoperative mortality for patients treated 
at low vs. high volume hospitals (3.5% at hospitals in the top-volume quartile vs. 5.5% at 
hospitals in the bottom-volume quartile). (see also Table 2.2)
Hospital volume is perhaps more important than individual surgeon’s volume in its 
effect on short-term outcomes, such as in-hospital mortality and two-year survival^^^ for 
colorectal cancer. Particularly, medium-volume surgeons achieved results equivalent to 
high-volume surgeons when they operated in high- or medium-volume hospitals but not in 
low-volume hospitals^^'. On the other hand, the results of low-volume surgeons, although
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improved with increasing hospital volume, never equalled those of the high-volume 
surgeons.
In a multilevel Cox proportional hazards model, after adjustment for patient 
characteristics (age, sex, Dukes’ stage, Townsend deprivation quintile), surgeon's caseload 
had no significant effect on colorectal cancer mortality at 2 years^^^. Hospital workload did 
have a significant impact on survival. However, missing tumour stage and social 
deprivation information for around 11% and 6% of patients, respectively, imprecise case- 
mix adjustment and in-exact measurement of clinician specific rates (the name of 
consultant surgeon was taken into account regardless of whether the surgery was actually 
performed by consultant or surgeon in training or both) are limitations for the study.
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2.4.3 Specialisation
Along with the volume-outcome studies, there is extensive literature about the 
impact of specialisation on outcome of care. In fact, some studies showed that specialist 
care was more important and beneficial than volume effect
For instance, according to one Finnish study, there were no significant differences 
in the rates of postoperative mortality, morbidity, and long-term overall survival between 
the volume groups^^^. On the other hand, in patients with colorectal cancer, there was a 
trend for better survival and fewer local recurrences for those operated on by the surgeons 
specialising in gastrointestinal surgery.
However, the definition of ‘specialist care’ provided in studies has varied and 
included membership in professional site-specific associations surgical subspecialty
230;233 . certification in surgery or being treated at multi-disciplinary specialist
units Some authors did not provide with the formal definitions employed
There is no systematic information about specialisation in the UK. While literature, 
in general, discusses the effect of specialist care in terms of ‘specialist surgeon’, in the UK, 
the approach is on multidisciplinary teams - ‘specialist teams’, as opposed to the notion of 
‘specialist surgeon’ prevailed in the literature. Since publication of the Calman-Hine report 
on reorganisation of cancer services in England and Wales, cancer centres and units in NHS 
hospital trusts adopted a multidisciplinary team (MDT) approach with the aim of providing 
specialist care to cancer patients.
No evidence was identified on relationship between multi-disciplinary team 
management of primary colorectal cancer and outcome of care, namely survival. A study in 
Scotland showed that ovarian cancer patients who were referred to multi-disciplinary team 
at a joint clinic had improved survival^^^. However, there were few studies dealing with 
some aspects of organisation and functioning of
Particularly, a study by Kelly et al aimed to ascertain nation-wide implementation 
of colorectal MDTs as part of the NHS Cancer Plan^ "^ .^ Another survey by Jenkins et al, 
taken during early stages of establishment of breast cancer MDTs (February -  August 
1999), showed that there were some discrepancies within MDT members’ views and 
expectations of their own and each other’s roles in providing different kinds of information 
to women with breast cancer^^\
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A prospective audit of the management of colorectal cancer patients by Smith et al 
investigated factors associated with variations in survival observed within the former UK 
Wessex region The greatest benefit was observed with respect to specialists versus non­
specialists, in terms of a lower postoperative mortality rate (OR=0.67 (95% Cl 0.53 to
0.84); lower anastomotic leak rates (OR=0.46 (0.31 to 0.66); higher local recurrence-free 
survival (hazard ratio 0.56 (0.44 to 0.71) and better long term survival (hazard ratio 0.76 
(0.71 to 0.83) However, the definition of ‘specialist’ employed as “a member of the 
Association of Coloproctology of Great Britain and Ireland with a commitment to and 
special interest in coloproctology”, may not be completely adequate since there is no agreed 
‘specialist’ definition in the UK. In fact, there is no requirement for a specialist to be a 
member of the Association and, vice versa, membership does not necessarily mean that 
someone is practising as a specialist, (see also Table 2.2)
The beneficial effect of specialist care in colorectal surgery was apparent also in 
studies in the US Canada as well as the Stockholm Rectal Cancer Study Group 
However, some of the results of the latter study were of borderline statistical significance. 
Similar to colorectal cancer cases, specialist care appeared to bring about survival 
advantage also for patients with other tumours, namely breast^^^’^ ^^  and ovarian^^" .^
No evidence was identified on the effectiveness of specialised colorectal cancer 
nurses, possibly because there are very few such nurses One published audit of a 
nurse-led colorectal cancer clinic within a London teaching hospital was identified This 
retrospective study of 600 cases diagnosed at a nurse-led one-stop diagnostic colorectal 
cancer clinic for patients aged 50 years or older reported high patient satisfaction with less 
anxiety and time waiting for results, although no comparison data and few quantitative 
results were presented.
Better outcomes for specialist vs. non-specialist care are probably related to the 
differences in processes of care. Particularly, audit review conducted in one hospital in 
England showed that colorectal specialists were more likely to comply with published 
guidelines, performed fewer abdomino-perineal resections and tended to perform more 
extensive lymphadenectomy Also, prospective study of emergency colorectal surgery in 
Oxford gives evidence for process variability between surgical teams headed by specialists 
and non-specialists^"^^. However, no information was provided in either of these studies as 
to whether specialist care led to better outcomes.
Data on 750 consecutive patients in the Lothians and Borders Large Bowel cancer
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project (1990-1992) revealed that five out of 28 consultants were responsible for over 50% 
of patients with rectal cancer "^^ .^ There was no evidence that these five were more likely to 
achieve anastomosis than the others. However, when the anastomosis was performed, it 
was less likely to leak if performed by one of the five with the highest volume (4% vs. 
14%; p<0.05). It is not clear whether the data were adjusted for differences in case-mix.
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2.4.4 Teaching status of hospital
There is a general assumption that the teaching (or academic) hospitals provide 
better care than non-teaching (or non-university) hospitals due to greater concentration of 
clinical expertise, a focus on clinical research, adherence to clinical guidelines and 
technological superiority (see also Table 2.2). According to the literature data,
most of the survival differences could be attributed to differences in the processes of the 
care, e.g. greater use of beta-blockers and aspirin after acute myocardial infarction or 
recommended breast-conserving surgery^^^.
Studies in Canada^ and assigned teaching status of hospitals according
to the formal classification of hospitals available in their countries, particularly Canadian 
Hospital Directory, which defines teaching hospitals as those with membership in the 
Association of Canadian Teaching Hospitals, and American Hospital Association’s annual 
hospital survey, respectively. No UK study or taxonomy was identified to provide with the 
definition of ‘teaching hospital’.
However, the effect on the outcome of hospital’s teaching status was not shown to 
be consistent and appeared to vary between different nosologies or even within the 
same condition studied
For instance, Chaudhry et al in Canada showed that survival advantage of breast 
cancer patients treated at teaching hospitals was apparent only among women with larger 
tumours Differences in age, socio-economic status, stage of disease or treatment 
variables did not explain the observed variations in survival between two types of hospitals. 
Another study of breast cancer patients by Richards et al, using data from the Thames 
Cancer Registry (1984 -  1988), indicated that despite marked variations in practice 
according to the type of hospital to which patients presented, among patients who 
underwent surgery, the type of hospital in which this was undertaken did not appear to 
influence survival significantly
Also, there was insufficient and equivocal evidence in relation to teaching status of 
hospitals for colorectal cancer outcomes.
A Stockholm Rectal Cancer Study Group showed lowered risk of death (in-hospital 
mortality) for patients operated on in university hospitals (RR of death from rectal cancer
0.8, 95% Cl 0.7-1.0) compared with community hospitals However, the results were of
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borderline statistical significance.
A study from Manchester (UK) of 578 patients treated for colorectal cancer in the 
north-west of England compared survival after surgery in teaching and non-teaching 
hospitals^^^. The number of operative mortalities and 5-year survival figures for all causes 
of death and for colorectal deaths alone were similar in teaching and non-teaching hospital 
patients. It was not clear whether the authors adjusted for patients’ case-mix. However, it 
was noted that a greater proportion of elderly and emergency patients were treated in the 
non-teaching hospitals.
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2.4.5 Compliance with clinical guidelines and standards of care
Compliance with guidelines was assessed in the literature mainly in terms of 
specific clinical interventions'^^ '^ ’^^ ^^ ’^ ^  ^A systematic review by Grimshaw and Russell^^^ 
concluded that in most published studies, compliance with clinical guidelines seem to 
improve process of care in the direction proposed by the guidelines and the outcome of 
care. However, the size of improvements varied considerably.
A review of the literature by Smith & Hillner described the impact of clinical 
practice guidelines on improvement in processes of care and outcomes in oncology^^^. 
Improvements have been demonstrated in compliance with evidence-based guidelines or 
evidence-based medicine, and in short-term length of stay, complication rates, and financial 
outcomes. The data suggest that patient satisfaction can be maintained despite a shorter 
length of stay. However, there was a lack of comprehensive evidence on whether 
compliance with guidelines affects long-term outcomes, particularly survival.
More recent reports have indicated links between treatment guidelines and long­
term survival for breast'^ ^ and ovarian"^ '^"^  ^cancer patients.
Variations in compliance with rectal cancer treatment guidelines and its effect on 
long-term outcomes were also investigated with data from the Munich Cancer Registry^^^. 
Patients diagnosed between 1996 and 1998 with an invasive primary rectal tumour were 
included in these analyses (n=884), and median follow-up was 5.7 years. Compliance with 
treatment guidelines was associated with significant survival advantage only in patients 
with more advanced stages. However, in examining multivariate associations, Cox 
proportional hazards model was employed and, thus, the analysis did not take into account 
background mortality. Also, no adjustment for social deprivation was carried out within the 
model.
In a Swedish study^^^ on colorectal cancer survival, university hospitals appeared to 
be more in compliance with clinical guidelines than district hospitals; and an audit study^ "^  ^
in England showed that colorectal specialists were more likely to comply with published 
guidelines. However, they did not relate compliance with survival.
As described in Introduction chapter (see 1.2), Morris studied adherence to cancer 
services standards for colorectal cancer in 14 hospital teams in Yorkshire (UK)"^ .^ 
Adherence was determined by questionnaire (not peer review assessed), and a composite
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score was used based on the number of standards that had been met. The study concluded 
that 25% increase in adherence was related to 8% reduction in the risk of death after one 
and two-year follow-up. However, it is difficult to interpret the meaning of the composite 
score as it combined standards of different importance. No evidence was required to prove 
the actual adherence as was the case in a national peer review process, (see also 
Introduction chapter, 1.2.; and Table 2.2)
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2.4.6 Waiting time
There is inconclusive evidence in the literature on the impact of referral and 
treatment delays on survival for cancer patients. Studies used different types of treatment 
and various tumour types. Also, there were differences in the degree of case-mix 
adjustment and definitions of ‘waiting time’ used.
A systematic review of the literature by Richards et al suggested that delays 
between the onset of symptoms and start of treatment for breast cancer patients were 
associated with a lower survivaf^^. However, the quality of reviewed studies and levels of 
adjustments for patients’ case-mix and other predictors of survival varied considerably, 
which made interpretations of these findings equivocal. In studies that controlled for stage, 
longer delay was no longer associated with shorter survival. Also, in another study of breast 
cancer patients, multivariate analyses indicated that the adverse impact of delay in 
presentation on survival was attributable to more advanced stage^^^ (see also Table 2.2). 
However, within individual stages, longer delay had no adverse impact on survival. 
Evidence for an association between age and delay by patients and providers for breast 
cancer patients was presented in a systematic review by Ramirez et al^ "^^ . Indeed, a number 
of studies have described and discussed the so called phenomenon of ‘waiting time 
paradox’, when patients with shorter waiting times have worse outcomes or more advanced 
disease^ ^^ '^ ^^ .
No significant correlation of waiting time from diagnosis to surgical treatment with 
recurrence rate was found in a German study of prostate cancer patients^^^. Likewise, there 
was no significant difference in seven-year survival according to delay from surgery to 
radiotherapy in Canadian study of breast cancer patients, although the risk of local 
recurrence for those who received radiotherapy more than 12 weeks after surgery was 
increased with borderline statistical significance^^^. However, a retrospective study of 
breast cancer patients by Mikeljevic et al (2004) in the UK Yorkshire region showed that 
patients with surgery to the start of radiotherapy intervals longer than 9 weeks had a trend 
towards an increased relative risk of death^^\ This reached a statistical significance at 20- 
26 weeks (RR 1.49, 95% Cl (1.16-1.92). Also, another Canadian study using data from 
Ottawa Regional Cancer Registry concluded that after adjustment for multiple prognostic 
tumour and treatment parameters, longer diagnosis to radiotherapy waiting times were
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associated with diminished survival for patients with cervix cancer^^^.
No primary evidence was identified on associations between waiting times and 
colorectal cancer survival. Two studies explored factors related to diagnostic delay (patient, 
primary care, referral, secondary care) for main cancers, including colorectal, using data 
from the National Cancer Patient Survey in England^^^’^ "^^ . This showed that breast cancer 
patients experienced the shortest delays (mean 55.2 days), while the longest delays were 
observed for colorectal and prostate cancer patients (mean 125.7 and 148.5 days, 
respectively). Patients who saw their GP prior to diagnosis experienced considerably longer 
total diagnostic delays than those who did not Findings from generalised linear 
modelling showed that for colorectal cancer the significant factors associated with 
diagnostic delays were marital status and age
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2.5 Summary of literature findings
Administrative databases can contribute to the assessment of the quality of care, 
case-mix and patient outcomes because they have advantages of population coverage and 
systematic collection. Factors that can influence the quality of such data are the methods by 
which the data are collected, standardisation of definitions and appropriate analytic 
techniques, as well as completeness and accuracy.
A factor in the use of routine data in assessing clinical outcomes is their ability to 
differentiate patients according to the severity of illness. Review of the literature showed 
that studies that performed risk adjustment by using clinical data were less likely to report 
significant associations than were studies that adjusted for risk by using administrative data.
Another aspect need to be considered in relation to the use of routine data for 
outcome research is temporal relationships between data elements. Temporality is 
important for risk adjustment and clarifying the order in which the exposure and outcome 
occur, thus making causal inferences. In this context, the use of cancer registry data to 
assess the effect of current changes in clinical management or organisational characteristics 
has particular limitations, since survival data reflect back in time.
Research into outcomes has primarily focused on the role of patient risk factors. 
Organisational determinants of outcomes have been investigated to a lesser extent, 
particularly in relation to cancer. In general, fewer studies were identified in relation to 
predictors for colorectal cancer outcomes as compared with other tumour types, particularly 
breast cancer. The majority of studies presented their results after adjustment for patient 
case-mix. However, the degree and completeness of this adjustment varied which may 
affect the comparison of the results.
Tumour stage is the crucial individual level determinant of the outcome for cancer 
patients. The literature also stressed the importance of age, social deprivation, type of 
admission (emergency vs. elective), and the presence of coexisting pathological conditions 
or diseases (comorbidity). On the other hand, compared with other diseases, comorbidity 
appears to have less impact on cancer survival, which is strongly dependant on tumour 
stage and age of patients. No robust measures to assess the impact of comorbidity in cancer 
patients were identified in the literature.
Relatively large number of studies on organisational determinants of outcomes 
analysed the effect of volume and specialisation both in cancer and non-cancer settings.
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Literature mainly supports the notion of ‘higher volume, better outcome’, particularly for 
high-risk conditions and complex surgical procedures. To a lesser extent, these associations 
were shown significant for colorectal cancer. As suggested in a number of studies, hospital 
volume is perhaps more important then individual surgeon’s volume in its effect on 
survival. However, studies used various definitions o f ‘volume’ and ‘specialisation’. In 
fact, as opposed to the current UK approach towards specialisation in terms of ‘specialist 
teams’, most studies in the literature consider the effect of specialisation in relation to 
‘specialist surgeon’. Most studies considered short-term outcomes, particularly in-hospital 
or 30-day mortality. Also, as in case of other organisational determinants, the degree and 
robustness of case-mix adjustment varied considerably between studies, which made 
comparisons between them difficult.
A number of studies showed survival advantage of patients treated in teaching 
hospitals as compared to patients in non-teaching hospitals, suggesting differences in 
expertise, equipment and processes of care. The evidence is, however, equivocal, and the 
impact of hospital’s teaching status appeared to vary by disease studied. Differences in 
case-mix and referral patterns may have an effect too.
There is equivocal evidence in the literature on the impact of referral waiting times 
and delays in treatment and diagnosis on survival for cancer patients. Studies used different 
definitions of ‘waiting time’ and different degrees of case-mix adjustment. No primary 
evidence was identified in relation to waiting times and survival of colorectal cancer 
patients.
The literature also indicates an association between staffing level and outcomes of 
care. While relatively large number of studies examines the effect of nurse staffing, there is 
scarce evidence on the impact of medical staffing, especially in cancer settings.
Clinical guidelines and standards of care are essential for effective management of 
quality and performance in healthcare settings, including cancer care. However, their 
impact on outcomes of care have not been comprehensively studied in the literature. While 
some studies suggest that compliance with guidelines for specific clinical interventions is 
associated with improved outcomes, others limited to the audit of compliance unrelated to 
the outcomes of care. Moreover, this association has been less explored in relation to 
standards on organisation of services.
Studies usually used Cox proportional hazards model to assess the potential 
associations between predictors and outcomes (crude survival, does not take into account
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background mortality of population). Very few studies employed relative survival 
modelling (takes into account background mortality of population) which was the main 
method of current study.
More consideration of findings from the literature, in relation to the methodology and 
results of this study is presented in Discussion chapter of the thesis.
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Table 2.2 Selected articles
Paper Commentary
INTERNATIONAL COMPARISON
Berrino et al (1995)'
International Agency for Research on Cancer 
“Survival o f Cancer Patients in Europe. The Eurocare 
study”
Between-country variations in Europe observed for all 
cancer sites examined using cancer registry data.
Absolute differences in survival were small ( ^ % ) for 
most cancer sites with poor prognosis, larger (>10%) 
for cancer sites for which the therapy choice and 
survival are significantly influenced by stage at 
diagnosis. Relatively smaller differences were 
observed for cancers sensitive to cytotoxic therapy 
(testis, Hodgkin’s disease and ovary) especially at 
younger ages.
Access to care is considered an important cause of  
between-country survival differences for these cancers.
Methodological differences that may bias survival 
comparisons must be taken into account - 
completeness o f case ascertainment; completeness 
o f follow-up; timeliness o f  survival statistics; 
differences in availability o f diagnostic means and 
registration practices.
Also, differences in representativeness in terms o f  
involvement o f number o f  cancer registries and 
their coverage, per country available for research 
groups.
Problems in comparing survival between 
populations may also arise within the same site- 
morphology, since not all cancer registries have 
detailed classification to the level o f sub-sites.
Further artefacts that affect survival analysis 
interpretation include so-called ‘stage migration’, 
lead-time bias, and ‘pseudo-cancers’ found in 
screening but would have never progressed to give 
clinical signs.___________________________________
USING SECONDARY DATA
Jarman B. et al (1999)^^
BMJ
“Explaining differences in English hospital death rates 
using routinely collected data”
To explore factors which best explain variations in 
standardised hospital death ratios in England.
Included 8 million discharges from NHS hospitals for 
diagnoses accounting for 80% o f inpatient deaths.
Weighted linear regression analysis o f data sets over 
four years: HES, patient survey, staffing levels and GP 
distribution. Comorbidity indices included the number 
of bodily systems affected by disease; presence o f one 
of the 15 common diagnoses; combination o f top two 
or three comorbidity diagnoses; and the percentage 
both o f cases and o f deaths with comorbidities.
The four-year standardised hospital mortality ratios 
ranged from 53 to 137. The percentage o f emergency 
admissions and the ratio o f hospital doctors per bed 
and GPs to head o f population were found to be 
predictors of observed variations in mortality.
The paper uses secondary data from several sources 
and makes a cross-sectional analysis to explain 
differences in death rates.
HES dataset for 1991/1992- 1994/1995 did not 
contain patient identifiers, so could not distinguish 
repeat admissions leading to over-counting patients 
(only from 1997 was ‘HES-ID’ introduced).
The paper was criticised (Bunker & Black, BMJ, 
1999;319:854) for limited clinical data to assess 
patient case-mix as a confounding factor.
The impact o f differences in time periods covered 
by different databases on study results was not 
discussed.
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Table 2.2 Selected articles (continued)
Paper Commentary
lezzoni L.A. (1997)^"
Annals o f Internal Medicine
“Assessing Quality Using Administrative Data”
A review o f the quality o f administrative data which 
need to be taken into account in outcome research.
It also discusses whether administrative data could 
produce useful judgements about the quality.
She identified and described major producers o f  
routine datasets in the US. The following issues related 
to the quality o f routine datasets were identified and 
reviewed: clinical content; coding accuracy; 
completeness o f coding; differences in data quality 
across hospitals. Administrative datasets contain 
limited clinical information to inform quality 
assessments. The accuracy o f diagnosis coding affects 
data quality.________________________________________
The paper provides an extensive overview o f the 
issues connected with the quality o f  routine, 
administrative data. It is not a systematic review, 
but rather a consideration o f  main challenges 
connected with the use o f datasets, based on key 
studies identified in the literature. Also, some o f  
the issues identified and conclusions forwarded are 
specific to the US insurance-based health care 
system, and thus may not be applicable to other 
countries.
The paper provides an overview o f  data quality 
issues in general, not nosology-specific. There is no 
specific discussion on cancer-related data-quality.
CANCER REGISTRATION
Pollock A.M. (1 9 9 5 /'
Quality in Health Care
“Reliability o f data o f the Thames cancer registry on 
673 cases o f colorectal cancer: effect o f the 
registration process”
Retrospective study o f completeness and accuracy o f  
the Thames Cancer Registry data on 673 cases o f  
colorectal cancer, using case notes as a standard, 
diagnosed in 1983 or 1988.
Registry data on district o f residence; sex; dates o f  
birth, diagnosis, and death were highly reliable, but 
treatment and tumour site data were less so. Lack o f  
follow up in death certificate only registrations and 
failure to monitor treatments during follow up period 
seemed to be associated with disagreements.
17% of cases in which diagnosis and treatment 
seem to have occurred outside the district o f  
residence, were excluded from the study. An 
unspecified number o f  case notes without a date o f  
diagnosis or a date o f death were excluded, which 
could affect the results o f  this audit study.
The major disagreement between the cancer registry 
and case notes in relation to treatment, tumour site 
and date o f diagnosis could have serious 
implications on reliability o f  cancer statistics. 
However, the study reflect the situation in mid to 
late 80s, and improvements in registration, 
informed by this study, since then were put in place.
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Table 2.2 Selected articles (continued)
Paper Commentary
COMORBIDITY
Read W.L. et al (2004)'""
Journal o f Clinical Oncology
“Differential Prognostic Impact o f Comorbidity”
The study investigated the impact o f comorbidity on 
survival in 11558 patients with breast, colon, lung and 
prostate cancers recorded at one US hospital 1995- 
2001 .
Severity o f comorbidity was classified on a 4-point 
scale using chart review according to a validated index 
(ACE-27). For each cancer site, there was a significant 
correlation between 1 -year overall survival rate and the 
adjusted hazards ratio for comorbidity.
The proportion o f variance explained by comorbidity 
ranged from less than 1 % to almost 9% (for colon 
cancer 0.6% to 5.5%) depending on tumour site and 
stage.___________________________________________
Data were for one hospital only. However, the 
sample size had sufficient statistical power. The 
staging system used was similar to other accepted 
tumour-specific staging, e.g. Dukes’ stage for 
colorectal cancer. Reliability o f  the comorbidity 
coding was not recorded. No adjustment was made 
for social deprivation.
Comorbidity has greater effect on survival in 
tumours o f early stage, and little in advanced 
tumours. Overall, the effect appears relatively small 
at less than 10%.
The results have been quoted by other cancer 
population survival researchers (Janssen-Heijnen M 
L G, Coebergh J W W. Comorbidity in elderly 
NSCLC patients. Thorax 2005;60:704.)
De Marco M.F. et al. (2000)
European Journal o f  Cancer
“Comorbidity and colorectal cancer according to
subsite and stage: a population-based study”
To investigate comorbidity in colorectal cancer 
patients, by age, sex, Dukes’ tumour stage, treatment 
and short-term survival.
The study used data on 3355 patients with colorectal 
cancer diagnosed in the period 1993-1995 and 
registered in the Eindhoven Cancer Registry (NL). 
Comorbidities were recorded using adapted version o f  
Chari son index.
Approximately 35% o f patients below 70 years o f  age 
and 61% o f patients over 70 years o f age had serious 
comorbidity, these proportions being higher for male 
than females.
After adjustment for age and stage, comorbidity was 
not associated with the resection rate but was 
negatively associated with short-term survival
The authors did not indicate whether patients with 
unknown stage had similar to stage D survival or 
whether their characteristics were similar to any o f  
known stage groups. It was not clear what type of 
modelling or methodology was used to estimate 
survival.
The comorbidity index used number o f  concurrent 
diseases or separate pathologies. It was developed 
and validated on the basis o f  cases in one hospital 
only, and did not use the standard Charlson index. 
Also, under-registration was found for specific 
conditions, particularly cardiovascular -  around 
20% o f cases.
Results indicate co-morbidity has less effect on 
survival in advanced cancers.
68
Table 2.2 Selected articles (continued)
Paper Commentary
VOLUME
Begg C .B .(1 9 9 8 f^
JAMA
“Impact o f Hospital Volume on Operative Mortality 
for major Cancer Surgery”
To determine whether hospital volume was inversely 
associated with 30-day mortality, after adjusting for 
case-mix. Incident cases (1984-1993) were cancer 
patients aged 65 or older (n=5013) who underwent 
major cancer surgery. Retrospective cohort study using 
SEER database using modified version o f Charlson 
index.
Higher volume was linked with lower mortality for 
pancreatectomy, esophagectomy, liver resection, and 
pelvic exenteration but not pneumonectomy. The 
results are particularly noticeable for esophagectomy, 
for which the 30-day mortality dropped from 17.3% 
(95% Cl 13.3%-22.0%) in the lowest volume hospitals 
to 3.4% (95% Cl G.7%-9.6%) in the highest volume 
hospitals. Adjustments for case-mix did not change 
these findings.
The study involved complex surgical procedures for 
which mortality differences were expected to be 
detectable between hospitals. The SEER database 
is only 10% sample o f US population.
A co-morbidity index was derived from SEER 
database records o f up to 5 diagnosis codes and up 
to 3 procedure codes, but completeness and 
reliability o f these were not assessed. Case-mix 
was not adjusted for deprivation category.
‘Volume’ in the model was a continuous variable, 
due to the lack o f sound cut-off points: this implies 
a linear relationship between ‘volume’ and 30-day 
mortality, which may not be the case.
Reliability o f 30-day mortality is not reported.
Schrag D et al. (2 0 0 0 f^
JAMA
“Influence o f Hospital Volume on Outcomes 
Following Surgery for Colon Cancer”
To determine whether hospital volume predicts 
survival following surgery. 27 986 colon cancer 
patients aged 65+ who had surgical resection for 
primary adenocarcinoma, 1991-1996.
Retrospective cohort study o f SEER data linked to 
Medicare database. Hospital volume in quartiles. 
Romano’s modification o f the Charlson comorbidity 
index was used.
Procedure volume was related to overall survival 
(?<0.001) after adjusting for age at diagnosis, sex, 
race, cancer stage, comorbidity, socio-economic status, 
and acuity o f hospitalisation. 5-year overall mortality 
for patients operated on at the very high-volume 
hospitals was 54.8% compared with very low-volume 
hospitals 50.4%. Similar results are obtained for colon 
cancer-specific survival (P<0.001). Comparing 30-day 
mortality data, 45% o f the survival difference can be 
attributed to the immediate postoperative period and 
55% to the later period.
Patients enrolled in a health maintenance 
organisation (HMO) were excluded from the cohort 
(16.5% of patients) because detailed claims are not 
submitted by HMOs to Medicare: this exclusion 
may affect the generalisability o f  study results.
No association between adjuvant therapy and 
procedure volume: differences in dosage and 
intensity o f chemotherapy could not be examined.
Although the association between postoperative 
mortality and hospital procedure volume is 
statistically significant, the absolute difference is 
small (1.7%-2%). Compared with the 7% to 15% 
differences observed by Begg et af^^ for 
pancreatectomy and esophagectomy
In the US, colon cancer surgery is performed at 
many hospitals with very low-case volumes. In this 
study, the top 5% o f  hospitals cared for 25% o f  
patients.
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Paper
Halm E.A. (2ÔÔ2)P 
Ann Intern Med
“Is Volume Related to Outcome in Health Care? A 
Systematic Review and Méthodologie Critique o f the 
Literature”
Systematic review o f the research 1980-2000 years for 
English language on volume and outcomes. 272 
studies reviewed, 137 met inclusion criteria and 
covered 27 procedures and clinical conditions. Mainly, 
in-hospital mortality, however, other clinical outcomes 
were also considered.
Most studies (60%) used administrative data to adjust 
for some combination o f age, sex, and discharge 
diagnoses. Approximately 28% o f studies used clinical 
data in their risk adjustment models; among this group 
only 10 studies (7%) reported risk adjustment models 
that were robustly discriminating and well calibrating.
Overall, 71% o f all studies o f hospital volume and 
69% o f studies o f physician volume reported 
statistically significant associations between higher 
volume and better outcomes. The strongest 
associations were found for AIDS treatment and for 
surgery on pancreatic cancer, esophageal cancer, 
abdominal aortic aneurisms and paediatric cardiac 
care. Volume-outcome relationship for CABG surgery, 
coronary angioplasty, carotid endarterectomy, other 
cancer surgery and orthopaedic procedures was of 
much smaller magnitude._______________________
Commentary
Studies included in systematic review were very 
heterogeneous in terms o f  outcomes employed (in- 
hospital, 30-day mortality, other clinical outcomes), 
units o f analysis (hospital and/or physician volume), 
sample size, methods used, type and degree o f risk 
adjustment and definitions o f ‘high’ and ‘low ’ 
volume employed, which made formal meta­
analysis impossible and affect comparability. Only 
few articles reported on long-term survival.
The review showed that studies that performed 
more complete case-mix adjustment were less likely 
to report a positive effect o f  high volume on 
outcomes. Therefore, it is possible that differences 
in severity o f patients’ condition between hospitals 
and incomplete adjustment for case mix may partly 
explain the observed associations between hospital 
volume and outcomes.
Also, as in case o f literature reviews, in general, it is 
impossible to exclude the possibility o f ‘negative 
publication bias’ that may diminish the number o f  
studies with no or ‘negative’ associations.
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SPECIALISATION
Smith J.A. E. (2 0 0 3 f^
British Journal o f Surgery 
“Evidence o f the effect o f ‘specialization’ on the 
management, surgical outcome and survival from 
colorectal cancer in W essex”
This is the rare study which explored the role o f  
‘specialization’ on colorectal cancer outcomes within 
one region in England. The study took place during a 
time when adjuvant oncological treatment 
(radiotherapy or chemotherapy) was unusual and 
formal multidisciplinary review was not established 
and is therefore predominantly an examination o f  
surgical expertise and management.
5173 patients (including 4562 surgically treated) with 
colorectal cancer diagnosed between 1991 and 1994 
were followed up for 5 years. Details o f referral, 
diagnosis, surgical treatment, postoperative 
complication and outcomes were collected.
There was an association between high volume 
operators (more than 50 operations per year) and 
specialisation. Specialists had lower postoperative 
mortality rate and complications, and better 5-year 
survival.
Improved outcomes following specialist treatment 
persisted, over and above allowance for case-mix 
factors. Benefits in short-term and long-term outcome 
were associated only with surgical caseloads 
exceeding 50 patients per year.
The definition o f a “specialist” may not include all 
surgeons who treat colorectal cancer patients.
Also, defining ‘high volume’ in colorectal surgery 
is subjective, in general, as no evidence-based cut­
off points are proposed in the literature.
Un staged patients were excluded from all 
multivariate analyses. Although they constituted 
very small proportion o f less than 5% o f the data 
set, they may differ from the rest by other factors 
which may affect prognosis.
Multivariate model was adjusted for main known 
predictors o f survival for colorectal cancer patients, 
but not deprivation. Although including a number 
o f significant diseases which could affect the 
outcomes, the comorbidity score employed in the 
model did not reflect severity o f concurrent 
conditions.
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Paper Commentary
STANDARDS
Morris E. ( 2 0 0 4 r
PhD thesis, University o f Leeds
“The Impact o f the Calman-Hine Report on the
Processes and Outcomes o f Care for Yorkshire's
Breast, Colorectal and Lung Cancer Patients”
The study aimed to quantify if  Calman-Hine 
recommendations o f multidisciplinary team formation 
and surgical site specialisation had been translated into 
practice by 2000, in the Yorkshire region o f the UK, 
and were associated with improvements in the 
outcome o f colorectal, breast and lung cancers.
The author studied reported adherence to cancer 
services standards for colorectal cancer patients in 14 
hospital teams in Yorkshire.
Multilevel binary logistic regression models were use 
to assess the associations with the outcome (survival), 
including age, gender and deprivation score 
(ecological), stage (Dukes’) and Calman-Hine 
implementation scores.
A 25% increase in adherence was related to around 8% 
reduction in the risk o f death after 1 and 2-year follow- 
up. The effect remained for colorectal cancers after 
adjustment for age, stage, socio-economic status and 
year o f diagnosis. However, this association was not 
sustained in relation to breast and lung cancers.
No evidence was required by the questionnaire to 
prove the actual compliance with the standard, as it 
was done in a national peer review process. Self- 
reported standards lack validity and may show 
confounding - for example, lower morale in 
hospitals with greater workload or more deprived 
patients.
Standards were summed with equal weighting 
However, individual standards differ in their 
clinical significance, while adding together 
standards will give an undue bias in areas where 
more standards were collected.
A sample survey by the Audit commission in 2001 
showed that about 2/3rds o f  hospitals had 
implemented multidisciplinary teams. The temporal 
relationship between team formation and treatment 
was not defined.
GUIDELINES
Wolfe C.D.A. (1997)''"
European Journal o f Cancer
“Management and Survival o f  Ovarian Cancer Patients 
in South East England”
Effect o f adherence to regionally developed guidelines 
on survival in women with ovarian cancer. A 
prospective audit o f 118 newly diagnosed cases of 
ovarian cancer in seven district health authorities o f  
South East Thames, U.K.
In multiple regression analysis, death was significantly 
more likely in women who had been inappropriately 
managed, those with more advanced disease and those 
with postoperative complications._______________
Despite the development o f  guidelines, 
investigation and management o f ovarian cancer 
varied considerably between hospitals. Pre­
operative and operative management was 
inappropriate for the majority o f  women and this 
significantly influenced survival.
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WAITING TIMES
Richards
British Journal o f Cancer
“The influence on survival o f delay in the presentation 
and treatment o f symptomatic breast cancer”
2964 breast cancer patient admitted to Guy's Hospital 
(London) between 1975 and 1990. Duration of  
symptoms prior to hospital referral was recorded. The 
impact o f delay (defined as having symptoms for 12 or 
more weeks) on survival was measured from the date 
o f diagnosis and from the date when the patient first 
noticed symptoms to control for lead-time bias.
Differences in survival rates were statistically 
significant. Multivariate analyses indicated that the 
adverse impact o f delay in presentation on survival 
was attributable to an association between longer 
delays and more advanced stage. However, within 
individual stages, longer delay had no adverse impact 
on survival. Analyses based on 'total delay (i.e. the 
interval between a patient first noticing symptoms and 
starting treatment) yielded very similar results in terms 
o f survival to those based on delay to first hospital 
visit (delay in presentation).
Recall bias -  patients were asked by questionnaire 
to report on duration o f symptoms. Also, this will 
not completely eliminate the effect o f lead time 
bias, although will minimise it.
Study is limited to one institution.
It was indicated that unspecified number o f patients 
over the period o f the study were entered into 
clinical trials. It is not clear how this would affect 
the results o f the study.
Cut-off points (as admitted by the authors) were 
arbitrary.
Stage was considered but not comorbidity or social 
status adjustments.
Study was not able to define the relative 
contribution o f  patient or GP delay.
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3 MATERIALS AND METHODS
3.1 Study Design
The design of the study is descriptive and observational (analysis of secondary 
data). Five data sets from administrative sources, the cancer registry, and special surveys 
have been assessed for content and reliability, and used to relate colorectal cancer survival 
with predictors at organisational level.
The following datasets have been used:
Cancer Services Peer Review was conducted in 2001. Expert regional teams assessed the 
compliance of cancer units and centres throughout the country with the published cancer 
standards.
Hospital Episode Statistics (HES) contain information on all admitted patients treated in 
National Health Service (NHS) hospitals in England (started 1989 and ongoing). Each 
record includes administrative, clinical and patient information describing the care and 
treatment a patient received while in a hospital.
Acute Hospital Portfolio (AHP) is a collection of ongoing audit reviews which are 
conducted by the Healthcare Commission (previously by the Audit Commission). They 
started audit surveys from 2000/2001 financial year, with the focus on service areas and 
resources and are not cancer specific.
Cancer Waiting Times are collected by NHS Trusts on patients referred by GPs with 
suspected cancer (from 20001/2002 financial year - ongoing). The primary target used up 
until 2005 was the “two week wait”.
Thames Cancer Registry (TCR) is one of (then) 12 population based cancer registries in 
the UK and covers the residential population of London, Surrey, Sussex, and Kent (since
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1960 - ongoing). The registry collects information about new cases of cancer and these are 
linked to death certificates to produce information on cancer prevalence and survival.
Further details and assessment of these datasets are presented in Results chapter (see 4.1).
3.2 Setting
The study was based on 28 NHS acute hospital trusts in London that provide 
colorectal cancer services (see Table 3.1). London is the second biggest region in England 
(after South East region) with population more than 7 million people^^^.
3.2.1 Hospital trusts in London
Hospitals in the National Health Service (NHS) in England are managed as ‘hospital 
trusts’. Many hospital trusts are sited on two or more different hospital locations. Hospital 
trusts are the standard level for analysis of much NHS administrative data and for 
performance management and comparison purposes. According to the NHS London 
Modernisation Board', there are 43 hospital trusts in London which provide hospital and 
mental health services: 27 acute trusts; 10 mental health trusts; 5 specialist trusts; 1 
ambulance trust. Within specialist hospital trusts, there are two trusts which provide 
specialist cancer care -  Royal Brompton and Harefield Hospital NHS Trust and Royal 
Marsden NHS Trust. (The Royal Brompton and Harefield NHS Trust provides specialist 
cardiothoracic, including lung cancer, care and therefore was not included in the study.) St 
Mark’s hospital, which is a part of North West London Hospitals NHS Trust, is a centre for 
intestinal and colorectal disorders.
The Thames Cancer Registry (TCR) contains data on hospital level. A ‘look-up 
table’ was provided by TCR to link individual hospitals into hospital trusts. The other data 
sources used only hospital trusts.
' htu?://\vw\v.lo n d o n .n h s .u k /a h o u tus n l is trus ls .h tn~i
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Table 3.1 List of all hospital trusts in London considered for the study
1. Barking, Havering & Redbridge Hospitals NHS Trust
2. Bamet and Chase Farm Hospitals NHS Trust
3. Barts and The London NHS Trust
4. Bromley Hospitals NHS Trust
5. Chelsea & Westminster Healthcare NHS Trust
6. Ealing Hospital NHS Trust
7. Epsom and St Helier University Hospitals NHS Trust
8. Guy’s & St Thomas’ Hospital NHS Trust
9. Hammersmith Hospitals NHS Trust
10. Hillingdon Hospital NHS Trust
11. Homerton University Hospital NHS Trust
12. King’s College Hospital NHS Trust
13. Kingston Hospital NHS Trust
14. Lewisham Hospital NHS Trust
15. Mayday Healthcare NHS Trust
16. Newham Healthcare NHS Trust
17. North Middlesex University Hospital NHS Trust
18. North West London Hospitals NHS Trust
19. Queen Elizabeth Hospital NHS Trust
20. Queen Mary’s Sidcup NHS Trust
21. Royal Free Hampstead NHS Trust
22. Royal Marsden NHS Trust
23. St George’s Healthcare NHS Trust
24. St Mary’s NHS Trust
25. University College London Hospitals NHS Trust
26. West Middlesex University Hospital NHS Trust
27. Whipps Cross University Hospital NHS Trust
28. Whittington Hospital NHS Trust
Based on agreement with custodians of the datasets, names of individual hospital trusts will 
not be disclosed while presenting the results of the study.
3.3 Study population and time period considerations
3.3.1 Study population: Datasets with hospital level data
Out of five datasets available for the study, the following two datasets contained hospital 
level data.
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3.3.1.1 Acute Hospital Portfolio (AHP)
All NHS acute hospital trusts are covered by the dataset. However, not all indicators within 
the AHP were available for all 28 hospital trusts considered in this study (see Table 4.2).
3.3.1.2 Cancer Services Peer Review
All cancer units and centres at NHS hospital trusts in England are covered by the dataset. 
Out of 28 hospital trusts included in the study, data for 3 hospital trusts have not been 
considered for this part of the analyses, due to differences in structure o f hospitals between 
the Thames Cancer Registry and the Cancer Services Peer Review datasets.
3.3.2 Study population: Datasets with individual (patient) level data
The following three datasets collected data on patient level.
3.3.2.1 Hospital Episode Statistics (HES)
HES contain data on inpatient and day cases admitted to NHS hospitals in England. It 
includes private patients treated in NHS hospitals, patients who were resident outside of 
England and care delivered by treatment centres (including those in the independent sector) 
funded by the NHS".
3.3.2.2 Cancer Waiting Times
Cancer Waiting Times contain data on all urgent GP referrals of patients with suspected 
cancer seen by a specialist. Patients’ records are aggregated at NHS hospital trust level. 
They include patients who may not turn out to have cancer and do not include patients
" http://www.hesonline.nhs.uk/Ease/servlet/ContentServer7siteID=1937&categoryID=456
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diagnosed by another route to have cancer. Data for all 28 NHS hospital trusts included in 
this study were available in the dataset.
3.3.2.3 Thames Cancer Registry
The study used colorectal cancer cases incident in London residents during the six- 
year period 1 January 1996 to 31 December 2001, and followed up until 31 December 
2001. The endpoint of the study was defined as 31 December 2001, and all patients alive 
were censored on that day. Patients who emigrated from the country or were lost to follow- 
up were censored at the time of emigration or loss to follow-up by TCR. This approach 
(‘right censoring’) is a standard practice in cancer survival analysis, to avoid biased over­
estimation of survival by retention in the analysis (as alive) of patients who can no longer 
be followed up to the date of death^.
Patients who satisfied all of the following inclusion criteria were considered during 
the study:
1. Diagnosis of primary colorectal cancer based on ICD-10: C l 8-21
2. London residents
3. Age range 15-99
4. Treated at acute or specialist NHS hospital trusts in London
The TCR dataset contained data on 17493 colorectal cancer incident cases among 
London residents, aged 15-99, during the years 1996-2001.
Patients diagnosed from a death certificate only (DCO) were excluded from analysis 
(548 cases have been excluded in this category). DCO cases cannot be included in survival 
estimates because their date of diagnosis and subsequent follow-up information is not 
known. The direction of any potential bias as a result of this exclusion is unpredictable and 
remains an unresolved issue in cancer survival statistics^^^.
Patients with primary treatment at non-London hospitals or classified as ‘home’;
International Classification o f Diseases, Tenth Revision (http;//vv\v\v 
icd.htni)
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‘hospice’; ‘independent’ (non-NHS) hospitals were excluded from the study, according to 
the inclusion criteria specified above (1442 cases have been excluded in this category).
Three patients with missing deprivation (IMD-2000, income quintile) information 
were excluded, since complete deprivation information was necessary to calculate relative 
survival rates based on sex and deprivation-specific life table.
Also excluded were 35 cases with no information on hospital of treatment.
After taking into account inclusion and exclusion criteria specified above, the final 
study population comprised of 15465 patients treated at 28 hospital trusts in London.
• Hospital of treatment
It is possible for cancer patients to be treated at more than one hospital if they need 
specialist forms of treatment (surgery, radiotherapy, chemotherapy, specialist palliative care 
and so on) available at different places.
There are three potential approaches in allocating the hospital of treatment. One is 
to consider all hospitals where a patient has been treated: however, this approach may lead 
to over-counting of patients and is difficult to employ for practical purposes. A second way 
is to consider hospital of first treatment. Thirdly, hospital of treatment could be assigned to 
the hospital of first attendance.
The TCR data showed that the “hospital of first attendance” variable had no missing 
values, while “hospital of first surgery” and “hospital of highest surgery” (main surgery) 
variables both had more than 11% missing values. Moreover, in more than 98% of cases, 
hospital of first attendance and hospital of first surgery were the same hospitals, and in 
more than 97% of cases hospital of first attendance was the same as hospital of main 
(‘highest’) surgery. Taking into consideration the completeness of data, and the fact that the 
hospital of first attendance was the place of main surgical treatment for more than 97% of 
cancer patients, for research purposes, hospital of first attendance was considered as the 
hospital of treatment.
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3.3.3 Time frame
The most recent available cancer registry data (incident cases 1996-2001, followed 
to 31 December 2001) were used for the study. This time frame allowed estimation of five- 
year survival using ‘complete analysis’ approach (see 3.6.2) and provided adequate power 
(sufficient numbers of events - “deaths”) to conduct survival analysis on hospital level (see 
3.6.4).
For this reason, the time period of the other datasets, if feasible, were chosen to be 
the closest possible to the cancer registry time frame, that is, the period from 2000 to 2002 
years (see Figure 3.1). For three of the data sets, this period was the first period of 
collection. The cancer registry data provided survival at this point, but related to earlier 
incidence and treatment. Therefore, it should be noted that cancer registry data preceded 
most of the organisational data in time.
The study used the data on hospital staffing from the Acute Hospital Portfolio for 
2000-2002 years since no data were available for earlier time periods. Compliance with 
cancer standards was first assessed by the national peer review survey in 2001 (the repeat 
of this survey is currently in process); therefore, this time period was employed in this 
study. Cancer Waiting Times statistics was formally launched in 2001-2002 years. For that 
reason, data for 2001/2002 was used in this study. Finally, to estimate hospital volume of 
patients, only the data from 1997 from the Hospital Episode Statistics were used, since 
special patient identifiers, which allow distinguishing each individual patient admission 
within a year, had been introduced in 1997.
A distinction need to be made between datasets covering ‘calendar’ and ‘financial’ 
year(s). While cancer registry data reflect calendar years, i.e. from C* of January to 3 of 
December, and peer review survey was conducted over 2001, all other datasets reflect 
financial years, i.e. from of April to 3F^ of March (see Figure 3.1).
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Figure 3.1 Time period of datasets used for the study
Datasets
Cancer Services 
Peer review*
Cancer Waiting 
Times**
Acute Hospital 
Portfolio***
Hospital Episode 
Statistics****
Thames Cancer 
Registry*****
1996
*for m ore  inform ation , see  4.1.1 
** fo r m ore inform ation , see  4.1.3 
* * * f o r m ore inform ation , see 4.1.2 
**** for m ore inform ation , see 4.1.4 
* * * * * f o r m ore inform ation , see  4.1.5
1997 1998 1999 2000 2001
Time period covered for the study (years)
2002
3.4 Review of the properties of available databases
The properties o f the datasets were reviewed using Directory o f Clinical Databases 
(DoCDat) assessment tool developed at the London School of Hygiene and Tropical 
Medicine^^^. This provides a framework to determine general characteristics and 
completeness of data.
The assessment covers the following aspects:
1. General aspects of the database, such as when it was set up, who it includes and 
what geographical area it covers;
2. Data set, such as how many individuals are included, data linkage, data security and 
confidentiality and a copy of the data collection questionnaire;
3. Outputs, including who can analyse the data, how frequently standard audit reports 
are produced, and a bibliography of published work;
8 2
4. Management of the database, such as who is involved in running it and who funds 
it;
5. Data quality, including several aspects of the coverage of the data (generalisability
of the data) and the accuracy of the data (validity and reliability of the data):
Coverage
■ Extent to which the eligible population is representative of the country (UK) or 
region (London);
■ Completeness of recruitment of eligible population;
■ Variables included in the database;
■ Completeness of data (the percentage of variables at least 95% complete).
Accuracy
■ Use of explicit definitions for variables;
■ Use of explicit rules for deciding how variables are recorded;
■ Extent to which data are validated.
The assessments were done using the DoCDat proforma adapted for employed 
datasets (see Results chapter and Appendices 11-15). Only 7 out of available 10 data 
quality criteria'^ were used for the assessments due to their relevance to employed datasets. 
Descriptive statistics, analysis of data manuals or dictionaries, other supporting documents, 
information from source websites were used while carrying out assessments. In addition, 
custodians of dataset were contacted, when appropriate, to clarify any unclear issues. Also, 
literature search and ‘grey literature’ in form of reports and other documents were used. A 
detailed review of the properties of the available datasets is attached (see Results chapter 
and Appendices 11-15).
http://www.docdat.org
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3.5 Model specifications
Donabedian’s classic studies in quality of health care identified three dimensions: 1) 
structure; 2) process; and 3) outcome^^’^ ’^^ ^
Structure
The ‘structure’ component relates to the conditions under which care is provided. These 
may include material resources such as facilities and equipment; human resources such as 
the number, variety, and qualifications of staff; organisational characteristics such as the 
organisation of the medical and nursing staff; and the presence of teaching and research 
functions.
Process
The ‘process’ component relates to the activities that constitute health care, including 
diagnosis, treatment, rehabilitation, prevention, and patient education, usually carried out 
by professional personnel, but also including other contributions to care, particularly from 
patients and family.
Outcomes
The ‘outcomes’ component is taken to mean changes, desirable or undesirable, in 
individuals and populations that can be attributed to antecedent health care. These may 
include changes in health status; ehanges in knowledge and behaviour of patients and 
family members that may influence future health; and satisfaction of patients and their 
family members with the care received and its outcomes.
3.5.1 Study model
This framework served as a basis for the model to assess organisational 
determinants of survival for colorectal cancer in London. In addition, case-mix adjustment 
has been introduced because outcomes partly depend on the severity of patients admitted to 
hospital. Particularly, these three dimensions of structure-process-outcomes of care (plus
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‘case-mix adjustment’) were incorporated into four main parts of the model, as shown in 
Figure 3.2, depending on the type of data available for the study: hospital level indicators 
(structure and process of care); clinical treatment (process of care); individual level 
indicators (patient case-mix); and outcome (five-year relative survival).
This means that the relationship between various indicators of structure or process 
of care and cancer survival has been assessed after adjustment for patients’ case-mix (thus, 
the solid lines in the model, from both ‘hospital level indicators’ and ‘clinical treatment’ 
parts towards the ‘individual level indicators’ part). The explanation of ‘dotted line’ 
between ‘hospital level indicators’ and ‘clinical treatment’ parts is given below (see 3.5.3).
The assessment is mainly directed towards exploring the predictors of survival 
using routinely collected data. The choice of indicators considered in the model was based 
on findings from the review of the literature (see 2.5, Review o f the literature chapter) and 
sources of data available for the study (see 4.1, Results chapter).
Model also specifies key indicators which have been identified through the 
literature review as potential important determinants of the outcomes of cancer care, but 
which were not available for the study: (a) ‘specialisation’ under ‘hospital level indicators’ 
(see 2.4.3, Review o f the literature chapter); (b) ‘adjuvant therapy: radio- and chemo­
therapy’ under ‘clinical treatment’ (see 2.3.5, Review o f  the literature chapter) ; (c) 
‘comorbidity’ under ‘individual level indicators’ (see 2.3.4, Review o f the literature 
chapter); and (d) ‘emergency admission’ under ‘individual level indicators’ (see 2.3.5, 
Review o f the literature chapter). Further considerations of these limitations of the study 
are provided in Discussion chapter.
Another important issue to take into account while considering the model is the 
temporal relationships between its data elements. One of the main limitations of the current 
study was that the patients’ treatment preceded the organisational data in time. The 
underlying assumption was that compliance with cancer standards or other organisational 
determinants estimated in 2000-2002 reflected similar values across the five years for 
which patients were first accrued. The issue of temporality was introduced in the Review o f  
the literature chapter (see 2.2.2), then presented in Materials and Methods chapter (see 
3.3.3), and further reviewed in Discussion chapter (5.3.5). Time periods covered by 
indicators, if applicable, are indicated in brackets. This was particularly relevant to 
‘hospital level indicators’. ‘Individual level indicators’ and ‘clinical treatment’ were 
available from the Thames Cancer Registry. For this reason, time period covered by
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registry data (1996-2001) is only indicated under the ‘outcome’ part of the model.
All sources of data were linked together at NHS hospital trust level and a single 
dataset had been created which contained all indicators considered within the model (see 
Results chapter). Due to confidentiality, no individual identifiers were provided for either 
the HES dataset or the cancer registry data, so it was not possible to link them at individual 
(patient) level.
3.5.2 Hospital level indicators
Hospital level ‘structure o f  care ’ indicators included (1) compliance with 35 
colorectal cancer-specific MDT standards; (2) several indicators of medical and nurse 
staffing level; and (3) teaching status of hospital trusts. Except for ‘teaching status’ and 
‘staffing level’ indicators, which refer to the hospital trust, in general, all other indicators 
were colorectal cancer-specific. ‘Teaching status’ refer to the organisation and functioning 
of the hospital trust as a whole. Regarding general staffing level, the underlying assumption 
was that general staffing level reasonably reflects cancer staffing, since no systematic 
information on specialisation is available in England, and most colorectal cancer patients 
are managed by general healthcare personnel (not colorectal cancer-specific).
Hospital level ‘process o f  care ’ indicators included (1) waiting time -  ‘meeting two 
week wait’ target; (2) hospital volume of cases; and (3) specialisation -  not available for 
the study. Although the literature mainly supports the belief that specialist care is associated 
with improved outcomes in cancer care, there is no systematic information on specialisation 
in the UK. Therefore, the effect of ‘specialisation’ per se, meaning ‘specialist surgeon’ -  
the main concept discussed in the literature, was not considered in the analysis. However, 
some of the cancer standards which considered under the ‘structure of care’ hospital level 
indicators, reflect the organisation of multi-disciplinary teams, which specifically aim to 
provide specialist care to cancer patients in England. Therefore, the impact of ‘specialist 
teams’ within the ‘compliance with cancer standards’ have been assessed in the model.
3.5.3 Clinical treatment
The ‘Clinical treatment’ part of the model reflects indicators of process o f  care (see 
4.1.5, Results chapter, for detailed description of variables). They included (1) type of
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surgery and (2) adjuvant therapy -  radio- and chemo-therapy. TCR data contain limited and 
insufficient information on clinical treatment: only broad categories of (mainly surgical) 
treatment are recorded. Also, the information on adjuvant therapy was largely missing or 
not recorded, and, thus, was not considered in the analysis. Therefore, no comprehensive 
analysis of the influence of clinical treatment on survival was carried out. The type of 
surgical treatment was considered as a separate variable, and its impact on survival was 
assessed after adjusting for available patient case-mix indicators.
There is also a possibility of a ‘hospital’ effect working through ‘treatment’ (thus, 
the dotted line in the model), but due to limited treatment information potential interactions 
between hospital level indicators and indicators of ‘clinical treatment’ were not considered 
in this study.
3.5.4 Individual level indicators: patient case-mix
The ‘Individual level indicators’ part of the model reflects patient case-mix. Patients 
vary in their medical and social characteristics, features that can of themselves influence 
outcome either independently of process or structure or by interacting with them. This 
necessitates correction for differences in such characteristics -  a procedure known as “case- 
mix adjustment”. The following variables were drawn from the TCR and used for case-mix 
adjustment:
a) age
Patients’ age was divided into 6 categories: 15-39; 40-49; 50-59; 60-69; 70-79 and 80-99 
years old, in accordance with the current national cancer statistics produced by OHS'".
b) sex
Sex of patients was entered into the model as a categorical variable: male and female.
c) tumour stage (see 4.1.5, Results chapter, for detailed description)
http://www.statistics.gov.uk/statbase/Expodata/Spreadslieets/D7899.xls
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d) indicator of social deprivation (IMD 2000 income quintile)
In the absence of individual data on personal conditions in the cancer registry, the 
socioeconomic status of cancer patients is routinely determined using an ecological 
approach. A census-derived or area-based score reflects aspects of material deprivation or 
socioeconomic status in the geographic area in which a person resides
In this study, social deprivation was measured by income domain of the Index of 
Multiple Deprivation 2000 (IMD 2000)^^^. The IMD 2000 income domain score was 
calculated based on electoral ward of residence as defined in 1998. Its purpose is to show 
proportions of the population experiencing income deprivation in an area. The income 
domain is the most comparable one to Carstairs index, and according to ONS, "in general, 
the same pattern of health inequalities exist using either the Townsend Index or the Index 
of Multiple Deprivation 2000" The indicators in this domain are in the form of non­
overlapping counts of people in families in receipt of means tested benefits'":
• Adults in Income Support households (DSS) fo r  1998
• Children in Income Support households (DSS) fo r  1998
• Adults in Income Based Job Seekers Allowance households (DSS) fo r  1998
• Children in Income Based Job Seekers Allowance households (DSS) fo r  1998
• Adults in Family Credit households (DSS) fo r  1999
• Children in Family Credit households (DSS) fo r  1999
•Adults in Disability Working Allowance households (DSS) fo r  1999
• Children in D isability Working Allowance households (DSS) fo r  1999
• Non-earning, non-ISpensioner and disabled Council Tax Benefit recipients (DSS) fo r  1998 apportioned to 
wards
Based on the literature, another important factor which may influence the outcome 
of cancer care is the type of admission of patients to the hospital (elective vs. emergency).
It has been shown that up to a third of colorectal cancer patients are admitted as emergences 
and over 20% of those patients died within a month after operation (see 2.3.5, Review o f  the 
literature chapter). However, due to confidentiality policies, it was not possible for this 
study to link HES data with cancer registry data on individual level; only hospital-level 
linkage has been conducted. For this reason, the information on urgency of admissions 
could not be considered in the analysis.
For similar reasons, the information on patients’ comorbidity, contained within the 
HES dataset, was not used for the analysis. The lack of adjustment for comorbidity and the
Indices o f Deprivation 2000. Regeneration Research Summary, Number 31, 2000. Department o f  the 
Environment, Transport and the Regions.
possible impact of unknown confounders on study results are considered in Discussion 
chapter.
However, as indicated above, tumour stage, as well as age, sex and social 
deprivation (IMD 2000, income quintile) have been accounted for in the model as 
indicators of patient case-mix. The impact of all organisational determinants of outcomes 
assessed in this study has been considered after adjustment for these factors. Also, it should 
be noted that the study used relative survival as outcome measure, while most studies in the 
literature used crude survival. Relative survival estimates take into account background 
(non-cancer specific) mortality, and thus, to some extent, indirectly reflect the presence and 
impact of comorbidity on population level.
3.5.5 Outcome (dependent variable) - five-year relative survival
To compare performance of healthcare institutions, most studies in the literature 
have used short-term mortality rates, e.g. in-hospital mortality, 30-day mortality. However, 
in contrast to most chronic diseases, long-term mortality (or survival) for cancer can be 
measured and is being routinely monitored through cancer registration. In the present study, 
the main outcome indicator (dependent variable) was five-year relative survival, as 
measured based on cancer registry data.
Other outcome measures, such as cancer recurrence rate, quality of life after 
discharge, postoperative complications (or complications after chemo- or radio-therapy) are 
not addressed here, since routinely collected data for these indicators are not available. 
Another measure of the outcome of care, patient experience of care, as measured based on 
the National Cancer Patient Survey^^\ could be a subject for a separate study. It should be 
noted that the information on selected indicators of patients’ experience of in-hospital care 
was missing for more than a half of hospital trusts included in the study.
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Figure 3.2
PROPOSED MODEL FOR ASSESSMENT
Five-year relative 
survival 
(1996-2001)
Outcome
(see 3.5.5)
Process o f care:
• Type o f  surgery
• Adjuvant therapy (N/A);
Radiotherapy
Chemotherapy
Clinical treatment
(see 3.5.3)
Patient case-mix:
•  Age
• Sex
• Tumour stage (Dukes’)
•  Social deprivation (IMD 
2000, income quintile)
• Comorbidity (N/A)
• Emergency admission 
(N/A)
Individual level indicators
(see 3.5.4)
Structure o f  care:
• Compliance with cancer 
standards (2001)
•  Staffing level (2000/01- 
2001/02)
•  Teaching status 
(assigned)
Process o f care:
•  Waiting time (2001/02)
•  Volume ( 1997/98- 
2000/01)
•  Specialisation (N/A)
Hospital level indicators
(see 3.5.2)
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3.6 Statistical considerations/methods
Statistical analyses were conducted using Stata statistical package (Intercooled Stata 8).
3.6.1 Data management
Data have been checked for completeness, unusual reporting frequencies and 
inconsistencies. Data errors and missing values have been verified by contacting custodians 
of appropriate data sets.
3.6.1.1 Handling missing data
Three approaches were used in this thesis to handle missing values, particularly for 
tumour stage (20.9% of missing values) and type of surgical treatment (11.6% of missing 
values).
Firstly, the study used ‘complete case analysis’, which means that cases with 
missing values are excluded from analyses. However, this approach excludes a proportion 
of patients from analyses and implies ‘missing at random’ assumption, which is difficult to 
prove.
Secondly, analyses of potential predictors of survival were repeated by creating an 
additional ‘not known’ category for each variable with missing values. Although widely 
used in the literature, the latter approach was shown to produce biased estimates with 
unpredictable results^*^’^ ^^ .
Thirdly, analyses of potential predictors of survival were repeated using multiple 
imputation approach, which is suggested as a method of choice in dealing with missing 
data^ "^^ . A five-fold multiple imputation was applied to the data used for modelling analyses 
to accommodate particularly missing tumour stage data. Multiple imputation is an unbiased 
method of imputing plausible values using an imputation model when data are missing at 
random^^ '^^^^. Even when data are not missing at random, multiple imputation has been 
shown to perform well^^ .^ With multiple imputation, the uncertainty about the missing data 
is accommodated, as a number of complete data sets are created. It has been shown to be 
superior to the ‘complete case’ approach which analyses only cases for which no
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information is missing, or the ‘indicator’ approach where missing data are grouped into a 
separate category in regression analyses^*^. ‘Rubin’s rules’ enable the recombination of 
multiple imputed estimates and their variances to provide one ‘complete data’ estimate and 
confidence interval for each parameter in the model^^^. The method of multiple multivariate 
imputation of missing values was employed using Royston’s programme developed for 
Stata statistical package^^^. However, this method is still under development and only 
recently became available to use with Stata statistical package for categorical variables^^^.
3.6.1.2 Categorisation
To simplify interpretation, continuous variables, such as ‘volume of patients’, 
‘staffing level’ and ‘meeting two-week wait target’, were grouped into discreet categories.
It should be noted that no agreed or clinically important cut-off points for these variables 
are suggested in the literature. As there do not appear to be logical (in a clinical sense) 
divisions, the values were ordered and split into quartiles. In addition, income domain of 
IMD 2000 had been assigned to individual patients within the Thames Cancer Registry in 
form of quintiles of ward-level deprivation scores. This approach is advantageous from the 
statistical viewpoint as it ensures reasonable numbers in each category.
The relationship between predictors and outcomes is based on pooled data for all 
trusts, as is usual for regression modelling (including relative survival modelling). The 
number of patients is divided into equal quartiles based on predictor values. Because Trusts 
are of different sizes, the total of Trusts may differ.
Alternatively, the actual values themselves could be considered and risks calculated, 
for example, per 1 % increase in meeting two-week wait target. In many way such an 
approach is better as it ‘uses all the data’, but the statistical methods for analysis would 
assume that the risk is linear, which may not be the case^^\
3.6.2 Choice of the method for survival analysis
The presence of censored data (cancer registry data) makes analytic techniques which 
handle censored observations the main methods to use.
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In traditional survival analysis of failure-time data, the proportion of subjects who 
have not yet experienced the event of interest is calculated for one or more time points after 
they are first exposed to the risk of experiencing the event. In such ‘cohort’ analyses, each 
subject in the study population has the potential to be followed for an equal and fixed 
period of time. Consequently, survival probabilities at a given interval since diagnosis 
cannot be calculated until the full period of follow-up has elapsed and the potential follow- 
up time of all subjects is equal to, or exceeds, the interval of interest. For this reason, cohort 
measures of cancer survival are less up-to-date than concurrent measures of incidence or 
mortality. This is because, for example, the proportion surviving five years after their 
cancer diagnosis can only be established from patients who were diagnosed five or more 
years ago, whilst the incidence and mortality rate can be calculated from the most recent 
data available.
Complete analvsis of survival includes in the calculation the experience of patients 
who have not had the opportunity to be followed for the full period o f time. A complete 
analysis of five-year survival would include the probability of surviving one year estimated 
from the experience of patients diagnosed up to one year ago, the probability of surviving 
two years from patients diagnosed up to two years ago, and so forth. Where survival is 
improving, or where an effective new treatment has been recently introduced, survival 
estimates using this method are higher than those obtained using the cohort method. This is 
because the estimation of the survival probability includes more recently diagnosed patients 
who have higher survival. Accordingly, complete estimates are more up-to-date than cohort 
estimates of survival. In this study, complete estimates of five year survival were estimated 
for patients diagnosed during 1996-2001.
Traditionally, in the literature, Kaplan-Meier crude survival estimates and Cox 
proportional hazards models are used to analyse survival data. However, these methods do 
not take into account population background mortality. For this reason, relative survival 
modelling and its estimates were the methods of choice in this study.
Relative survival is the ratio of the survival observed in a group of cancer patients to 
the survival expected if they were only subject to the general (all cause) mortality in a 
standard population. Relative survival may be interpreted as survival corrected for 
background mortality Relative survival takes into account the underlying mortality in the 
population from which the cancer patients are drawn, and can be used to adjust for
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differences and trends in background mortality in each age, sex and socioeconomic group 
and over time.
The cumulative relative survival rates by hospital trusts were calculated according 
to the Esteve’s maximum likelihood method using the ‘streT program^^^’^ ^^ . Also, 95% 
confidence intervals for cumulative relative survival rates were estimated.
3.6.3 Multivariate relative survival model
The impact of potential predictors on survival has been examined using a 
multivariate relative survival model (generalised linear model) as described by Dickman et 
al In such a model, the risk function is the sum of an expected mortality risk 
(background mortality) and an excess mortality risk which represents the effect of the 
cancer since its diagnosis. The background mortality is that would have been expected for 
patients with the same characteristics (namely, age, sex, calendar period, deprivation 
category) as the general population and were taken from sex, calendar period (1996- 
2001) and deprivation-specific London life table
As was indicated earlier in this chapter, five-year relative survival has been 
considered as the main outcome measure. The relationship between potential predictors and 
five-year relative survival has been assessed using the estimates of relative excess risk of 
death (RER)''". The estimates of RER were calculated after adjustment for differences in 
years of follow-up, age, sex, deprivation category and tumour stage. The statistical 
significance of each of these case-mix variables was initially tested in the univariate 
relative survival model.
Bivariate correlations among all covariates were examined to avoid potential 
problems due to collinearity, which might confound the analyses^^^’^ ^^ . Collinearity inflates 
the variances of the parameter estimates, and may reduce statistical significance of 
individual independent variables while the overall model may be strongly significant. 
Collinearity may also result in wrong signs and magnitudes of regression coefficient
T h e  e x ce ss  r is k  o f  d e a th  in a  g iv e n  g ro u p  o f  p a tie n ts  w ith in , say , f iv e  y e a r s  o f  d ia g n o s is  is  th e  r is k  o f  d e a th  o v e r  a n d  
a b o v e  w h a t w o u ld  h a v e  b e e n  e x p e c te d  i f  th e y  h a d  e x p e r ie n c e d  o n ly  th e  d e a th  ra te s  see n  in th e  g e n e ra l  p o p u la t io n  fo r  th e  
s a m e  a g e , sex  a n d  d e p r iv a tio n . T h e  r e la t iv e  e x ce ss  r isk  o f  d e a th  r e f le c ts  th e  e x te n t to  w h ic h  th e  e x c e s s  r is k  o f  d e a th  d if f e r s  
f ro m  th e  e x c e s s  risk  in a  b a s e l in e  g ro u p , a f te r  a d ju s tm e n t fo r  o th e r  c o -v a r ia te s .
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estimates, and consequently in incorrect conclusions about relationships between 
independent and dependent variables.
Standard errors were adjusted for a clustering effect of hospital trusts (using the 
‘robust cluster’ command in Stata). It adjusts for ‘nested’ effects within trusts: for example, 
cancer patients within a specific trust might be more similar to each other (perhaps with 
similar referral patterns, or catchment areas) as compared with the whole population of 
cancer patients Failure to adjust for clustering by hospital trust could lead to 
underestimation of standard errors
The relationship was considered as statistically significant when p  < 0.05 (or 95% 
confidence interval (Cl) did not contain “1”). Likelihood-ratio and Wald tests were used to 
compare the goodness of fit o f models and assess statistical significance of categorical 
variables within the survival model. The relationships between various independent and 
dependant variables were also assessed by Spearman rank correlation tests.
As with the Cox proportional hazards model, the key assumption here is that the 
relative excess risk of the event in any group is a constant multiple of the risk in any other. 
This assumption implies that the relative excess risk curves for the groups should be 
proportional and cannot cross. ‘Proportional hazards’ assumptions were tested by creating 
interaction terms of covariates with the follow-up time (time dependent covariates) and 
assessing their statistical significance. If the interaction term for any of covariates assessed 
was statistically significant, then it was considered a violation of the assumption and 
therefore left in the modeC".
For comparative purposes only, the assessed relationship was also tested using a 
Cox proportional hazards model, taking into account that this method is traditionally used 
in the research of cancer outcomes. However, the results obtained using these two methods 
were generally similar, and hazards ratios from the Cox model are indicated in few 
examples with cancer standards, for illustrative purposes only (see Results chapter).
http://\v\vw.ats.ucla.edu/staFstata/faq/test propoitionality.htm
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3.6.4 Sample size and statistical power considerations
The power of a survival analysis is related to the number of events rather than the 
number of participants. According to the literature, simulation work has suggested that at 
least 10 events (“deaths”) need to be observed for each covariate considered, and anything 
else will lead to random instability and then unreliable estimates With the total sample 
size of 15465 patients treated at 28 hospital trusts and number of events (“deaths”) equal to 
8059, this study had enough power to determine the effect of each covariate considered.
3.7 Ethical permission
No contact with patients was sought or required, and patient identifiers were not 
needed. Therefore, formal ethical approval was not necessary for this study. However, as 
was noted before, current research work was related to the MQiCS study which was 
sponsored by Department of Health and received permission from the South East Research 
Ethics Committee^^^.
Permission to gain access to the data was obtained from custodians of each dataset 
employed in the study.
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CHAPTER 4
RESULTS
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4 RESULTS
Introduction
The focus of this chapter is to describe the datasets providing hospital and 
individual data relating to colorectal cancer survival in London, and to present analyses of 
the data. Because these datasets were assembled for the first time in this way for this study, 
and because only certain parameters were eventually drawn for the explanatory analysis, 
details are presented here in the Results, showing the feasibility of the datasets for the 
study.
Cancer registry data provide individual level factors, such as age, sex, social 
deprivation and tumour stage. They also contain information on clinical treatment of 
patients received within the first six months after diagnosis, and the place of treatment. 
Further hospital explanatory variables were sought from outside the cancer registry dataset, 
using existing data that were already collected nationally, and that were available for the 
London region. The five datasets employed to draw hospital level indicators, along with 
indicators of clinical treatment, were Cancer Services Peer Review, Acute Hospital 
Portfolio, Cancer Waiting Times, Hospital Episode Statistics, and Thames Cancer Registry.
4.1 Datasets for the explanatory variables
The literature review indicated that using routine or administrative datasets for 
research purposes has limitations depending on content and the quality of data. Therefore, 
before exploring hospital level indicators within the frame of the proposed model, it was 
necessary to consider the feasibility of using these datasets for the study.
As indicated in the Methods chapter, the properties of the datasets were reviewed 
using DoCDat assessment tool. The feasibility of using the datasets was considered 
depending on whether necessary parameters (predictors) identified by the literature review 
were in datasets, and whether they are reliable enough to use in the model and draw 
conclusions. Detailed assessments using the DoCDat approach are provided in Appendix 1. 
Key summary results are presented below. Further discussion on the feasibility of using 
available routine datasets to investigate hospital-level determinants of survival for
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colorectal cancer in London is provided in the Discussion chapter.
Data quality (coverage and accuracy) was assessed using a 4-point scale, where “4” 
indicates the highest level of quality, and “ 1” - the lowest level of quality, in accordance to 
DoCDat assessment tool'^ (see Figures 4.1 - 4.10).
4.1.1 Cancer Services Peer Review
The Peer Review was undertaken in 2001. It was based on the Manual of Cancer 
Services Standards'"^ published by the Department of Health in 2000, and which had 
developed standards based on professional advice. The Peer Review assessed the 
compliance with the standards by cancer units and centres in hospital trusts throughout the 
country. It was undertaken by visiting teams of clinicians and healthcare professionals, 
organised regionally.
Source: The Cancer Services Peer Review (2001) dataset was provided by the NHS Cancer 
Action Team.
Content: The Peer Review dataset contains data on compliance with all standards specified 
within the Manual. There were altogether around 200 standards which covered 10 topics for 
each main cancer types. The topics assess compliance with non cancer type-specific 
standards, such as patient centred care, diagnostic services, oncology, radio- and chemo­
therapy, training, communication, and tertiary services. Only standards on multi­
disciplinary teams (MDT) were designed for particular cancer types (breast, colorectal, 
lung and gynaecological cancers).
Variables chosen for the study: The 35 colorectal cancer-specific MDT standards were 
included in analyses. In the Cancer Standards Peer Review, teams assessed compliance 
with standards as absent, partially present or fully present. Relatively few standards were 
recorded as completely absent, so it was chosen to amalgamate contrast absent/partially
http://www.docdat.org
99
present against full compliance.
The Standards are grouped in themes in the Manual: some of these standards are 
different in character, others are overlapping (see Table 4.1). Moreover, they differ in their 
clinical importance in relation to outcome as opposed to organisational arrangements. 
Therefore, along with the composite score for all 35 standards, it was subsequently decided 
to analyse all 35 of them separately in the model.
Coverage: All cancer units and centres in England are covered by the dataset. Six regions 
used the final version of the cancer services standards (Manual of Cancer Services 
Standards, 2000), while Eastern Region used the draft version and Trent used "Trent 
Standards". London used the national version.
Out of 28 hospital trusts included in the study, data for 3 hospital trusts could not be 
included in the analysis of associations o f compliance with cancer standards and survival, 
because o f differences in structure of hospitals between the Thames Cancer Registry and 
the Cancer Services Peer Review datasets. Therefore, only data on 25 hospital trusts in 
London were considered in the model.
Figure 4.1 Cancer Services Peer Review data quality: Coverage*
Cancer Services Peer Review data quality: Coverage
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Accuracy: Clear definitions of all variables are available in the Manual, although no clear 
rules on how to code variables in the dataset were specified. However, the “Manual of 
Cancer Services Standards” (Department of Health, 2001) sets out for each standard the 
information that would demonstrate that the standards have been complied with. No 
published information has been identified as to whether data have been validated.
Figure 4.2 Cancer Services Peer Review data quality: Accuracy*'
Cancer Services Peer Review data quaiity: Accuracy
Explicit definitions Explicit rules 
DoCDat criteria
Data validation
assessed using DoCDat 4-point scale (http://www.docdat.org)
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Table 4.1 shows definitions of the standards taken from the Manual of Cancer 
Services Standards (2000)
Table 4.1 The list of colorectal cancer MDT standards (extract from the Manual of
Cancer Services Standards, 2000*“*)
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4.1.2 Acute Hospital Portfolio
The Acute Hospital Portfolio (AH?) is an annual, rotating national collection of 
selected indicators in acute hospital trusts in England and Wales. They are not cancer- 
specific and have a focus on key service areas or resources, e.g. medical and ward staffing, 
radiology and so on. The data sets were developed to assist the work of the Audit 
Commission (Healthcare Commission) from 2000/2001 financial year onwards.
Source; The Acute Hospital Portfolio (2000 - 2002) dataset was received from the former 
Audit Commission (AC), currently Healthcare Commission (HC).
Content: Literature suggested that levels of staffing may influence the outcome of health 
care, including cancer survival. The evidence, however, is equivocal, as shown in Review o f  
the Literature chapter.
The data of the earliest period of AHP (for 2000/2001-2001/2002 financial years) 
were used in this study, since it was the most comparable with other datasets in relation to 
time period covered. Within that time period, the following national reviews on various 
indicators of staffing level were published by Audit Commission/Healthcare Commission 
(indicated years are ‘financial’ years -  of April to of March) and available in Acute
Hospital Portfolio:
• Medical Staffing 2001/02
• Radiology 2001/02
• Ward Staffing 2000/01 ; 2004/05
Variables chosen for the study: There were many variables available in Acute Hospital 
Portfolio for each specific topic. For instance, only one field of ‘Medical Staffing’ 
contained more than 190 variables. Only selected indicators which reflect medical, ward or 
radiology staffing level, were considered because of their relevance to study objectives, in 
relation to the literature findings, and completeness. They were presented as rates and are 
not cancer-specific.
The general staffing level indicators selected for the research are:
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• medical WTE^" per 1000 admissions;
• consultant WTE per 1000 admissions;
• medicine consultant WTE per 1000 admissions;
• anaesthetist consultant WTE per 1000 admissions;
• pathology consultant WTE per 1000 admissions;
• radiology consultant WTE per 1000 admissions;
• radiographers per 1000 FCEs^'";
• clinical nurse specialists per 1000 FCEs.
There are no agreed (from research or clinical practice point of view) cut-off points 
as to what level of staffing is appropriate, sufficient or necessary target to achieve. For this 
reason, and to simplify interpretations, staffing level variables were used as categorical, 
divided into quartiles, where the quartile is the lowest level and 4^  ^quartile -  the highest 
level of staffing.
Coverage: All NHS acute hospital trusts in England are covered by the dataset. Eiowever, 
not all indicators within the AHP were available for all 28 hospital trusts included in the 
study (see Table 4.2). According to personal communications with the representatives of 
the Healthcare Commission, this was due to the failure by some trusts to provide the data. It 
was often unclear whether the absence of data was due to it being missing or not relevant.
For two Trusts (Barking, Havering & Redbridge Hospitals NHS Trust and Barnet 
and Chase Farm Hospitals NHS Trust), mean of estimates for hospital sites within the Trust 
was presented, since in the dataset they were separated according to the sites.
Whole time equivalent (WTE)
' Finished consultant episode (FCE)
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Table 4.2 Number of hospital trusts available for each indicator of staffing level
Indicator No. o f hospital trusts
Radiographers per 1000 FCEs 27
Radiology consultant WTE per 
1000 admissions
25
Consultant WTE per 1000 
admissions
25
Medicine consultant WTE per 
1000 admissions
25
Anaesthetist consultant WTE per 
1000 admissions
25
Pathology consultant WTE per 
1000 admissions
25
Clinical nurse specialist WTE 
per 1000 FCEs
24
Medical WTE per 1000 
admissions
23
Figure 4.3 Acute Hospital Portfolio data quality: Coverage*
Acute Hospital Portfolio data quality: Coverage
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Accuracy: The definitions of most of variables are provided in national overview reports or 
published guides to indicators. Clear rules on how to code variables in the dataset were 
available for indicators of medical staffing and radiology, but not for ward staffing. No 
published information has been identified as to whether data have been validated.
assessed using DoCDat 4-point scale (http://www.docdat.org)
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Figure 4.4 Acute Hospital Portfolio data quality: Accuracy’
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4.1.3 Cancer Waiting Times
Cancer Waiting Times Statistics (2001/2002) contain data on the waiting time of 
patients with suspected cancer and those subsequently diagnosed with cancer. Data are 
submitted quarterly by hospital trusts. For study purposes, quarterly data have been 
summed into annual data.
Source: Cancer Waiting Times Statistics was received from the NHS-Cancer Action Team; 
also available on the Department of Health website: 
http://www.performance.doh.gov.uk/cancerwaits/
Content: Cancer Waiting Times Statistics monitors the following waiting time targets:
• ‘Two week wait’ from urgent GP referral to first outpatient appointment for all 
patients with suspected cancer.
• ‘One month wait’ from urgent GP referral to treatment for children’s cancers, 
testicular cancers and acute leukaemia.
• ‘One month wait’ from diagnosis to treatment for breast cancer.
• ‘Two month wait’ from GP referral to treatment for breast cancer.
• ‘One month wait’ from diagnosis to treatment for all cancers.
assessed using DoCDat 4-point scale (http://www.docdat.org)
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• ‘Two month wait’ from GP referral to treatment for all cancers.
Variables chosen for the study: As indicated in previous section, several waiting time 
targets are currently monitored by Department of Health. However, only two week cancer 
waits were used in this study. It was the only target monitored in relation to lower 
gastrointestinal cancer patients in 2001/2002 financial year; and the time period was 
comparable with other datasets.
Waiting time is defined as a percentage of meeting two week wait standard from 
urgent GP referral to first outpatient appointment for all patients with suspected lower 
gastrointestinal cancer for 2001/2002 financial year. It is impossible to differentiate cancer 
sites under ‘lower gastrointestinal cancer’ though it is assumed to reasonably reflect waiting 
times for colorectal cancer.
To simplify interpretation, compliance with meeting the waiting time standard was 
considered as categorical variable -  divided into quartiles. Separately, the two week wait 
standard was assessed for referrals received within 24 hours, as was presented in original 
dataset.
Coverage: All urgent GP referrals of patients with suspected cancer are included in the 
Cancer Waiting Times dataset, including those whose diagnosis was not subsequently 
confirmed. On the other hand, the dataset does not include cancer patients with non-urgent 
GP referrals and those who admitted to the hospital without GP referral. All 28 hospital 
trusts included in this study, were covered in the dataset. It is difficult to determine to what 
extent the recruitment of eligible population is complete, since it depends on reporting from 
each NHS Trust.
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Figure 4.5 Cancer Waiting Times data quality: Coverage*
Cancer Waiting Times data quaiity: Coverage
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Figure 4.6 Cancer Waiting Times data quality: Accuracy*
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4.1.4 Hospital Episode Statistics
The Hospital Episode Statistics (RES) contain information on all admitted patients 
treated in NHS hospitals in England. The data are captured from hospital patient 
administration systems, and HES now collects around 12 million records per year from all 
hospital trusts in England.
Source: Hospital Episode Statistics received from the NHS Health and Social Care 
Information Service.
Content: Each record contains administrative, clinical and patient information describing 
the care and treatment a patient received while in a hospital. There are more than 160 fields 
available for each patient.
Variables chosen for the study: Due to confidentiality regulations, it was not possible to 
receive data with the level of identifiers to allow linkage with cancer registry at individual 
level. For this reason, the data on comorbidity of patients and type of admission 
(emergency vs. elective), as well as other individual level variables from HES dataset, were 
not used in this study. The average annual volume of colorectal cancer patients at each 
acute and specialist hospital trust in London was estimated based on HES data and used in 
the analyses.
Special patient identifiers were introduced in 1997, to link different episodes of care 
or multiple admissions within a year, thus preventing their over-counting^'^"'. Therefore, 
only data from 1997/1998 to 2001/2002 financial years were used in this study.
There is no agreed definition as to what level of patients’ or procedures’ volume 
should be considered high or low while making volume-outcome assessments in terms of 
management of colorectal cancer patients. For this reason, as well as to simplify 
interpretations, based on data distribution and examples from the literature, the variable 
‘volume’ was considered in the model as categorical variable -  divided into quartiles.
Coverage: HES contain data on inpatient and day cases admitted to NHS hospitals in
’‘‘ ' ‘(hilp:/:;w\vvv jics(in linc ,o rg ,.uk /rasc /sc ry lc l:.C 'o^  1073]< & hcadcrll)
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England. It includes private patients treated in NHS hospitals, patients who were resident 
outside of England and care delivered by treatment centres (including those in the 
independent sector) funded by the NHS^'^. Out of 28 NHS hospital trusts included in this 
study, only data for patients treated in one hospital trust were not available in the HES 
dataset.
Figure 4.7 Hospital Episode Statistics data quality: Coverage*
Hospital Episode Statistics data quality: Coverage
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4.1.5 Cancer Registry
Cancer registration in the UK is conducted by twelve population based cancer 
registries which collect data on cancers incident in residents of their regions.
Cancer registries receive routine (often electronic) notifications from a variety of 
sources. These sources include district general hospitals, cancer centres, hospices, private 
hospitals, cancer screening programmes, other cancer registers, primary care, nursing homes 
and death certificates forwarded by the Office of National Statistics (ONS) to each registry 
on every person dying for whom cancer is mentioned. Data are frequently received from 
several sources within an individual institution (e.g. pathology departments, medical records 
and radiotherapy databases). Increasingly the main sources of data for cancer registries are 
computerised hospital systems within pathology, oncology and other departments.
Death certificates also enable registries to identify cases not registered in life and 
initiate a new registration. Those cases not traced by following up case notes at hospitals 
and treatment centres defined as death certificate only (DCO) registrations.
Source: The Thames Cancer Registry (TCR).
assessed using DoCDat 4-point scale (http://www.docdat.org)
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TCR covers the residential population of London, Surrey, Sussex and Kent, approximately 
14 million. London forms about half the total population.
Content: Colorectal cancer incident cases in London residents during 1996-2001, and 
followed up until the end of 2001, were included. These were the most recent available 
cancer registry data.
The chosen time frame (1996-2001) allowed estimation of five-year survival and 
provided adequate power to conduct survival analysis on hospital level (for details, see 
Materials and Methods chapter).
Variables chosen for the study: Thames Cancer Registry (TCR) was used to derive 
individual level and clinical treatment related indicators. Also, variables necessary for 
survival estimations were drawn from the registry data.
The variables from the TCR dataset used in this study are: age; sex; Index of 
Multiple Deprivation 2000 (income domain) quintile; tumour stage; hospital of first 
attendance/treatment; type of treatment/surgery; date of diagnosis; days to end of follow- 
up; vital status at the end of follow-up. Date of diagnosis; days to end of follow-up; and 
vital status at the end of follow-up were used for survival estimations.
• Individual level variables of patient case-mix
As noted in the Methods chapter, indicators of patient case-mix, such as age, sex, 
tumour stage and social deprivation measured by IMD-2000 income quintile, taken from 
the TCR, were essentially complete, except for ‘tumour stage’ which contained 20.9% of 
‘not known’ values.
There were two tumour stage variables available in TCR dataset: clinical stage 
(mainly Duke’s) and TCR stage. TCR stage is an in-house system which is based on WHO 
recommendations and means that the majority solid tumours are assigned to a stage [TCR, 
personal communication]. This is similar to Dukes’ staging and allows cancer registry 
personnel to assign broad stage groupings as follows (see Table 4.3).
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Table 4.3 Comparisons between Dukes’ and TCR in-house staging system
Dukes’ stage Definition TCR stage Definition
A Tumour is confined to the 
bowel wall
Stage1 Local; The tumour is 
confined to the organ o f  
origin
B Tumour penetrates the 
bowel wall into serosa or 
perirectal fat
Stage 2 Direct extension: The 
tumour has spread to 
surrounding tissues and 
organs
C Lymph node metastasis is 
present
Stage 3 Local nodes: There is 
local nodal involvement
D Distant metastasis is 
present
Stage 4 Métastasés: Distant 
métastasés are present
For case-mix adjustment, TCR in-house staging was employed since it contained 
only 20.9% ‘not known’ entries as compared to more than 42% of ‘missing’ values and 
‘not known’ entries under the clinical stage variable.
Income quintile of IMD 2000 was routinely assigned by TCR to cancer patients’ 
registration. This facilitated linkage between TCR data and sex and deprivation specific life 
table to estimate relative survival.
■ Clinical treatment
Thames Cancer Registry contained information on surgical treatment and adjuvant 
therapy (radiotherapy and chemotherapy).
Data on type of surgery were available for all 28 hospital trusts included in the 
analyses. It was divided into broad surgical categories at initial intervention. No 
information on specific surgical operations was available for the study. Type of treatment 
(surgery) variable was considered in the model in two ways -  as divided into two or five 
categories. Categories were defined according to information recorded by the registry.
Type of treatment (2 categories):
1. Any surgical operation;
2. Investigative procedure only
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Type of surgery (5 categories):
1. Total removal of organ -  ‘radical’;
2. Partial removal of organ -  ‘radical/sub-radical’ ;
3. Tumour/lymph node removal -  ‘ non-radical ’ ;
4. Non-tumour removing surgery -  ‘non-radical’ ;
5. Investigative procedures only.
However, information on surgical treatment was missing for 1793 patients (11.6%). 
In addition, information on radiotherapy or chemotherapy was overwhelmingly missing in 
the dataset (in 87.3% and 73.6% cases, respectively), therefore was not used in the analyses 
(see Table 4.4). It was not possible to distinguish whether the data were missing because 
patients did not receive adjuvant therapy or because the information was not recorded. For 
these reasons, the assessment of the impact of surgical treatment on survival within the 
study model has limited explanatory value.
Table 4.4 Completeness of data on clinical treatment
Indicator % of missing values
Type o f surgery 11.6
Adjuvant therapy 
Radiotherapy 87.3
Chemotherapy 73.6
Coverage: Ad hoc studies by the Thames Cancer Registry have shown that the database 
includes 90-97% of the eligible population. Systematic levels of case ascertainment in the 
Registry are impossible to obtain as there is no independent source with which to compare. 
The level of ascertainment can be judged indirectly by the proportion of cases which are 
registered through death certificates only (DCO).
The colorectal cancer patients in this study had a relatively low percentage of DCO 
cases (548 patients - 3%). Even though these cases have been excluded from analysis (see 
Materials and Methods chapter, 3.3.2.3), they have been assessed in terms of distributions 
per hospital trust and correlation with survival.
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Within the cancer registry dataset, most of DCO cases had been assigned to the 
hospital trust of patient’s referral area (498 assigned DCO cases in total) assuming that 
these patients were most probably managed by these hospitals. The information on hospital 
was missing in 50 cases. The percentage of DCO cases per assigned hospital trust varied 
from 0.8% to 10.2% (mean 3.3%; median 2.6%). No significant correlation was found 
between the proportion of DCO cases and 5-year relative or crude survival estimates per 
hospital trust (Spearman coefficient was -0.3279 (p=0.0885) and -0.2803 (p=0.1485), 
respectively). Appendix 1 shows distribution of DCO cases by hospital trust, along with 5- 
year survival estimates.
Figure 4.9 Thames Cancer Registry data quality: Coverage*
Thames Cancer Registry data quality: Coverage
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source documents agreed between the Department of Health and the UK Association of 
Cancer Registries. Likewise, most variables (>97%) have clear rules on how to code them 
in the database.
The Thames Cancer Registry validates its datasets by range and consistency checks, 
plus external validation using an alternative source. Regional registries are required to audit 
a sample of their cases, although this is done infrequently and differently between registers.
assessed using DoCDat 4-point scale (http://www.docdat.org)
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Proposals for a standard audit programme are currently being developed.
Figure 4.10 Thames Cancer Registry data quality: Accuracy^
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s
tf)
Ï  2 
5Q.
Thames Cancer Registry data quality: Accuracy
Explicit definitions Explicit rules 
DoCDat criteria
Data validation
4.1.6 Teaching status of hospital trusts
Although not a separate ‘dataset’, teaching (or ‘academic’ in North America) status 
of hospitals is recognised in the literature as a hospital level determinant o f outcomes.
No agreed or unified definition of ‘teaching hospitals’ has been identified. For the 
purposes o f the study, teaching hospitals were defined as long established or specialist 
hospitals which provide undergraduate and/or postgraduate teaching. Out o f 28 hospital 
trusts included in this study, 11 have been classified as ‘teaching’ hospital trusts and 17 -  as 
‘non-teaching’ hospital trusts (see Table 4.5). This division was based on the categorisation 
of hospital trusts employed by the Healthcare Commission^^'''.
assessed using DoCDat 4-point scale (http://www.docdat.org) 
http://ratings2004.healthcaiecominission.org.uk/Downloads/aciite cliisters.xls
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Table 4.5 Assigned teaching status of hospital trusts
H osp ita l T rust T each in g  statu s
Yes No
Barking, Havering & Redbridge Hospitals V
Barnet and Chase Farm Hospitals V
Barts and The London
Bromley Hospitals V
C helsea & W estm inster Healthcare V
Ealing Hospital
Epsom  and St Helier University Hospitals V
Guy's & St T hom as’ Hospital
Ham mersm ith Hospitals V
Hillingdon Hospital yf
H om erton University Hospital
King's C ollege Hospital s f
Kingston Hospital V
Lew isham  Hospital V
M ayday Healthcare V
N ew ham  Healthcare
N orth M iddlesex University Hospital d
North W est London Hospitals (including St 
M ark’s hospital)
s [
Queen Elizabeth Hospital V
Queen M ary's Sidcup yf
Royal Free Hampstead V
Royal M arsden
St George's Healthcare V
St M ary's d
University College London Hospitals d
W est M iddlesex University Hospital yf
W hipps Cross University Hospital xA
W hittington Hospital V  ....
4.1.7 Summary points
The information for this study came from administrative sources, from cancer 
registry and from special surveys and initiatives. For use in the analytic model (see 
Materials and Methods chapter), the sources of data were divided into those reflecting 
structure, process and outcome of care:
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Model Dataset Source Variables
Structure Cancer Services Peer Review 
(2001)
NHS Cancer Action 
Team
* 35 colorectal cancer multi­
disciplinary team (MDT) 
standards
Acute Hospital Portfolio (2000 
- 2002),
Audit Commission 
(currently Healthcare 
Commission)
* staffing level indicators 
(medical; consultant; medicine 
consultant; anaesthetist 
consultant; pathology 
consultant; radiology 
consultant; radiographers; 
clinical nurse specialists)
Assigned""" Healthcare
Commission
‘teaching status ’
Process Cancer Waiting Times 
Statistics (2001 - 2002)
NHS Cancer Action 
Team;
* two week wait target from  
urgent GP referral to first 
outpatient appointment fo r  all 
patients with suspected lower 
gastrointestinal cancer
Hospital Episode Statistics 
(1997 -2001)
NHS Health and Social 
Care Information 
Service
* average annual hospital 
volume o f  patients
Cancer registration data Thames Cancer 
Registry (1996 -  2001)
* individual level indicators o f  
patients ’ case-mix
* type o f  treatment (surgery)
Outcome Cancer registration data Thames Cancer 
Registry ( 1996 -  2001 )
5-year survival
This division is partly arbitrary, since datasets listed, for instance, under ‘structure’ 
category may well contain data on process indicators and so on. For example, some of the 
colorectal cancer MDT standards reflect the aspects of process of care. Likewise, hospital 
volume of patients may be indicative not only of processes of care, but also structural 
aspects of hospitals. However, this division helps to illustrate the main focus of the datasets 
and their potential place within the framework of proposed model.
Indicators for the analysis were selected from the datasets, based on relevance to 
literature findings on organisational determinants of survival, study objectives, 
completeness of data and following discussions with a number of healthcare professionals 
and researchers.
Table 4.6 below specifies the number of hospital trusts for which data were available 
per each dataset; and Table 4.7 indicates completeness of data, expressed as percentage of
http:/-'ratinüs2004 .hea ltl icareco iT im iss io n .o rg . Ilk/ [dow nloads-acu te  c li is ters .x ls
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variables at least 95% complete within each dataset.
Table 4.6 Number of hospital trusts for which data were available within each dataset
Dataset No. of hospital trusts
Acute Hospital Portfolio 23 to 27 (depending on topic)*
Hospital Episode Statistics 27
Cancer Waiting Times 28
Cancer Standards Peer Review 25
Thames Cancer Registry 28
*detailed Table on num ber o f  hospital trusts available per each staffing level indicator considered is p resented  in Table 4.2
Table 4.7 Completeness of data (% variables at least 95% complete)*
Datasets Few (<50%) or 
unknown
Some (50-79%) Most (80-97%) All or almost all 
(>97%)
Acute Hospital 
Portfolio X
Hospital Episode 
Statistics X
Cancer Waiting 
Times X
Cancer Services 
Peer Review X
Thames Cancer 
Registry X**
*assessm ent o f  variables em ployed in analysis 
**tum our stage was m issing in 20.9%  o f  cases
As indicated previously, further discussions on feasibility of using available datasets 
to investigate hospital-level determinants of colorectal cancer survival in London, are 
provided in Discussion chapter.
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4.2 Descriptive statistics. Hospital level analysis
4.2.1 Five-year colorectal cancer survival estimates for hospital trusts in London
Both relative and crude five-year survival of colorectal cancer patients by hospital 
trust of treatment were calculated. Crude survival was considered for comparative, 
illustrative purposes only, since it is still widely used in the literature. However, relative 
survival estimates are preferred, as they take into account population background mortality.
As indicated in the Materials and Methods chapter, the study used colorectal 
cancers incident in London residents during 1996-2001 and followed up until December 31, 
2001, drawn from the Thames Cancer Registry (TCR). Figure 4.11 below shows that, after 
taking account of differential background mortality by age, sex and social deprivation 
(IMD 2000, income quintile), variability in five-year relative survival between hospital 
trusts remains significant, ranging from 31.3% (95% Cl 23.4% -  39.4%) to 55.4% (95% Cl 
50.6% - 60.0%) (see also Table 4.8).
1 2 0
Figure 4.11*
s? 50
E  20
F ive-year  rela tive  su rv iva l (w ith  95%  C I) for co lorecta l ca n cer  p atien ts by h osp ita l tru st, 
L ondon R egion , 1996-2001
H ospital tru s ts
*dots represent cumulative relative survival rate, and the lines are 95% confidence intervals
[Ranking o f hospital trusts based on relative or crude survival rates brings about similar 
results. These two estimates were highly correlated: Spearman rank correlation coefficient 
between crude and relative survival measures was 0.94 (p<0.001).]
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Table 4.8 Five-year crude and relative survival estimates for colorectal cancer patients in 
London, by hospital trust, 1996-2001 years
Hospital
trust
Crude Survival 
(% )
95% Confidence 
Interval
Relative 
Survival (%)
95% Confidence 
Interval
No. of 
patients
No. of 
deaths
A 30.9 27.5 34.3 39.5 35.2 43.7 1443 760
B 31.9 27.8 36.0 42.4 37.3 47.5 856 470
C 33.4 27.6 39.3 41.7 34.5 48.8 506 255
D 33.4 28.3 38.6 41.6 35.3 47.8 664 346
E 34.7 27.6 41.9 46.2 36.9 55.0 337 169
F 27.0 20.3 34.1 35.6 27.0 44.4 308 180
G 36.7 31.8 41.7 46.7 40.6 52.6 614 315
H 27.6 23.0 32.3 37.1 31.0 43.1 638 367
I 24.8 18.6 31.5 31.3 23.4 39.4 505 271
J 32.7 26.7 38.8 43.3 35.5 50.8 420 233
K 31.5 23.9 39.3 40.2 30.5 49.7 298 154
L 35.2 28.9 41.7 45.1 37.1 52.7 403 206
M 31.4 26.1 36.9 43.2 35.9 50.3 657 339
N 35.8 30.7 40.9 47.1 40.6 53.4 605 316
O 27.9 21.8 34.4 34.7 27.0 42.5 378 211
P 29.9 23.7 36.4 37.6 30.0 45.2 287 172
Q 42.9 38.9 46.7 55.4 50.6 60.0 1173 525
R 33.0 27.6 38.6 43.0 35.9 49.8 559 295
S 31.9 26.5 37.4 41.2 34.4 48.0 538 287
T 39.7 34.4 44.9 51.3 44.6 57.6 561 272
U 34.6 29.8 39.5 44.1 38.1 50.0 632 335
V 34.7 27.2 42.4 45.9 35.9 55.4 364 171
w 31.9 26.1 37.8 39.8 32.6 46.9 443 245
X 42.3 36.9 47.7 50.1 43.7 56.2 596 256
Y 34.7 28.9 40.6 44.0 36.6 51.1 423 221
Z 37.9 31.7 44.0 46.6 39.1 53.8 397 194
AA 32.2 25.6 39.1 40.7 32.4 48.9 291 165
BE 33.0 28.5 37.7 43.0 37.3 48.7 569 329
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4.2.2 Distribution of selected individual level indicators by hospital trust in London
Table 4.9 shows the distribution of individual patient characteristics by hospital 
trust which are then adjusted for in the model. For the purposes of visualisation, only one 
item from each ‘concept’ (indicator) within the model is presented below (see Table 4.9). 
Full distributions of each individual-level indicators are available in Appendices 2-5.
Table 4.9 Distribution (%) of selected individual level indicators by hospital trust in 
London
H ospital
trust
A ge group, years Sex Social deprivation  
(incom e quintile)
T um our stage
15-39 80-99 M ale Fem ale 1 5 I IV
A 1.9 22.6 50.9 49.1 9.0 35.3 22.0 21.6
B 2.0 30.6 51.3 48.7 8.1 10.9 16.4 22.0
C 2.4 17.0 58.7 41.3 1.0 83.8 11.1 28.5
D 1.0 25.4 49.5 50.4 51.7 5.3 8.9 21.4
E 3.0 25.5 51.3 48.7 19.9 7.7 11.3 24.0
F 3.6 29.5 54.2 45.8 4.9 20.8 13.6 27.9
G 1.6 29.5 45.4 54.6 32.7 12.2 21.3 22.3
H 2.5 20.4 54.2 45.8 4.7 68.0 13.5 21.2
I 2.6 20.2 54.6 45.3 8.5 26.7 14.1 22.6
J 1.2 26.7 54.5 45.5 14.5 2.6 30.5 23.6
K 2.7 24.5 54.7 45.3 0.0 98.3 15.8 29.5
L 2.7 21.3 52.6 47.4 1.2 67.0 13.1 22.6
M 0.8 33.5 47.5 52.5 43.4 2.9 19.6 21.3
N 1.5 25.8 48.4 51.6 10.4 14.2 24.0 21.5
O 2.6 20.4 48.9 51.1 0.3 97.6 13.8 33.3
P 2.8 19.9 49.1 50.9 0.7 72.1 12.9 21.9
Q 2.8 24.7 51.9 48.1 6.3 14.1 25.9 22.0
R 1.2 24.0 52.6 47.4 3.0 58.1 28.4 20.2
s 0.6 25.8 51.3 48.7 22.3 11.3 8.4 26.9
T 2.7 22.1 49.0 51.0 5.5 20.9 18.4 20.7
U 2.1 25.6 53.6 46.4 10.1 11.2 19.8 21.8
V 2.7 21.7 56.6 43.4 2.7 44.8 22.8 21.4
w 2.7 22.1 53.9 46.0 0.4 55.8 24.8 21.4
X 6.5 11.6 55.2 44.8 27.7 13.4 2.7 5.5
Y 2.6 21.7 50.8 49.2 0.7 70.4 37.6 20.8
Z 2.5 21.9 51.1 48.9 3.8 60.7 32.5 18.4
AA 1.7 29.2 48.8 51.2 33.3 8.2 14.8 22.3
BE 1.9 30.8 52.7 47.3 2.5 30.9 45.2 23.4
There were relatively balanced distributions of age and sex by hospital trust. On the 
other hand, distribution of the deprivation indicator varied considerably, particularly if we 
compare (least deprived) and (most deprived) income quintiles. Likewise, there were 
considerable variations for tumour stage. However, in case of stage variable, the presence 
of missing values should be taken into account (for full distribution of tumour stage by 
hospital trust, including ‘Not Known’ values, see Appendix 5).
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Table 4.10 below presents a summary of frequencies and relative frequencies for 
individual level variables obtained from the TCR. Except ‘tumour stage’ (with 20.9% of 
missing values), all other variables were complete.
Table 4.10 Frequencies and relative frequencies of individual level variables from the 
Thames Cancer Registry (TCR)
Variable Frequency Relative frequency 
(%)
Age group:
15-39 349 2.3
40-49 665 4.3
50-59 1812 11.7
60-69 3722 24.1
70-79 5169 33.4
80-99 3748 24.2
Sex:
Male 8002 51.7
Female 7463 48.3
Tumour stage: 
I 3065 19.8
II 2964 19.2
III 2795 18.1
IV 3411 22.1
Not known 3230 20.9
Social deprivation 
(income quintile):
I (least deprived) 1932 12.5
2 2221 14.4
3 2784 18.0
4 3508 22.7
5 (most deprived) 5020 32.5
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4.2.3 Distribution of selected hospital level indicators by hospital trust in London
Table 4.11 illustrates the variations in distribution of hospital-level indicators: one 
variable has been taken from each data set as used within the model.
Table 4.11 Distribution of selected hospital level indicators by hospital trust 
in London
Hospital
trust
Volume: 
average 
annual 
number of 
patients
Waiting 
time: 
percentage 
of meeting 
two week 
wait target
Staffing level: 
consultant 
WTE per 
1000 
admissions
Compliance 
with 
standards: 
“Operational 
policy -  
MDT review 
of cancer 
patients” 
standard 
(Yes -  1; No 
- 0 )
Teaching 
status of 
hospitals 
(Yes -  1; No- 
0)
A 1491 92.6 1.7 n/a 0
B 602 87.9 2.1 n/a 0
C 1090 92.9 2.5 1 1
D N/A 983 n/a 1 0
E 245 95.8 2.5 1 1
F 254 95.4 1.8 0 0
G 627 94.7 2.5 0 0
H 1205 78.4 3.2 0 1
I 1511 96.1 2.6 1 1
J 286 85.4 1.9 0 0
K 150 90.8 2.1 1 0
L 362 96.9 3.6 1 1
M 339 968 2.9 0 0
N 404 98.7 2.2 1 0
O 313 97.0 1.7 1 0
P 792 96.9 2.0 1 0
Q 563 80.7 2.4 n/a 0
R 430 94.6 1.9 1 1
S 325 95.7 1.6 0 0
T 484 94.2 n/a 0 0
U 892 95.9 3.2 1 1
V 776 98.1 3.2 1 1
w 285 100.0 2.4 0 1
X 2525 100.0 2.3 1 1
V 374 75.4 2.3 1 0
z 837 93 6 n/a 1 1
AA 284 91.1 2.6 1 0
BB 593 94.1 2.1 0 0
The average annual number of colorectal cancer patients per hospital trust in 
London varied from 150 to 2525 (mean 754; median 593 patients). A percentage of 
meeting two week wait standard varied from 75.4% to 100% per hospital trust (mean 
92.4%; median 94.6%). There was a range of 1.6 to 3.9 consultants per hospital trust as 
measured by Whole Time Equivalent (WTE) per 1000 admissions (mean 2.4; median 2.3).
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(For full distribution of all staffing level indicators per hospital trust, see Appendix 7). As 
indicated previously (see Table 4.5), 11 hospital trusts were assigned teaching status, while 
17 hospital trusts were considered non-teaching.
Sixteen hospital trusts were compliant with “Operational policy -  MDT review of 
cancer patients” standard, and six hospital trusts were not compliant with that standard (for 
full distribution of compliance with all cancer standards, see Table 4.27). As shown in 
Table 4.12, depending on standard, the number of compliant hospital trusts ranged from 4 
to 25 (the maximum number of hospital trusts available to the study in relation to 
compliance with cancer standards). All hospital trusts were in compliance with the 
‘standard 1 ’ ( “Named Lead clinician fo r  the colorectal specialist M DT”). Also, only one 
hospital trust was non-compliant with the standards 7 and 29 ( “Lead imaging consultant fo r  
the M D T” and “Treatmentplanning decisions recorded”, respectively). These three 
standards were therefore not considered in subsequent multivariate relative survival 
modelling, because of their statistical distributions.
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Table 4.12 Number of hospital trusts compliant with each colorectal cancer specific 
standard
Cancer standards No. of 
compliant 
hospital trusts
1. Named Lead clinician for the colorectal specialist MDT 25
2. Lead clinician written responsibilities 23
3. Names o f  core members o f MDT 23
4. Lead Histopathologist for the MDT 23
5. Histopathologist attendance at MDT 17
6. Consistency between histopathologist audit 7
7. Lead imaging consultant for the MDT 24
8. Lead imaging consultant attendance at MDT 7
9. Pre-operative core MDT members 14
10. MDT meetings -  frequency and attendance records 17
11. Core members attendance at MDT 17
12. Cover arrangements for core members 16
13. Operational policy meetings 15
14. Operational policy -  MDT review o f new cancer patients 16
15. Written operational policy -  communication o f a patient’s diagnosis to their 
general practitioner
18
16. Implementation o f the policy -  timeliness o f communication o f a patient diagnosis 
to their general practitioner following diagnosis
4
17. Written operational policy -  provision o f information on the appropriateness and 
timeliness o f urgent referrals
13
18. Colorectal nurse specialist qualifications -  registered ENB 237 course 5
19. Colorectal nurse specialist qualifications -  obtained ENB 237 course 6
20. Colorectal nurse specialist qualifications -  obtained the ENB 216 and/or cancer 
related nursing degree
12
21. Written agreement describing referrals guidelines -  core team and clinical 
oncologist
6
22. Written operational policy for stabilising and treating emergency admissions 11
23. Names o f  extended team members 18
24. Arrangements for access to MDT 22
25. Survey o f  patients experience undertaken/being undertaken 14
26. Survey results presented and discussed at MDT 5
27. Actions taken as a result o f the survey 4
28. Written information material (for patients) available 22
29. Treatment planning decisions recorded 24
30. Network wide clinical guidelines for the cancer site 9
31. Referral guidelines for the cancer site 14
32. Network wide dataset for the cancer site 19
33. Recording o f dataset for individual patients 19
34. Network wide audits 6
35. List o f agreed clinical trials 13
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4.2.4 Distribution of clinical treatment indicators by hospital trust in London
As indicated previously, information on adjuvant therapy (chemotherapy, 
radiotherapy or other) was mainly missing in the Thames Cancer Registry dataset (see 
Table 4.4). Therefore, only data on type of surgical treatment have been considered in this 
study. Table 4.13 shows apparent variations in distribution of type of treatment by hospital 
trust in London. For example, the proportion of radical surgery (‘partial removal of organ’) 
by hospital trust varied from 16.3% to 59.8%; while the proportion of patients who 
underwent investigative procedure only ranged from 4.2% to 13.2% by hospital trust. This 
division into five treatment categories was defined by the Thames Cancer Registry (TCR).
Table 4.13 Distribution (%) of type of treatment by hospital trust in London
H ospita l trust Type o f  treatm ent
Total rem oval o f  
organ
Partial rem oval o f  
organ
Tum our/lym ph  
node rem oval or  
exclusion
N on-tum our
rem oving
surgery
Investigative  
proced ure only
A 21,2 51,9 8,1 4,2 7,0
B 16,7 582 6,3 2,6 6,0
C 24,5 3 9 9 12,1 1,2 11,5
D 19,0 43,4 8,1 2,6 10,1
E 20,8 47,2 10,7 5,0 9,2
F 20,4 4&8 5,5 3,6 8.8
G 17,1 57,2 4.9 4,4 10,1
H 15,7 4&3 8.9 3,1 9.9
I 15,6 45,9 11,5 1,8 9,7
J 20,7 49.0 5.5 5,0 12,6
K 2&2 38,9 10,4 2,0 10,4
L 12,2 55,3 7,2 3,0 9,7
M 19,0 57,4 5,6 4,0 6,7
N 13,5 59.8 5,0 7,1 6,6
O 32 8 3 6 0 10,0 1,6 13,2
P 21,2 47,4 3,8 5,2 4,2
Q 17,7 54,0 7,1 3,5 10,2
R 19,3 50,6 9,8 1,4 8,0
S 17,1 51,1 9,7 1,3 8.4
T 2 23 50,1 8,0 0,7 10,2
U 15,5 50,9 13,3 2,1 9.8
V 12,6 56,6 12,6 2,2 11,3
w 17,6 45,4 13,1 1,8 9,3
X 4,7 16,1 1,8 21,0 1,3
V 16,5 57,4 11,8 3,1 5,0
z 13,1 51,6 15,9 0.8 11,6
AA 14,8 49,5 9,3 1,4 8.2
BB 18,8 523 8,4 6,5 6,0
Table 4.14 below presents a summary of frequencies and relative frequencies for 
‘type of treatment’ variable obtained from the TCR. As indicated previously (see Table 
4.4), ‘type of treatment’ variable had 11.6% of missing values.
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Table 4.14 Frequencies and relative frequencies for ‘type of treatment’ variable from 
the Thames Cancer Registry dataset
Variable Frequency Relative frequency 
(% )
Type of treatment (surgery):
Total removal o f organ 2783 18.0
Partial removal o f organ 7673 49.6
Tumour/lymph node removal or 
excision 1305 8.4
Non-tumour removing surgery 589 3.8
Investigative procedures only 1322 8.5
Not known 1793 11.6
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4.3 Individual variables -  univariate relative survival model
Initially, a relative survival model was used to assess the impact of four individual 
level variables - age, sex, deprivation category and tumour stage. These four variables 
reflect patient case-mix and are widely considered to be among the main factors influencing 
survival of cancer patients. As shown in Table 4.15, all these variables were significantly 
associated with five-year relative survival.
Table 4.15 Relationship between age, sex, social deprivation and tumour stage and 
relative excess risk of death**'^ ‘ within five years of diagnosis, for colorectal cancer 
(univariate model)
Variable Relative excess risk of 
death (RER)
95% confidence interval 
(Cl)
p-value
Age group:
15-39 1.00
40-49 1.09 0 .8 9 -1 .3 3 0.406
50-59 1.20 1.001 -  1.43 0.048
60-69 1.29 1 .0 9 -1 .5 3 0.003
70-79 1.83 1 .5 6 -2 .1 7 <0.001
80-99 2.95 2 .4 2 -3 .6 0 <0.001
Sex:
Male 1.00
Female 1.06 1 .0 0 5 - 1.12 0.031
Deprivation
category:
1 (least deprived) 1.00
2 1.05 0 .9 0 -1 .2 1 0.540
3 1.02 0 .9 3 -1 .1 3 0.665
4 1.05 0 .9 6 -1 .1 4 0.269
5 (most deprived) 1.17 1 .0 6 -1 .2 8 0.001
Tumour stage: 
I 1.00
II &83 0 .7 3 -0 .9 4 0.003
III 1.33 1 .2 0 -  1.49 <0.001
IV 5 J # 5 .0 6 -6 .0 8 < 0.001
The excess risk o f death in a given group o f  patients within, say, five years o f  diagnosis is the risk o f  death over and  
above  what would have been expected if  they had experienced only the death rates seen in the general population for the 
same age, sex and deprivation. The relative excess risk o f  death reflects the extent to which the excess risk o f  death differs 
from the excess risk in a baseline group, after adjustment for other covariates.
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There was an expected gradient effect of age on survival, with patients in age-group 
80-89 having almost 3 times higher relative excess risk of death (RER) as eompared with 
patients younger than 40 years old (RER 2.9; 95% Cl 2.4 -  3.6).
Likewise, patients in stage IV had more than five times higher RER than patients in 
stage I (RER 5.5; 95% Cl 5.1 -  6.1). There was a higher proportion of older (age group 80- 
89) and more deprived patients among those with missing tumour stage. Also, a higher 
proportion of patients with known tumour stage received more radical surgery (total or 
partial removal of organ) as compared with patients whose stage information was missing 
(79.6% vs. 60.8%), while more patients in the latter group underwent an investigative 
procedure only (15.7% vs. 8.45%). These patients had slightly lower five-year relative 
survival than patients whose tumour stage was recorded in the TCR (41.0% vs. 44.2%) (see 
Table 4.16).
Table 4.16 Five-year relative survival and patient distribution by tumour stage
Tumour
stage
No. & % 
of patients
No. of 
deaths
Relative 
survival, %
95% Cl
I 3065
(19.82%) 1196 64.52 61.25 -67 .59
II 2964
(19.17%) 1041 66.34 63 .14-69 .34
III 2795
(18.0794) 1249 45.64 42.41 - 48.80
IV 3411
(22.06%) 2784 9.94 8.48 - 11.54
All patients 
with known 
stage
12235
(79.11%) 6270 44.17 42.72 - 45.60
Stage Not 
Known’
3230
(20.89%) 1789 41.03 38.34-43.71
All patients 15465
(100%) 8059 43.54 42.27 - 44.80
The gradient effect was not so clear for deprivation; however the most deprived 
patients had a significant 17% rise in RER as compared with the least deprived patients 
(RER 1.17; 95% Cl 1.1 -  1.3). Also, women seemed to have relatively smaller survival 
disadvantage compared with men (RER 1.06; 95% Cl «1.0 -  1.1), although analysis 
indicated that the sex effect changes with age. Male patients tended to have higher relative
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survival as compared with females, in younger age groups (from 15 to 49), while female 
patients experienced higher relative survival, in older age groups (from 50 onwards) (see 
Table 4.17).
Table 4.17 Five-year relative survival by sex and age group
Sex
Age groups, years
Total15-39 40-49 50-59 60-69 70-79 80-99
Rel** Rel** Rel** Rel** Rel** Rel** Rel**
Male 61.42 58.03 49.21 47.66 37.45 28.47 43.11
(51.31- (51.15- (44.73- (44.38- (34.08- (23.49- (41.28-
70.04) 64.29) 53.53) 50.85) 40.82) 33.64) 44.93)
Female 56.91 52.88 51.79 51.65 42.63 32.93 43.85
(46.79- (44.62- (46.81- (47.96- (39.49- (29.12- (42.08-
65.81) 60.47) 56.53) 55.21) 45.73) 36.78) 45.59)
All 59.22 55.74 50.37 49.38 40.30 31.46 43.54
patients (52.07- (50.50- (47.05- (46.93- (37.98- (28.40- (42.27-
65.67) 60.65) 5T59) 51.78) 42.60) 34.56) 44.80)
*5-year crude survival (%) with 95% Confidence Interval (in brackets)
** 5-year relative survival (%) with 95% Confidence Interval (in brackets)
4.4 Adjusted relative survival model. Assessing hospital predictors of survival
The relationship between hospital predictors and relative survival has been analysed 
within an adjusted relative survival model. As was indicated in the Materials and Methods 
chapter, the estimates of RER were calculated after adjustment for differences in years of 
follow-up, age, sex, deprivation category and tumour stage. Standard errors were adjusted 
for clustering effect on NHS hospital trust. The relationship was considered as statistically 
significant whenp  value was less than 0.05 or 95% confidence interval (Cl) did not contain 
“ 1” .
Time dependent covariates (interaction with follow-up time) were statistically 
significant for age (p<0.001), sex (p<0.001) and tumour stage (p<0.001). For this reason, 
interaction terms with these three variables were included into the model in all subsequent 
analysis.
The relationship between potential predictors and relative survival was also assessed 
separately by year of follow-up (1-year; 2-5 years) because short term associations may 
differ from long term associations. However, in general, there was no statistically 
significant interaction effect between year of follow-up and potential predictors.
For missing data, particularly the tumour stage variable, a ‘complete case analysis’
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was conducted. Thus, ‘not known’ stage values were considered missing in the analysis and 
patients with ‘not known’ stage were excluded from the analysis. However, analyses of 
potential predictors were repeated a) including ‘not known’ values as an additional separate 
category and b) after multiple imputation of missing values (see Materials and Methods 
chapter). Neither of these methods had substantial impact on statistical significance or 
direction of associations found (see Table 4.28).
Overall, similar results to those estimated using multivariable relative survival 
model were obtained when hazard ratios were calculated using the Cox proportional hazard 
model. For illustrative purposes only, hazards ratios from Cox model are indicated in a few 
examples with cancer standards (see 4.4.7).
4.4.1 Hospital trust and cancer survival
To examine whether observed variability in five-year relative survival between 
hospital trusts remained statistically significant, after adjusting for patient case-mix, 
‘hospital trust of treatment’ was assessed within the multivariate relative survival model as 
an independent variable. The results of this analysis are presented in Table 4.18.
Overall significance of the effect of being treated at a particular hospital trust was 
assessed based on the likelihood-ratio test comparing models with and without hospitals. 
Hospital trust with the highest estimate of five-year relative survival (55.4% - hospital ‘Q ’) 
was considered as a ‘baseline variable’ with relative excess risk of death (RER) equal to 
‘ 1’ .
After adjustment for case-mix, there remained a statistically significant association 
between being treated at particular hospital trust and five-year relative survival for 
colorectal cancer patients in London (overall p-value<0.001).
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Table 4.18 Relative excess risk of death for colorectal cancer patients by hospital trust 
of treatment, within five years of diagnosis, unadjusted and adjusted for patient case- 
mix (age, sex, social deprivation (income quintiles) and stage)
H ospital
trust
RER 95%  C l
unadjusted  
for patient 
case-m ix*
adjusted for  
patient case- 
mix**
A djusted for case- 
mix; after multiple 
im putation of 
m issing tum our  
stage values**
unadjusted  
for patient 
case-m ix*
adjusted for  
patient case- 
mix**
A djusted for case- 
mix; after m ultiple  
im putation o f  
m issing tum our  
stage values**
Q I
A 1.36 1.20 1.28 1.19-1.56 1.03-1.39 1.23-1.33
B 1.44 1.25 1.35 1.23-1.67 1.06-1.47 1.30-1.40
C 1.29 0.87 0.91 1.07-1.54 0.70-1.08 0.85-0.97
D 1.33 1.17 1.26 1.13-1.57 0.96-1.42 1.19-1.35
E 1.28 1.01 1.06 1.04-1.58 0.80-1.29 0.97-1.17
F 1.75 1.47 1.52 1.44-2.14 1.18-1.82 1.43-1.61
G 1.30 1.37 1.31 1.10-1.54 1.15-1.63 1.26-1.37
H 1.52 1.45 1.43 1.29-1.78 1.21-1.73 1.35-1.52
I 1.41 1.31 1.31 1.18-1.68 1.08-1.59 1.26-1.36
J 1.59 1.59 1.55 1.33-1.91 1.31-1.93 1.48-1.62
K 1.53 0.94 0.94 1.24-1.90 0.72-1.23 0.87-1.02
L 1.35 1.21 E28 1.11-1.63 0.98-1.50 1.22-1.34
M 1.38 1.40 1.30 1.17-1.63 1.17-1.67 1.23-1.37
N 1.27 1.28 1.19 1.07-1.50 1.07-1.53 1.17-1.22
O 1.61 0.98 1.00 1.33-1.95 0.78-1.23 0.94-1.08
P 1.61 1.55 1.58 1.31-1.97 1.23-1.95 1.52-1.65
R 1.36 1.45 1.44 1.14-1.62 1.21-1.74 1.38-1.50
S 1.39 1.23 1.21 1.17-1.66 1.02-1.50 1.15-1.28
T 1.27 1.18 1.19 1.07-1.52 0.97-1.43 1.12-1.26
U 1.41 1.40 1.44 1.19-1.66 1.17-1.66 1.40-1.48
V 1.09 0.97 0.99 0.87-1.35 0.77-1.22 0.95-1.04
w 1.44 1.43 1.46 1.20-1.73 1.18-1.73 1.41-1.52
X 0.98 0.86 1.05 0.82-1.17 0.60-1.22 0.98-1.13
Y 1.25 1.20 1.17 1.03-1.52 0.98-1.47 1.11-1.22
Z 1.27 1.13 1.14 1.04-1.55 0.92-1.42 1.09-1.20
AA 1.50 1.53 1.39 1.22-1.85 1.22-1.92 1.33-1.45
BB 1.46 1.47 1.39 1.24-1.73 1.24-1.75 1.35-1.44
"adjusted for follow-up time
"*including interaction terms with follow-up time for age, sex and tumour stage
Figure 4.12 below shows that after taking into account differences in years of 
follow-up, age, sex, social deprivation and tumour stage, variability in RER remains 
significant, ranging from 0.86 (95% Cl 0.60-1.22) to 1.59 (95% Cl 1.31- 1.93). Note, in 
comparing this with unadjusted data (Figure 4.11), Figure xx shows Relative Excess Risk 
of death estimates adjusted for patient case-mix and years of follow-up, while Figure 4.11 
shows five-year unadjusted relative survival estimates only, unadjusted for years of follow- 
up.
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Figure 4.12
R e la tiv e  e x c e s s  r isk  o f  d ea th  (w ith  95%  C l)  fo r  c o lo r e c ta l c a n c e r  p a t ien ts  by h o s p ita l tr u s t ,  
w ith in  fiv e  y e a r s  o f  d ia g n o s is ,  a d ju sted  fo r  p a t ie n t  c a se -m ix , L ondon 1 9 9 6-2001
2.5
2
1.5
1
0.5
0
H o sp ita l T rusts
♦  RER adjusted for  
patient case-m ix
After multiple imputation of missing tumour stage, confidence intervals o f RER 
became noticeably narrower and thus variation in Trust-specific RER turned to be more 
significant (see Table 4.18 and Figure 4.13), ranging from 0.91 (95% Cl 0.85 -  0.97) to 
1.58 (95% Cl 1 .5 2 - 1.65).
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Figure 4.13
R e la tiv e  e x c e s s  r isk  o f  d ea th  (w ith  95%  C l)  for  c o lo r e c ta l c a n c er  p a t ien ts  by h o s p ita l tr u s t ,  
w ith in  five  y e a r s  o f  d ia g n o s is ,  a d ju sted  fo r  p a t ie n t  c a s e -m ix , L ondon 1 9 9 6 -2 0 0 1 *
2.5
1.5
?  1
0.5
♦  RER adjusted for 
patient case-m ix
H o sp ita l T rusts
♦after multiple imputation o f  m issing tumour stage values
To illustrate the relative ‘importance’ of case-mix indicators in explaining survival 
differences between hospital trusts, the subsequent results in this section are presented for 
two hospital trusts with the highest ( ‘hospital Q ’) and the lowest (‘hospital I’) five-year 
relative survival estimates (see Table 4.8), with the highest survival trust as a ‘baseline 
variable’. Case-mix indicators were considered separately and as a group.
As shown in Tables 4.18 and 4.19, in a model without case-mix indicators, patients 
treated in ‘hospital I’ had 41% increase in excess mortality as compared with patients at 
‘hospital Q ’ (RER 1.41, 95% Cl 1.18 -  1.68; p<0.001). Even after adjustment for all 
available case-mix indicators (age, sex, social deprivation and tumour stage), patients 
treated at hospital ‘T still had 31% higher relative excess risk of death within five year of 
diagnosis, than patients treated at hospital ‘Q ’ (RER 1.31, 95% Cl 1.08 -  1.59; p=0.006).
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Separate adjustments for age, sex and, to some extent, social deprivation did not 
explain observed differences in survival. This may be due to the following reasons.
Age: Although there was clear gradient effect of ‘age’ on survival (see Table 4.15), there 
was small difference in age distribution by hospital trusts (see Appendix 2). Therefore, 
adjusting by age did not explain variations in survival by hospital trust.
Sex: Our analyses showed marginal significant effect of ‘sex’ on survival (see Table 4.15) 
and small difference in sex distribution by hospital trust (see Appendix 3). Therefore, 
adjusting by sex did not explain variations in survival by hospital trust.
Deprivation: Although there were substantial variations in deprivation distribution by 
hospital trust (see Appendix 4), our analyses showed that there was little gradient effect of 
‘deprivation’ with survival (see Table 4.15). Therefore, adjusting by deprivation index did 
not explain variations in survival by hospital trust.
Tumour stage:
The most substantial explanatory value was obtained for tumour stage, adjustments 
for which decreased the difference in excess mortality between hospital trusts by 37%
(RER 1.41 for the model without adjustment decreases to 1.26 after adjustment for stage -  
the highest level decrease, as compared with other indicators). However, the remaining 
variance of more than 60% between hospital trusts remained unexplained. After multiple 
imputation of missing values for stage, this result did not change substantially, with RER 
decreasing from 1.41 to 1.29, leaving even more proportion of unexplained variations. Our 
analyses showed that increasing stage significantly decreases survival (see Table 4.15), and 
as shown in Appendix 5, there was considerable difference in relative frequencies 
distribution of tumour stage (including ‘Not Known’ values) between hospital trusts.
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Table 4.19 Relative ‘importance’ of case-mix indicators in explaining survival 
differences between hospital trusts with the highest and the lowest five-year relative 
survival for colorectal cancer in London
Model* RER 95% Cl p-value
Trust only 1.41 1.18 1.68 <0.001
Trust + age group 1.42 1.20 1.69 <0.001
Trust + sex 1.41 1.18 1.68 <0.001
Trust + social deprivation 1.39 1.16 1.66 <0.001
Trust + tumour stage 1.26 1.03 1.53 0.023
Trust + case-mix** 133 1.10 1.61 0.003
Trust + case-mix** + interaction*** 1.31 1.08 1.59 0.006
*the highest survival trust was considered  as a ‘baseline variable’
* ’^ age, sex, social deprivation and tum our stage
*** including interaction term s w ith follow-up tim e for age, sex and tum our stage
Type o f  treatment:
In addition, the effect of type of treatment (surgery) as a possible explanatory factor 
in observed survival differences between hospital trusts was assessed (see Table 4.20).
Type of surgery may be considered as a ‘proxy’ for patient severity and, thus, case-mix. 
However, adjustment for type of surgery did not result in a substantial difference from that 
of case-mix indicators per se (RER 1.36 for the model with adjustment for type of 
treatment and RER 1.31 after case-mix adjustment), and particularly tumour stage (RER 
1.26 after adjustment).
There was a clear gradient effect of ‘type of treatment’ on survival: more radical 
surgery was associated with improved survival (see Table 4.22). In fact, as shown in 
Appendix 6, there was a difference in relative frequencies distribution of type o f treatment 
by hospital trust, though to a lesser extent compared with stage distribution (see Appendix
5).
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Table 4.20 Relative ‘importance’ of type of treatment and case-mix indicators in 
explaining survival differences between hospital trusts with the highest and the lowest 
five-year relative survival for colorectal cancer in London
Model* RER 95% C l p-value
Trust only 1.41 1.18 1.68 <0.001
Trust + type o f surgery**** 1.36 1.12 1.66 0.002
Trust + type o f surgery**** + case-mix** 1.34 1.09 1.65 0.005
Trust + type o f surgery**** + case-mix** + 
interaction***
1.33 1.09 1.64 0.006
Trust + type o f treatment***** 1.38 1.13 1.68 0.001
Trust + type o f treatment***** + case-mix** 1.34 1.09 1.64 0.006
Trust + type o f treatment***** + case-mix** + 
interaction***
1.32 1.07 1.62 0.008
*the highest survival trust was considered as a ‘baseline variab le’
**age, sex, social deprivation and tum our stage
*** including interaction term s with follow-up tim e for age, sex and tum our stage 
♦ ♦♦♦divided into five categories (see M ethods, page 76)
’•‘***’"divided into tw o categories (see M ethods, page 76)
To conclude, even after considering the effects of case-mix variables or tumour 
stage, there still remained unexplained variation between hospital trusts suggesting that 
other factors related to hospital may be important. The potential impact of unknown 
confounders is discussed in Discussion chapter.
At the next stage of the analysis, along with the type of treatment (surgery), the 
impact of each available hospital level independent variables of structure and process of 
care was assessed within the multivariate relative survival model to ascertain their effect on 
survival.
As mentioned in Materials and Methods chapter, bivariate correlations among all 
covariates were examined to avoid potential problems due to collinearity. Consequently, all 
hospital predictors were tested in the model separately, since they were significantly 
correlated with each other (p<0.01).
4.4.2 Type of treatment (surgery) and cancer survival
Patients who underwent investigative procedures only had a more than two-fold 
increase in excess mortality as compared with patients who underwent surgical intervention 
(RER 2.52, 95% Cl 2.22 -  2.86) (see Table 4.21).
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Table 4.21 Relationship between type of treatment and relative excess risk of death 
within five years of diagnosis, for colorectal cancer, after adjustment for age, sex, 
social deprivation (income quintiles) and stage*
Type of treatment RER 95% Cl p-value
Any surgical operation 1
Investigative procedures only 2.52 2.22 -  2.86 < 0.001
♦including interaction term s with follow-up tim e for age, sex and tum our stage
Survival improved along with the increasing extent of surgery: patients who 
underwent radical surgery (total or partial removal of an organ) had a better prognosis than 
patients who had only a non-radical intervention (tumour/lymph node removal or non­
tumour removing surgery) (see Table 4.22).
Table 4.22 Relationship between type of surgery and relative excess risk of death 
within five years of diagnosis, for colorectal cancer, after adjustment for age, sex, 
social deprivation (income quintiles) and stage*
Type of treatment RER 95% Cl p-value
Total removal of organ 1
Partial removal of organ 1.08 0 .97-1 .20 0.141
Tumour/lymph node removal 
or excision
2.01 1.71-2.36 <0.001
Non-tumour removing surgery T58 2 .87-4 .46 <0.001
Investigative procedures only T20 2.79-3 .67 < 0.001
"including interaction term s w ith follow-up tim e for age, sex and tum our stage
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4.4.3 Average annual hospital volume of patients and cancer survival
No relationship was found between the average annual number of patients treated at 
hospital trust and 5-year relative survival (see Table 4.23).
Table 4.23 Relationship between average annual number of patients per hospital trust 
and relative excess risk of death within five years of diagnosis, for colorectal cancer, 
after adjustment for age, sex, social deprivation (income quintiles) and stage*
Variable No. of 
hospital 
trusts
No. of 
patients
RER 95% C! p-value
Volume
(in quartiles)**:
T‘ (lowest) 9 3670 1
6 3724 0.91 0 .7 7 -1 .0 8 0.27
grd 6 3087 1.00 0 .8 6 -1 .1 5 0.95
4^ (highest) 6 4320 0.95 0.81 -  1.10 0.48
*including interaction term s with follow-up tim e for age, sex and tum our stage
** num ber o f  patients is divided into equal quartiles based on predictor values o f  pooled data for all trusts; because T rusts are  o f  d ifferent 
sizes, the total o f  Trusts per quartile differ, see also M aterials and M ethods, 3.6.1.2
4.4.4 Meeting two week wait target and cancer survival
Meeting two week wait target was assessed separately for urgent referrals received 
within the 24 hours and urgent referrals not received within the 24 hours, as was presented 
in original dataset. However, neither of these ‘waiting time’ indicators was found to be 
associated with 5-year relative survival (see Table 4.24).
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Table 4.24 Relationship between meeting 2-week wait standard and relative excess 
risk of death within five years of diagnosis, for colorectal cancer, after adjustment for 
age, sex, social deprivation (income quintiles) and stage*
Variable No. of 
hospital 
trusts
No. of 
patients
RER 95% Cl p-value
Waiting time 
(achievement 
quartiles)**:
1 (lowest) 6 3808 1
2 n d 6 3767 1.01 0 .8 4 -1 .2 1 0.942
3 r d 7 3493 1.10 0 .9 3 -1 .3 0 0.250
4^ (highest) 9 4397 1.02 0 .8 5 -1 .2 2 0.818
Waiting time - 
referrals received 
within 24 hours 
(achievement 
quartiles)**:
1 (lowest) 4 3674 1
2 n d 8 3833 1.05 0 .8 8 -1 .2 5 0.619
3 r d 7 3956 1.05 0 .8 9 -1 .2 4 0.558
4^ (highest) 9 4002 1.00 0 .8 2 -1 .2 2 0.996
* including interaction term s w ith follow-up tim e for age, sex and tum our stage
** num ber o f  patients is divided into equal quartiles based on predictor values o f  pooled data for all trusts; because T rusts are o f  d ifferent 
sizes, the total o f  Trusts per quartile differ, see also M aterials and M ethods, 3.6.1.2
4.4.5 Teaching status and cancer survival
Colorectal cancer patients who were treated at teaching hospitals had a statistically 
significant 13 % reduction of excess mortality compared with patients who were treated at 
non-teaching hospitals (RER 0.87, 95% Cl 0.77 -  0.99; p=0.032) (see Table 4.25).
Table 4.25 Relationship between teaching status of hospitals and relative excess risk of 
death within five years of diagnosis, for colorectal cancer, after adjustment for age, 
sex, social deprivation (income quintiles) and stage*
Teaching status RER 95% Cl p-value
No 1
Yes 0.87 0.77 -  0.99 0.032
"including interaction terms with follow-up tim e for age, sex and tum our stage
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4.4.6 Staffing level and cancer survival
No relationship was found between indicators of staffing level at hospital trusts and 
5-year relative survival for colorectal cancer patients (see Table 4.26).
Table 4.26 Relationship between medical, ward and radiology staffing level indicators 
and relative excess risk of death within five years of diagnosis, for colorectal cancer, 
after adjustment for age, sex, social deprivation (income quintiles) and stage*
Staffing level indicator No. o f  
hospital 
trusts
No. o f  
patients
RER 95%  C l P value
M edical W TE per 1000 adm issions (in quartiles)**:
1® (low est) 4 2928 1
2"d 6 2919 111 0 .9 8 -  1.26 0.101
3"* 6 3093 1.01 0 .9 0 - 1 .1 4 0.815
4'*' (highest) 7 3171 0.98 0 .8 2 - 1 .1 8 0.866
C onsultant W TE per 1000 adm issions (in quartiles)**:
1" (low est) 5 3087 1
2"d 7 3597 1.05 0 .9 2 - 1 .1 9 0.453
3"* 6 3669 0.87 0.73 -  1.04 0.140
4* (highest) 7 3490 1.06 0 .9 4 - 1 .2 0 0.336
M ed icine consultant W TE per 1000 adm issions 
(in quartiles)**:
1^ (low est)
5 3176 1
2"d 7 3380 1.05 0 .9 0 - 1 .2 3 0.532
3"d 6 3375 1.06 0.94 -  1.20 0.315
4* (highest) 7 3912 0.91 0 .7 9 -  1.06 0.238
A naesthetist consultant W TE per 1000 adm issions 
(in quartiles)**:
1“ (low est)
4 3185 1
2"d 5 3362 0.91 0 .7 5 - 1 .0 9 0.296
3"d 9 3718 0.94 0 .8 2 - 1 .0 8 0.419
4*  (highest) 7 3578 0.92 0 .7 7 - 1 .0 9 0.333
Pathology consultant W TE per 1000 adm issions 
(in quartiles)**:
1" (low est)
6 3184 1
2 n d 5 3559 0.98 0 .8 2 - 1 .1 7 0.827
3-d 7 3500 1.10 0 .9 4 -  1.29 0.214
4* (highest) 7 3600 1.06 0 .9 2 - 1 .2 2 0.406
R adiology consultant W TE per 1000 adm issions 
(in quartiles)**:
1" (lowest)
6 2534 1
2"d 6 4220 0.99 0 .8 6 - 1 .1 4 0.890
3"* 6 3483 0.85 0 .7 2 -1 .0 1 0.062
4'*’ (highest) 7 3606 1.08 0 .9 5 - 1 .2 3 0.225
R adiographers per 1000 FCEs (in quartiles)**:
1" (lowest) 6 3246 1
2"d 5 3263 0.95 0 . 7 8 -  1.15 0.574
3 r d 7 4298 1.03 0 .9 0 - 1 .1 7 0.697
4'*’ (highest) 9 4235 0.99 0 .8 6 - 1 .1 5 0.940
C linical nurse specialists W TE per 1000 FCEs 
(in quartiles)**:
1^ (lowest)
5 2807 1
2"d 5 2500 1.00 0 .8 7 -  1.16 0.947
3 r d 7 3008 0.96 0 .8 3 -  1.10 0 549
4d" (highest) 7 3109 0.92 0 .7 7 -  1.10 0.377
including interaction terms with follow-up tim e for age, sex and tum our stage 
** num ber o f  patients is divided into equal quartiles based on predictor values o f  pooled data for all trusts; because Trusts are o f  d ifferent 
sizes, the total o f  Trusts per quartile differ, see also M aterials and M ethods, 3 .6.1.2
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4.4.7 Compliance with colorectal cancer MDT standards and cancer survival
The effect of compliance of hospital trusts with cancer standards on cancer survival 
have been assessed in more detail because of their potential practical impact and the fact 
that they have never been explored in this way before.
Firstly, the impact of the composite score for all 35 standards was considered, and 
found to be positively associated with five-year relative survival, although the effect 
seemed to be marginal (RER 0.98, 95% Cl 0.97-0.997; p=0.012). Subsequently, each 
standard was examined separately within the model, as it had been by peer review.
In examining compliance with individual colorectal MDT standards, no relationship 
was found between the majority of published standards and cancer survival. However, 
positive independent relationships were found for four aspects of the cancer standards peer 
review: compliance with standards defining the structure of MDT (standard 3); operational 
policies (standard 14); availability of patient information (standard 28); and clinical 
guidelines (standard 30). The results are presented in Table 4.27.
All 35 colorectal cancer MDT standards were grouped under 11 sub-headings 
(topics) within the Manual of Cancer Services Standards to describe various aspect of 
management of colorectal cancer patients by multi-disciplinary teams (see Table 4.27). 
Number of standards grouped under each topic varied from one to ten. However, some of 
the groupings seem arbitrary. For example, a standard ‘Names of extended team members ’ 
under the ‘Extended team’ sub-heading reflects the same theme as standards gathered under 
the ‘MDT structure’. On the other hand, ‘Consistency between histopathologist audit’ 
included under MDT structure’ reflects rather a process of care than a structure of MDT.
Only one standard out of eight under the ‘MDT structure’ (standard 3) showed 
significant association with survival. Particularly, compliance with that standard was 
associated with statistically significant 17% reduction of excess mortality compared with 
non-compliant trusts (RER 0.83, 95% Cl 0.78-0.88; p<0.001). Similar results were obtained 
when the association was tested using Cox proportional hazard model (HR 0.84; 95% Cl 
0.81 -  0.88; p<0.001).This may be due to the fact, that essentially this standard defines the 
structure of MDT as a whole, and thus may partly reflect other standards under the MDT 
structure’. However, only 2 NHS hospital trusts were not in compliance with this standard.
None of the four standards grouped under the topic ‘MDT meetings’ showed
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association with survival, although one of those standards -  ‘Pre-operative core MDT 
members’, reflects rather a structure of MDT than ‘MDT meetings’ per se.
Only one out of ten standards under the ‘Organisational policies’ (standard 14) 
showed significant association with survival. Particularly, compliance with that standard 
was associated with statistically significant 14% reduction of excess mortality compared 
with non-compliant trusts (RER 0.86, 95% Cl 0.78-0.95; p=0.002). Similar results were 
obtained when the association was tested using Cox proportional hazard model (HR 0.88; 
95% Cl 0.82 -  0.96; p=0.002). This is one of the important standards within the topic 
which defines the availability of operational policies on MDT review of new cancer 
patients, and therefore, may partly reflect other standards included in that topic.
The availability of patient information (standard 28) also showed positive 
association with survival. Particularly, compliance with the standard was associated with 
statistically significant 16% reduction of excess mortality compared with non-compliant 
trusts (RER 0.84, 95% Cl 0.79-0.90; p<0.001). Similar results were obtained when the 
association was tested using Cox proportional hazard model (HR 0.87; 95% Cl 0.82 -  0.93; 
p<0.001). Other four standards within the ‘Functions of the team providing patient centred 
care’ were not significantly associated with survival.
Compliance with the ‘clinical guidelines’ standard (standard 30) was associated 
with statistically significant 19% reduction of excess mortality compared with non- 
compliant trusts (RER 0.81, 95% Cl 0.72-0.92; p—0.001). Similar results were obtained 
when the association was tested using Cox proportional hazard model (HR 0.84; 95% Cl 
0 .77-0 .91; p<0.001).
However, compliance with standards on referral guidelines or treatment planning 
decisions was not associated with survival. Likewise, compliance with standards on 
network-wide datasets and audits, as well as clinical trials, did not show significant 
association with survival.
It should be noted that out of 35 colorectal cancer MDT standards analysed in this 
study, three standards were excluded from the model since either all hospital trusts were 
compliant with the standard (standard 1) or only one hospital trust was not compliant with 
the standard (standards 7 and 29).
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Table 4.27 Relationship between compliance with selected colorectal cancer MDT 
standards (Cancer Services Peer Review 2001) and relative excess risk of death (RER) 
within five years of diagnosis for colorectal cancer, after adjustment for age, sex, 
social deprivation (income quintiles) and stage*
Cancer standards C om pliant RE R 95%  C l p-value
No. o f  
hospital 
trusts
N o. o f  
patients
M D T structure
1. N am ed Lead clinician for the colorectal specialist M DT All hospital trusts were compliant with this standard
2. Lead clinician w ritten responsibilities 23 10765 1.01 0 .8 2 - 1 .2 4 0.934
3. N am es o f  core m em bers o f  M DT 23 11265 0.83 0 .7 8 - 0 .8 8 < 0 .0 0 1
4. Lead H istopathologist for the M DT 23 11307 1.06 0.81 -  1.38 0.668
5. H istopathologist attendance at M DT 17 8081 0.98 0 .8 7 -1 .1 1 0.771
6. C onsistency betw een histopathologist audit 7 3024 0.86 0 .7 2 - 1 .0 2 0.076
7. Lead imaging consultant attendance a t M DT Only one hospital trust was not compliant with this standard
8. Lead imaging consultant attendance a t M DT 7 1 3544 1 1.03 1 0.91 -  1.17 | 0 .610
M D T  m eetings
9. Pre-operative core M DT m em bers 14 6461 1.06 0 .9 4 - 1 .1 8 0.344
10. M DT m eetings -  frequency and attendance records 17 7801 1.03 0 .9 2 -  1.15 0.640
11. Core m em bers attendance at M DT 17 8324 1.02 0 .9 0 - 1 .1 4 0.776
12. Cover arrangem ents for core m em bers 16 7689 0.91 0.81-1.01 0.082
O perational policies
13. Operational policy m eetings 15 6983 0.95 0 .8 5 -  1.06 0.383
14. O perational policy -  M DT review  o f  new  cancer patients 16 7245 0.86 0 .7 8 - 0 .9 5 0.002
15. W ritten operational policy -  com m unication o f  a patien t’s 
diagnosis to their general practitioner
18 8554 0.98 0 .8 7 -  1.10 0.688
16. Im plem entation o f  the policy -  tim eliness o f  com m unication 
o f  a patient diagnosis to their general practitioner following 
diagnosis
4 2096 1.04 0 .9 0 -  1.19 0.605
17. W ritten operational policy -  provision o f  inform ation on the 
appropriateness and tim eliness o f  urgent referrals
13 6305 0.92 0 .8 2 - 1 .0 4 0 .176
18. Colorectal nurse specialist qualifications -  registered ENB 
237 course
5 2292 0.93 0 .7 7 -  1.12 0.427
19. Colorectal nurse specialist qualifications -  obtained ENB 237 
course
6 2998 0.96 0 .8 3 -  1.11 0 .569
20. Colorectal nurse specialist qualifications -  obtained the ENB 
216 and/or cancer related nursing  degree
12 5481 0.98 0 .8 7 - 1 .1 0 0.721
21. W ritten agreem ent describing referrals guidelines -  core 
team  and clinical oncologist
6 2897 0.95 0 .8 3 - 1 .0 9 0.455
22. W ritten operational policy fo r stabilising and treating 
em ergency adm issions
11 4703 0.99 0 .8 7 -  1.13 0.872
E xtended team
23. N am es o f  extended team  m em bers 18 8869 0.99 0 .8 8 - 1 .1 2 0.903
Functions o f the team  providing patient centred care
24. A rrangem ents for access to M DT 22 10398 0.94 0 .8 2 - 1 .0 7 0.338
25. Survey o f  patients experience undertaken/being undertaken 14 6393 0.99 0 .8 8 -1 .1 1 0.845
26. Survey results presented and discussed at M DT 5 2451 1.10 0 .9 8 - 1 .2 4 0.119
27. A ctions taken as a result o f  the survey 4 1882 1.06 0.91 -  1.23 0.469
28. W ritten information m aterial (forpatients) available 22 10756 0.84 0.79 -  0.90 < 0 .0 0 1
Treatm ent planning decision
29. Treatm ent planning decisions recorded Only one hospital trust was not compliant with this standard
C linical guidelines
30. Netw ork wide clinical guidelines for the cancer site 9 3853 0.81 0.72 -  0.92 0.001
Referral guidelines
31. Referral guidelines for the cancer site 14 6861 0.92 0 .8 2 -  1.03 0.148
D ata collection
32. N etwork wide dataset for the cancer site 19 9152 0.90 0 .8 0 -  1.01 0.081
33. Recording o f  dataset for individual patients 19 8982 0.94 0 .8 4 -  1.05 0.248
N etw ork audit
34. Netw ork wide audits 6 2962 0.93 0 .8 4 -  1.01 0.101
Participation in approved clinical trials
35. List o f  agreed clinical trials 13 5709 0.90 0.81 -  1.01 Œ080
"including interaction term s with follow-up tim e for age, sex and tum our stage
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Full definitions of those standards which seem to significantly predict survival for 
colorectal cancer are specified below. The definitions of cancer standards provided are 
taken from the Manual of Cancer Services Standards (December 2000)
Standard 3. Names of core members of MDT
The MDT should provide the names o f  core team members for named roles in the team. The core team  specific to the 
colorectal MDT should include: designated colorectal surgeon(s); oncologist(s); physician gastroenterologist; radiologist; 
histopathologist; skilled colonoscopist o f  any discipline; nurse specialist(s).
Notes: The MDT m ay choose to name additional core members, for instance stom a nurse. This may or m ay not be one o f  
the skills o f  the nurse specialist. These are not subject to assessment. W here a medical specialty is referred to, the core 
team member should be a consultant. The cover for this m em ber need not be a consultant.
Demonstration o f  compliance: Name o f  each core team m ember with their role, agreed by the Lead C linician o f  the M DT. 
Standard 14. Operational policy -  MDT review of new cancer patients
There should be an operational policy for the team whereby it is intended that all new cancer patients will be review ed by 
a multidisciplinary team.
Notes: As stated in the NHS Cancer Plan, the care o f  all patients should be formally reviewed by a specialist team. This 
will be done either through direct assessment or through formal discussion with the team  by the responsible clinician. This 
will help ensure that all patients have the benefit o f  the range o f  expert advice needed for high quality care.
Demonstration o f  compliance: Operational policy.
Standard 28. Written information material [for patients] available
The MDT should provide written material for patients which includes: information specific for that M DT about local 
provision o f  the services offering the treatm ent for tat cancer site; information about patients self-help groups if  available; 
information about the services offering psychological, social and spiritual/cultural support if  available; inform ation 
specific to the MDTs cancer site or group o f  cancers about the disease and its treatm ent options 
Demonstration o f  compliance: The written (visual an audio is used -  see note below) material.
Notes: Its content and format are not subject to assessment save as per the standard. It is recom mended how ever that it is 
available in languages and formats understandable by patients including local ethnic minorities. This m ay necessitate the 
provision o f  visual and audio material.
Standard 30. Network wide clinical guidelines for cancer site
The M DT should agree specified network-wide clinical guidelines""'^" with the N etwork Site Specific Group (N SSG ) for 
that cancer site. W here there are agreed national clinical guidelines, the network and the MDT should accept these.Notes: 
Regionally agreed clinical guidelines are not precluded but are not part o f  the standard since netw orks m ay operate in 
parts o f  m ore than one region. For compliance the NSSG should produce an agreed guideline and the individual M D T, for 
their compliance, should agree to abide by it.
Demonstration o f  compliance: The clinical guidelines agreed by the Lead Clinician o f  the M DT and the C hair o f  the 
NSSG
Note: The contents, completeness or judgem ents on the appropriateness o f  the guidelines are not subject to assessm ent 
save as per the standard.
i.e. how a given patient should be clinically managed (usually at the level o f which modality o f treatment 
is indicated for a given set o f clinical circumstances, rather than detailed regimens or details o f  surgical 
techniques etc). Source: Manual o f  Cancer Services Standards (December 2000).
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4.4.8 Comparison of results obtained using alternative approaches to handle missing 
stage data
As mentioned earlier in this chapter, a ‘complete case analysis’ was conducted in 
relation to tumour stage variable, which contained 20.9% of missing values. This implies 
that ‘not known’ values were considered missing in the analysis and patients with ‘not 
known’ stage were excluded from the analysis. However, for comparative purposes, 
analyses were repeated including ‘not known’ values as an additional separate category. 
Analyses were also repeated after multiple imputation of missing values, (see Table 4.28) 
As indicated in Materials and Methods chapter, the main disadvantage of using 
‘complete case analysis’ is in its inefficiency as cases with missing data are excluded from 
the analysis. On the other hand, although creating an additional ‘Not Known’ category is 
widely used by epidemiologists for handling missing data because of its simplicity, it was 
found to produce biased estimates under most conditions^^^’^ ^^ . The impact of this method 
depends on how the missing values are divided among the real categories, and how the 
probability of a value being missing depends on other variables. This method can lead to 
misleading results as very dissimilar classes may be lumped into one category.
Multiple imputation technique, although still under development, is currently 
considered as a method of choice for handling missing data as it allows imputation of 
missing values based on all available variables.
However, using either of those methods brought about similar results. The Table 
4.28 below specifies and compares the results obtained using three alternative approaches 
in an example of significant predictors of survival, described in this chapter.
This comparison shows no difference between estimates of RER under any of 
employed approach of handling missing data. For example, RER for ‘clinical guidelines’ 
standard under ‘complete case analysis’ was equal to 0.81 (95% Cl 0.72-0.92), under 
‘additional Not Known category’ -  0.80 (0.71-0.90), and using multiple imputation of 
missing values -  0.82 (0.74-0.91). These last two methods did not change significance or 
direction of associations found. The comparison suggests that the mechanism of missing 
data was ‘missing completely at random’.
Data is said to be missing completely at random (MCAR) when there are no 
systematic differences between complete and incomplete records^^^^^^. Missing values are
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not related to any observed or unobserved values, and that the missing cases are a random 
sample of the complete cases.
Table 4.28 Comparison of results obtained using alternative approaches to handle 
missing stage data
Indicator
‘Not known’ values 
considered ‘missing’
‘Not known’ values 
included as additional 
separate category
Multiple imputation of 
missing values
RER 95% Cl Pvalue RER 95% Cl
P
value RER 95% Cl
P
value
Type o f  
treatm ent:
Total rem oval o f  
organ
1
Partial rem oval o f  
organ 1.08 0 .9 7 -1 .2 0 0.141 1.09 0 .9 9 - 1 .2 0 0.064 1.09 1 .0 0 -1 .2 0 0.06
Tum our/lym ph 
node rem oval or 
excision
2.01 1 .7 1 -2 .3 6 <0 .001 1.93 1 .6 4 -2 .2 8 < 0.001 1.87 1 .5 8 -2 .2 0 <0.001
N on-tum our 
rem oving surgery 3.58 2 .8 7 -4 .4 6 < 0.001 3 36 2 .6 3 - 4 .2 9 < 0 .001 3 d 8 2 .3 9 -4 .2 3 <0.001
Investigative 
procedures only 3.2 2 .7 9 -3 .6 7 < 0.001 3.07 2 .6 8 - 3 .5 2 < 0 .001 2 95 2 .5 7 -3 .3 8 <0.001
Teaching status:
No 1
Yes 0.87 0.77 -  0.99
0.032 0.88 0 .7 7 - 0 .9 9 0.037 0 89 0 .7 9 -0 .9 9 0.038
Cancer
standards:
Standard 3. 
Nam es o f  core 
m em bers o f  M DT
0 83 0 .7 8 -0 .8 8 <0 .001 0.81 0 .7 6 - 0 .8 5 < 0 .001 0.81 0 .7 7 -0 .8 6 <0.001
Standard 14. 
Operational 
policy -  M DT 
review  o f  new 
cancer patients
0.86 0 .7 8 -0 .9 5 0.002 0  85 0 .7 7 - 0 .9 4 0.002 0.87 0 .8 0 -0 .9 6 0.005
Standard 28.
W ritten
information
material [for
patients]
available
0.84 0 .7 9 - 0 .9 0 <0 .001 0.84 0 .7 8 -0 .9 1 < 0 .001 0.85 0 .7 9 -0 .9 2 <0.001
Standard 30. 
Network wide 
clinical guidelines 
for the cancer site
0.81 0 .7 2 -0 .9 2 0.001 0.8 0 .7 1 - 0 .9 0 < 0 .001 0.82 0 .7 4 -0 .9 1 <0.001
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5 DISCUSSION
5.1 Introduction
This study was undertaken during the period of implementation of the Cancer Plan 
for England (DH 2000), and is based on data relating to the start of the Plan. The Plan set a 
ten-year programme of change for NHS cancer services, through increasing resources for 
treatment (including staffing, equipment, pharmaceuticals) and new organisation of 
services (including waiting times, multi-disciplinary teams and cancer networks linking 
units and centres).
Cancer is unique among the main diseases in having, through cancer registration, a 
nation-wide system recording incidence and death. Incidence data from cancer registration 
have been used to investigate disease aetiology, through classic studies of time, place and 
person, and trends in incidence can be used to assess the impact of environmental changes 
and preventive interventions^^"^. However, linking cancer registration to deaths, which is 
feasible in the UK through the NHS Central Register provides data on survival -  a 
reflection of the ability of health services to treat cancer at population level^.
Clinical trials can show the efficacy of a specific intervention. But the results of 
trials may not be translated into effectiveness, the impact on the population, for several 
reasons: the intervention may not be implemented everywhere; implementation may not be 
at the standard of the original trial; and the trial may have been selective in the population 
sub-groups studied. Surveillance using cancer registration allows public health assessment 
of the overall impact of new treatments in cancer services.
The Department of Health for England commissioned ‘Improving Outcomes 
Guidance’ reports for several tumour types^'^^’^ ’^^ ,^ including colorectal*^’'^’^ ’^^  ^ cancer, 
providing extensive reviews of determinants of cancer outcomes. The reviews suggest that 
there has been more intervention research on clinical practice, usually trials, than on 
organisational interventions. There was partial evidence on the benefits of reducing waiting 
times, while multi-disciplinary teams and cancer networks had not been researched.
Colorectal cancer is the second commonest cancer in England by incidence, and 
cause of cancer death, and has an average 5-year survival of around 40-45% - providing a 
statistically sufficient number of events for the statistical analysis chosen in this study.
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Clinical reports indicate that the quality of surgical treatment is important in survival, 
especially for rectal cancer* and the Cancer Plan for England considers that the
organisation of treatment at hospital level can also have an impact. Data on colorectal 
cancer survival in London were available through the Thames Cancer Registry, and formed 
the dependent variable for analysis in the study, while measures of hospital charaeteristics 
were drawn from several sources. The study demonstrates the feasibility of identifying and 
using explanatory variables from these datasets, which has not been done before. It also 
demonstrates limited feasibility in terms of limitations of inferences while using routine 
databases for explanatory purposes. Interpretation is limited due to the methodological 
limitations, temporal relationships, incomplete adjustments for confounding factors, lack of 
some disease-specific indicators (e.g. cancer-specific staffing), and concerns over data 
accuracy. The analysis supports some, but not all, hypotheses based on the literature.
5.2 Data sets
At the time of this study, each of the five data sets was currently used alone by the health 
service. Cancer survival data has been available for many years through eaneer registration 
and death certification. Hospital Episode Statistics in England started in 1989, while the 
other three data sets were only available for the period of 2000 onwards. The study has 
made the first national use of the cancer standards, and the other data sets have not 
previously been used together to address cancer services. The data sets were assembled, 
assessed for quality, and individual items from each were drawn to use as explanatory 
variables within the model.
5.2.1 Quality of the data
Although major concerns have been expressed about the completeness and accuracy 
of diagnosis and procedures^*^’^ ,^ missing data^ **’^ *’^ **^; and variations in data collection 
routine datasets have been used in performance evaluation and outcome research. 
Availability, relative inexpensiveness and coverage of defined or regional populations are 
among the main reasons ' Hence, initial steps in this study were to assess the quality of 
the data, ‘clean’ them if possible, and to consider potential limitations during statistical 
analysis and subsequent inferences.
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• Properties
DoCDat assessment tool was used to review the properties of the datasets^^^. This 
structured questionnaire has proved useful for structured appraisal of national datasets (see 
Results chapter and Appendices 11-15), although it was originally developed for datasets, 
which contain individual level data^ "^^ ’^ ^^  and, thus, has limitations in describing properties 
of hospital level data. Nevertheless, the present study suggests that the criteria developed 
by DoCDat can be applied broadly to assess quality for research use, taking into account 
specific circumstances in each case.
Data quality (coverage and accuracy) was assessed using a 4-point scale, where “4” 
indicates the highest level of quality, and “ 1” - the lowest level of quality, in accordance to 
DoCDat assessment tool.
• Coverage 
Cancer Services Peer Review
All cancer unites and centres in England are covered by the dataset, (level 4 for 
‘representativeness’). However, out of 28 hospital trusts included in the study, data for 3 
hospital trusts could not be included in the analysis because of differences in structure of 
hospitals between the Thames Cancer Registry and the Cancer Services Peer Review 
datasets. Therefore, only data on 25 hospital trusts in London were considered in the model 
(level 2 for ‘recruitment’). No data on major eonfounders are available in the dataset; 
therefore, level 2 was assigned for the ‘variables included’ in the dataset criterion.
Data were mostly complete (level 3 for ‘completeness of variables’). For more details, see
4.1.1 and Appendix 14.
Acute Hospital Portfolio (AHPl
All NHS acute hospital Trusts are covered by the dataset (level 4 for ‘representativeness’ ). 
However, as per Table 4.2, not all indicators within the AH? were available for all 28 NHS 
Trusts considered in this study. This availability (‘recruitment’) varied from 23 to 27 
hospital trusts (level 2). Dataset does not include information on major known eonfounders 
(level 2 for ‘variable included’). Data were mostly complete (level 3 for ‘completeness of 
variables’). For more details, see 4.1.2 and Appendix 11.
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Cancer Waiting Times
All urgent referrals of patients with suspected cancer are included in the dataset. However, 
it does not include non-urgent referrals and those admitted to the hospital without GP 
referral. Therefore, there is only “some evidence” that the eligible population is 
representative (level 2 for ‘representativeness’). On the other hand, all 28 hospital trusts 
included in the study were covered by the dataset (level 4 for ‘recruitment’). Dataset does 
not include information on major known eonfounders (level 2 for ‘variables included’).
Data were mostly complete (level 4 ‘completeness of variables’). For more details, see
4.1.3 and Appendix 13.
Hospital Episode Statistics (HES)
All NHS patients treated in NHS Trusts are covered by the dataset (level 4 for 
‘representativeness’). Out of 28 hospital trusts included in the study, only data on one 
hospital trust were not available in the dataset (level 3 for ‘recruitment’). Various 
administrative and clinical data, along with some of the known eonfounders and outcome 
data are recorded in the HES (level 3 for ‘variables included’). On a national level, most 
variables are at least 95% complete (level 3 for ‘completeness of variables’). For more 
details, see 4.1.4 and Appendix 12.
Cancer Registry
Total population of the covered region included (level 4 for ‘representativeness’). Dataset 
includes 90-97% of the eligible population (level 3 for ‘recruitment’). Various 
administrative and clinical variable are included in the dataset. However, not all 
confounding factors are available there (level 2 for ‘variables included’). All variables 
necessary for survival analyses were complete except for tumour stage and type of 
treatment received (level 3 for ‘completeness of variables’). For more details, see 4.1.5 and 
Appendix 15.
• Accuracy 
Cancer Peer Review
Explicit definitions and rules for coding were set out in the Manual of Cancer Services
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Standards (Department of Health, 2001). (level 4 for ‘explicit definitions’ and ‘explicit 
rules’) However, no information on data validation has been identified (level 1 for ‘data 
validation’) . For more details, see 4.1.1 and Appendix 14.
Acute Hospital Portfolio (AHP)
The definitions of most variables are provided in accompanied reports or guides to 
indicators (level 4 for ‘explicit definitions’). However, coding rules were available for 
indicators of medical staffing and radiology, but not for ward staffing (level 3 for ‘explicit 
rules’). No information on data validation has been identified (level 1 for ‘data validation’). 
For more details, see 4.1.2 and Appendix 11.
Cancer Waiting Times
All variables have clear definitions and coding rules (level 4 for ‘explicit definitions’ and 
‘explicit rules’). No published information has been identified as to whether data have been 
validated (level 1 for ‘data validation’). For more details, see 4.1.3 and Appendix 13.
Hospital Episode Statistics (HES)
All or almost all variables have clear definitions and coding rules (level 4 for ‘explicit 
definitions’ and ‘explicit rules’). Data are validated by range and consistency checks (level 
3 for ‘data validation’). There are also reports on regular external audits, although no 
vigorous validation at source is conducted. For more details, see 4.1.4 and Appendix 12.
Cancer registry
All or almost all variable have clear definitions and rules of coding (level 4 for ‘explicit 
definitions’ and ‘explicit rules’). Data are being validated by range and consistency checks, 
supplemented by external validation using an alternative source (level 4 for ‘data 
validation’). For more details, see 4.1.5 and Appendix 15.
Coverage of datasets vary depending on criteria, and, in general, allowed for 
feasibility of getting and analysing data. Nevertheless, lack of information on some major 
known eonfounders, as well as noticeable proportion of missing tumour stage data in cancer 
registry were the main limitations in terms of data coverage. In relation to data accuracy, 
datasets normally provided with the clear definitions and rules of coding for variables
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included in the study. However, lack of data validation for most of the datasets may hinder 
feasibility in terms of limitations of inferences due to concerns over data accuracy.
• DCO registrations
One indicator of the quality of the cancer data was the proportion of death 
certificate only (DCO) registrations^ DCO cases are excluded from survival analysis 
since their date of diagnosis and subsequent follow-up information is not available. Studies 
by the Thames Cancer Registry have shown that DCO registrations are higher with 
increasing age and decreasing survival^^. Whereas in the literature, the percentage of DCO 
cases varied from 1% to 25% of all registrations^^’^  ^’^ ,^ our study had a low percentage of 
DCO cases (548 patients - 3%), which were excluded from the analysis.
• Selection of variables
Selected variables from the larger datasets were used for analysis in this study. 
Factor analyses can be used to reduce the number of variables and detect structure in the 
relationships between variables of data sets However, the method is statistical and does 
not value the dimensions in a qualitative way. The selection for this study was based on the 
completeness of the data, their relevance to study objectives, in relation to the literature 
findings, and the time period covered in relation to other datasets, supported with expert 
advice.
5.2.2 Handling missing data
One of the main concerns for data quality in the five datasets was missing data.
Some variables were not recorded or available for particular hospital trusts (or sometimes 
the hospital trusts themselves were differently designated because they were merging or 
splitting). According to personal communications from representatives of the Healthcare 
Commission, the main reason of lack of data for some hospital trusts and variables within 
the Acute Hospital Portfolio was failure to provide the data. Also, data were missing for 
specific variables within individual datasets, in particular tumour stage or type of treatment 
information from TCR. For this reason, not all statistical analyses were run for all patients 
or all hospital trusts. In fact, as was noted in the Results chapter, depending on the predictor
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examined, the number of Trusts included in the analysis varied from 23 (medical staffing) 
to all 28 (waiting times; teaching status).
Of several common approaches which researchers use to deal with missing 
data^ ^^ '^ "^*'^ ^^ , four -  least observation carried forward; creating an extra category for the 
missing variable; replacing missing observations by the mean of the variable; and mean 
imputation using regression -  are not recommend, since they can give unpredictable results 
and are not underpinned by statistical theory^*^’^ ^  ^ (Although, the use of ‘creating an extra 
category’ approach is particularly widespread in the literature.) A new approach to dealing 
with missing data is multiple im putation^H ow ever, this method was not available in 
Stata statistical package until 2004/5, and for categorical variables and it is still under 
development^^^. This study therefore employed ‘complete case analysis’.
In complete case analysis, all ‘not known’ or not recorded values are considered as 
‘missing’ for statistical investigations and modelling. However, this approach is 
‘inefficient’, since it reduces the numbers of study subjects, and gives varying totals for 
each data item analysed. In addition, this method implies a ‘missing at random’ assumption 
which is difficult to prove. On the other hand, as was indicated in Materials and Methods 
and Results chapters, analyses of potential predictors were repeated including ‘not known’ 
values as an additional separate category (i.e. using ‘creating an extra category’ approach) 
and after multiple imputation of missing values. This did not have substantial impact on the 
statistical significance or direction of associations found.
Tumour stage was an important prognostic variable for which analysis was limited 
because it is not well recorded in cancer registry datasets. The overall trend of distribution 
by age, sex and deprivation between patients with known and missing stage information 
was similar, although there were more older (age 80-89) and more deprived patients among 
those with missing tumour stage. It is known that these two factors are associated with poor 
prognosis^^’^ ’^^ ’^^ ’^*'^ ’^''^\ A more visible difference is observed when comparing relative 
frequencies by type of treatment received. A higher proportion of patients with known 
tumour stage received more radical surgery (total or partial removal of organ) as compared 
with patients whose stage information was missing (79.6% vs. 60.8%), while more patients 
in the latter group underwent an investigative procedures only (15.7% vs. 8.45%). As 
indicated in Results chapter, more radical surgery appeared to be associated with better 
survival. Hence, patients with missing tumour stage information were more likely to have 
worse prognosis than those whose tumour stage was recorded.
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More older and more deprived patients had missing tumour stage (see Results 
chapter, 4.3). On the other hand, adjustments for age and deprivation index did not explain 
variations in survival by hospital trust. The most significant explanatory value was obtained 
for tumour stage (see Results chapter, 4.4.1). It is impossible to accurately determine 
whether patients with missing data had more advanced tumour stage as this very 
information was missing. A higher proportion of patients with known tumour stage who 
received more radical surgery as compared with patients whose stage information was 
missing may suggest such possibility, although the presence of comorbid conditions may 
have an impact too.
On the other hand, as mentioned above and specified in Results chapter (see 4.4.8), 
the comparison of results obtained using alternative approaches to handle missing stage 
data showed that regardless of the method employed (including multiple imputation of 
missing values), it did not have an impact on significance or direction of associations 
found, i.e. there were no systematic differences between complete and incomplete records. 
This suggests that the mechanism of missing data was ‘missing completely at 
random’^ ^^ ’^ ^^ .
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5.3 Statistical and methodological considerations
5.3.1 Sample size and power
Sample size estimation and power calculation for survival analysis of clustered data 
is not straightforward and still under development. There are no sound statistical tools and 
programmes available similar to those for studies with control groups^^^’^ ^^ '^ '*^ . According 
to some assessments, in order to get reliable survival and hazard function estimates with 
their standard errors at each time interval, the minimum recommended sample size is 30^'*. 
Also, the power of a survival analysis is related to the number of events (i.e. deaths) rather 
than the number of participants. Simulation work has suggested that at least 10 events need 
to be observed for each covariate studied and anything less will lead to problems, for 
instance the regression coefficients become biased^®'.
In the current study, the total sample size was comprised of 15465 patients treated at 
28 hospital trusts; there were 8059 events (deaths) observed and the maximum number of 
covariates in any one model was 10, depending on specific organisational determinant 
considered and including interaction terms where appropriate. Even though, as was noted, 
not all conducted analyses included all patients or hospital trusts, the numbers were still 
large enough to get reasonable power for statistical tests.
Although the number of cases was sufficient for estimating survival, the other 
limiting factor was the variability, in aggregate, of the organisational determinants, based 
on hospital trusts. While survival showed significant differences between the 28 hospital 
trusts (see Figures 4.11 -  4.13), the variance was smaller for some of the non-continuous 
variables. Thus, three cancer standards (see Table 4.27, standards 1; 7 and 29) were 
excluded from the analysis, since either all hospital trusts complied with them or only one 
Trust was non-compliant; and still included in the model were five standards (see Table 
4.27, standards 2; 3; 4; 24; 28) where only two or three hospital trusts were non-compliant 
with the standards.
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5.3.2 Choice of the method for cancer survival estimation
Five-year survival is routinely used as the main outcome measure for cancer care. 
From the patient and service perspectives, other measures of outcome may also be of great 
importance, such as postoperative mortality, postoperative complications (or complications 
after chemo- or radio-therapy), cancer recurrence rate and quality of life after discharge. In 
fact, quantifying such qualitative complaints or conditions as pain or discomfort, loss of 
mobility etc. is quite difficult and needs to be validated by rigorous research. These 
important issues are not addressed here because routinely collected data for these indicators 
are not available, but this might be of interest in future studies.
As indicated in Materials and Methods chapter (3.6.2), there are two main 
approaches to estimate survival for cancer patients in epidemiological studies: ‘cohort 
analysis’ and ‘complete analysis’. Cohort method requires full period of follow-up time for 
all patients, thus reflecting the full five-year follow-up experience of all patients included in 
the study. On the other hand, for the that reason, cohort measures of cancer survival are less 
up-to-date, require more time to accomplish and could be more appropriate in clinical 
follow-up studies.
Another approach, widely used in cancer epidemiology and employed in this study 
is ‘complete analysis’, which takes into account experience of patients who have not had 
the opportunity to be followed-up for the full period of time. A complete analysis of five- 
year survival would include the probability of surviving one year estimated form the 
experience of patients diagnosed up to one year ago, the probability of surviving two years 
from patients diagnosed up to two years ago, and so forth. Therefore, complete estimates 
are more up-to-date than cohort estimates as the estimation of survival includes more 
recently diagnosed patients. However, if survival is improving over time, or new effective 
treatment or diagnostic methods introduced, this will affect the five-year survival estimates, 
making them higher than those obtained using the cohort method. While acknowledging 
that survival could be changing over five years, it must be noted that no substantial changes 
in treatment or diagnoses were introduced over the study time frame for colorectal cancer 
patients. Also, a sub-analysis comparing annual trends in colorectal survival (Appendix 9) 
shows that, while national survival for colorectal cancer was rising over the period, in 
London there was no significant change.
This approach has limitations in relation to temporal relationships as more patients
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were in early years of the time frame of this study when no information on organisational 
factors was available. However, relative survival modelling employed to assess 
relationships between organisational determinants and survival takes into account 
differences in follow-up time by adjusting it within the model (see 3.6.3, Materials and 
Methods chapter).
5.3.3 Use of multiple testing
According to various simulation studies, the danger with conducting numerous 
comparisons is that the type I error rate (i.e. that rejecting the null hypothesis when it is true 
and concluding that there is an effect when in reality there is none) increase 
substantially^12;313 recommendation to avoid such ‘chance alone’ effect detection is to
perform a small number of tests chosen to relate to the primary aims of the study. In testing 
compliance with the cancer standards, separate statistical tests were made with each 
variable. An alternative was to combine standards and create a single score based on the 
number of standards that had been met, the approach used by Morris"^ .^ However, as the 
cancer standards data set had not been used before in a national study, and because the 35 
colorectal cancer standards had been formally chosen by a peer-review process, it was 
decided to examine associations with all the variables separately, along with the composite 
score (see also 5.5.1). For the other larger data sets (Hospital Episode Statistics, Acute 
Hospital Portfolio) individual variables were selected.
5.3.4 Hierarchical data
This study used data of hierarchical nature with variables reflecting two levels -  
patient and hospital trusts. To take into consideration the hierarchical nature of the data, a 
clustering effect of NHS hospital trusts has been accounted for within the model. 
Adjustment of standard errors for clustering effect of NHS hospital trusts allowed for the 
fact that patients treated within the same NHS hospital Trust may have more similar 
characteristics, treatment or referral patterns and experiences than those from other 
hospitals^^^. Studies that fail to allow for this have been shown to underestimate standard
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errors and, hence, overestimate effects^® .^ Therefore, the adoption of this approach 
increases the reliability of study results.
Another potential option to deal with the hierarchical data would be to use 
multilevel modelling (MLwiN softfware)^^^’^ ' .^ However, the use of multilevel modelling 
with relative survival has yet to be developed. In fact, no study was identified to use this 
approach involving relative survival estimates.
5.3.5 Temporal relationships
• Exploring new data
The Bradford Hill criteria for inferring causality in epidemiological studies include 
the temporal relationship. Nevertheless, cross sectional studies are frequently used for 
exploratory epidemiological studies where longitudinal data do not exist. In the present 
study, the survey of cancer standards in 2000 was the first ever in the country (indeed, 
perhaps in the world) and has not previously been used for statistical analysis. Moreover, 
other data sets, including Waiting Times and the Acute Hospital Portfolio were also only 
available for the first time at 2001-2. Apart from cancer survival, only the Hospital 
Episode Statistics data set was collected in the 1990s. Therefore, the study made the best 
use of newly available data.
• Contemporary data
The study used data from different sources to obtain a unique set of explanatory 
factors for survival. Multiple datasets have been used previously to provide more 
comprehensive data for the research, where a single source has only limited indicators for 
different domains of health care Cancer registrations of adult residents in London,
who were diagnosed with colorectal cancer between 1996 and 2001, and with follow-up to 
the end of 2001, were available for analysis. Survival data reflect back in time^ '^^^, and, 
thus, preceded organisational data in time. However, these were the most recent available 
data. The chosen time frame (1996-2001) allowed sufficient numbers of cases and events 
(deaths) for estimation of five-year relative survival on hospital level. The other data sets 
reflected the time period around 2000 to 2002 (see Figure 3.1), which is the period of the 
start of the Cancer Plan for England.
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• Changing services
The underlying assumption of this study was that the organisational determinants 
estimated in 2000-2002 were of similar value over the five years for which the cancer 
diagnosis made and treatment given. Unknown differences during the time periods covered 
by various datasets is a limitation of the study. While multi-disciplinary teams were 
beginning to be implemented for breast cancer during the 1990s^ ^^ , and were proposed for 
colorectal cancer in the Improving Outcomes Guidance for colorectal cancer in 1997* ,^ 
there is no information about their use in colorectal cancer at that time. Indeed, the 
development of multidisciplinary teams for most cancers, and cancer networks, followed 
implementation of the Cancer Plan for England.
Likewise, no comparative data were available for referral waiting time and staffing 
level to indicate changes (if any) in indicators between 1996 and 2001. However, average 
annual volume of patients admitted to NHS hospital trusts did not change from 1997/98 to 
2001/02: 1997/98 -  704; 1998/99 -  655; 1999/00 -  663; 2000/01 -  653; 2001/02 -  676 
(Appendix 8). While it was not feasible to assess accurately the state of organisational 
determinants back to 1996-1999, this study suggests that the employed methodology could 
be feasible for future analyses when data become available.
• Period analysis
A potential tool for improving temporal relationships in future research is period 
analysis of cancer survival data. First described by Brenner and Gefeller (1997)^'^, this 
approach includes the most recent probabilities of death, and excludes probabilities 
obtained from patients diagnosed in the past, to make future calculations of survival based 
on contemporary data. However, the calculation of period survival is analogous to the 
calculation of life-expectancy at birth from a period life table: while it provides estimates of 
future trends, it needs cautious interpretation since it does not relate to the real experience 
of a specific group of patients.
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5.4 Individual level determinants of survival
5.4.1 Patient case-mix
Comparisons of outcomes between hospital are very dependent on the condition of 
the patients admitted, that is, patient case-mix^^’^ .^ Risk-adjusted models have been 
proposed to take into account differences in severity of illness and, thus, provide more 
reliable estimates of observed associations^^’^ '^ '^ ’^’^ '^^ ^^ . However, there is a problem of 
knowing when adjustment of severity is sufficient^^.
Although the data obtained from the Thames Cancer Registry (TCR) were quality 
assured and the methods of their collection were uniform across the region, they only 
contain limited information on the extent (stage) of disease for each patient, and none on 
comorbidity. The HES dataset contains patient level information on comorbidities, number 
and type of intervention, method of admission (elective; emergency; other) for patients and 
their length of stay^ .^ But at the time of the study, methods to link HES and cancer registry 
data at individual level had not been developed. (This work is now being 
undertaken^^'^'"’^ '^^ ’^ ^^ ) If successful, and available for researchers, this will provide an 
important new approach for survival analyses, to include patient case-mix.
No personal data on socioeconomic conditions were available for the study. 
However, in the absence of individual data on personal conditions, the socioeconomic 
status of cancer patients is routinely determined using an ecological approach. A census- 
derived or area-based score reflects aspects of material deprivation or socioeconomic status 
in the geographic area in which a person resides^^^.
Whilst this study has not been able to adjust comprehensively for all factors that 
could affect outcome, it has attempted to adjust for the most important prognostic factors 
suggested in the literature^^'^^’*^ ’^^ ^^ ’''^ ’^*'^  ^ age, stage and level of social deprivation have 
been accounted for. All these individual level variables were significantly associated with 
five-year relative survival for colorectal cancer in London and the patterns of associations 
observed were similar to those shown in cancer literature^^’^ ’^^ ’^'^ '^^^ ’^^ *. Moreover, stage 
is of greater prognostic importance in cancer outcomes than co-morbidity ^  ^ . In the
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present study, even after adjusting for stage, significant relationships were still found for 
some factors in the statistical analysis. In general, while epidemiological studies may 
always have the possibility of unknown confounding factors, either clinical or 
organisational, the hypothesis tested in the present analysis was based on expected 
predictive factors and a clear analytic model.
However, adjustments for tumour stage requires careful evaluation of the 
investigations used to determine the stage of disease*^^ '^ .^ Stage-specific comparisons may 
be biased by so-called “stage migration”, or Will Rogers p h e n o m e n o n D a t a  suggest that 
a higher proportion of older and more deprived patients were among those with missing 
tumour stage (4.3). On the other hand, adjustments for age and deprivation index did not 
explain variations in survival by hospital trust, and the most significant explanatory value 
was obtained for tumour stage (4.4.1). Therefore, missing stage information (in 20.9% of 
patients) was one of the main limitations of this study. However, the comparison of study 
results using alternative methods of handling missing data (including multiple imputation 
of missing values) suggests that the mechanism of missing data was ‘missing at random’ 
(4.4.8). Further discussion on handling missing data and its impact on study results is 
provided in 5.2.2.
5.4.2 Type of surgery
The type of surgery received by colorectal cancer patients was an independent 
predictor of the outcome (five-year relative survival); the more radical the surgery, the 
better the survival. Equally, patients who only had investigations, without formal treatment, 
had a more than two-fold excess mortality. There were also statistically significant 
interactions between the type of surgical treatment, age and tumour stage. These results are 
expected, and concur with the findings n a t i o n a l l y ' C h o i c e  of type of surgery is 
strongly related to clinical characteristics at presentation, and is not an independent 
prognostic factor.
There were no data available to assess the influence of adjuvant therapy (radio-and 
chemo-therapy), which may modify the effect of the main surgical treatment. One of the 
explanatory variables of the difference found between hospitals was their compliance with 
‘clinical guidelines’ standard, and this might have been led to differences in adjuvant
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therapy. On the other hand, adjuvant radiotherapy and chemotherapy are recommended 
only for a relatively small proportion of colorectal cancer patients, particularly those with 
advanced stages and with rectal cancer (for radiotherapy)^^.
5.5 Organisational determinants of survival
Hospital Trusts are the standard level for analysis of much NHS administrative data 
and for performance management and comparison purposes^^’^ ^^ ’^ '^. However, changes in 
population boundaries (catchment areas) and structure of hospital trusts over time may 
influence the validity of comparisons between them. Also, while justification was provided 
(see Materials and Methods chapter) in allocating the hospital trust of first attendance as 
‘hospital of treatment’, this issue remains an unresolved problem in cancer research and 
should be regarded as a limitation of the study.
The study shows that variability in five-year relative survival between hospital 
trusts in London was significant and wide ranging from 31.3% (95% Cl 23.4%-39.4%) to 
55.4% (95% Cl 50.6%-60.0%). These differences were not completely accounted for by 
differences in patient case-mix: even after considering the effect of case-mix variables, 
there still remained unexplained variation, which may be accounted for by other factors 
related to the hospital.
5.5.1 Compliance with cancer standards
Clinical guidelines are commonly regarded as a means of assisting physicians in 
making therapeutic decisions, and compliance with guidelines was assessed in the literature 
mainly in relation to clinical interventions^®'^^’^ ^^ ’^ ^^ . However, another purpose of 
guidelines implementation reflects organisational goals and aimed at managed care^“^. This 
aspect has been less explored in the literature.
Management of cancer patients intrinsically involves participation of specialists 
from various disciplines. The organisation and functioning of MDTs were set out in the 
Manual of Cancer Services Standards These standards were not evidence-based, but 
developed with expert opinion, current directions of cancer policy and general consensus 
among professionals. There were overall about 200 standards, divided into ten groups 
reflecting organisational characteristics of clinical services. Compliance with cancer
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standards was determined by teams of health care professionals and managers in the course 
of peer review visits at each cancer unit and centre at NHS hospital trusts.
One of the ten groups of standards was for multi-disciplinary teams (MDT), for 
each of four cancer diagnoses -  breast, lung, colorectal and gynaecological. There were 35 
colorectal cancer specific MDT standards in the Manual and dataset.
To investigate the impact of MDT criteria on cancer survival, two approaches were 
considered: composite score (overall measurement for the compliance with all 35 cancer 
standards), and compliance with the 35 individual cancer standards. The composite score 
was marginally but significantly associated with five-year relative survival. While no 
relationship was found between compliance with majority of standards and five-year 
relative survival, positive independent associations with cancer survival were observed for 
standards defining
• the structure of MDT ;
• operational policies;
• availability of patient information;
• and clinical guidelines.
However, the use of individual scores has disadvantages. There may be problems 
of collinearity. The individual standards reflect different aspects of care under MDT 
management of cancer patients: some of these aspects are described by one standard, and 
some by a group of standards. While all 35 standards carried equal weight in the analyses, 
adherence to some may have had more influence on clinical outcomes than others. For 
example, compliance with the ‘clinical guidelines’ standard is arguably more important 
than ‘recorded attendance at MDT meetings’. Also, as indicated in this chapter above (see 
5.3.3), while testing all 35 standards separately (“use of multiple testing”), the possibility to 
obtain associations by ‘chance alone’ increases.
Although all these findings could potentially have important policy implications, the 
strongest association was found in relation to compliance with ‘clinical guidelines’ 
standard. Even after adjustment for available case-mix indicators of age, sex, tumour stage 
and social deprivation, patients treated at hospital trusts which complied with ‘Having a 
written agreement describing clinical guidelines’ standard, had a 19% reduction of excess 
mortality compared with patients treated at hospital trusts ‘not having such an agreement’ 
(relative excess risk of death 0.81, 95% Cl 0.72-0.92; p=0.001). This finding fits with the
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concept that delivery of efficacious treatment can have clinical impact.
No study has previously explored the association between compliance with the 
published cancer standards, as assessed by national peer review, and cancer survival. 
However, Morris studied adherence to self-assessed MDT standards (total score) for 
colorectal cancer patients in 14 hospital teams in Yorkshire region (UK)'^ .^ The results of 
her study were similar to our findings. She concluded that 25% increase in adherence was 
related to around 8% reduction in the risk of death after one and two-year follow-up.
But compliance with ‘clinical guidelines’ standard reflects only the fact that clinical 
guidelines have been ‘agreed’ by MDT. Their actual adherence or implementation was not 
subject to the Cancer Services Peer Review, and, thus, was not considered in this study.
This is true for all 35 standards assessed.
Taking into account the significant association of compliance with specific cancer 
standards (in particular, ‘clinical guidelines’ one) and survival, we can propose that hospital 
trusts which had ‘agreed guidelines’ were more likely to adhere to them in practice as 
compared to non-compliant trusts. However, it was not possible to validate this assumption. 
Nevertheless, the results of the study gave an initial indication that, if the assumption is 
true, compliance with ‘clinical guidelines’ could significantly improve population-level 
survival of colorectal cancer patients. This, in turn, could have important policy 
implications and practical impact in clinical settings, stressing the necessity to conform to 
guidelines to achieve better outcomes. However, these results need to be viewed within the 
context of the study as a whole, taking into account its weaknesses and limitations.
5.5.2 Teaching status of hospitals
Unlike in US^ or Canada^^" ,^ no formal definition or taxonomy was identified in 
the UK for a ‘teaching hospital’. In this study, teaching hospitals were defined as long- 
established or specialist hospitals which provide undergraduate and/or postgraduate 
teaching. Out of 28 hospital trusts in London providing colorectal cancer care, 11 have been 
classified as ‘teaching’ and 17 -  as ‘non-teaching’ hospitals. The complete list is provided 
in the Results chapter.
In the literature, teaching hospitals were not shown to have consistently better 
outcomes compared with non-teaching hospitals^^®'^^^’^ ^^  and there was insufficient and
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equivocal evidence in relation to colorectal cancer survival^ "^ "^ ’^ ^^ . These inconsistencies 
may partly be explained by various definitions employed and degree of adjustments for 
patient case-mix.
In this study, there was a 13% survival advantage for patients treated at teaching 
hospitals as compared with patients in non-teaching hospitals. The definition of ‘teaching 
hospital’ employed, and subsequent division of hospitals into two groups, was a practical 
way to examine the effect of teaching status on the outcomes of care. In fact, our grouping 
of teaching and non-teaching hospitals was similar to the categorisation of hospital trusts 
employed by the Healthcare Commission’^ ’^^% It would be useful for any future studies in the 
UK to use a unified and agreed formal definition of ‘teaching hospital’, to get more 
repeatable results.
Behind from the identify of a ‘teaching’ hospital itself, there are structures and 
processes of care which, according to the literature and common knowledge, may be 
important determinants of outcomes of care. Possible explanations of the observed 
variations may include differences in the process of care in teaching and non-teaching 
hospitals involving greater use of multidisciplinary teams in teaching hospitals, and 
differences in resources^^^’^ "^ '^^ ^^ . However, incomplete adjustment for case-mix; different 
patterns of detection; referral or artefact of misclassification of cases by disease stage may 
also play role in the observed differences.
Teaching hospitals may also be more likely to adhere to clinical guidelines than 
non-teaching hospitals^^^'^^\ Our analyses showed that 50% of teaching hospitals were in 
compliance with the ‘clinical guidelines’ standard, while only 27% of non-teaching 
hospitals did comply with it. In addition, there was a statistically significant correlation 
between teaching status of hospitals and compliance with the ‘clinical guidelines’ standard. 
There was also a statistically significant correlation between teaching status and hospital 
volume. However, lack of significant survival impact of the volume effect may suggest that 
factors associated with teaching status of hospitals play a more important role. These issues 
need further investigation.
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5.5.3 Staffing level
No study was identified that had examined the relationships between different levels 
or types of staffing and cancer survival. Evidence from other fields suggests that doctor and 
nurse staffing may have an impact on postoperative mortality and complications^^'^ 12,213
A national study in England concluded that medical staffing level was one of the 
main predictors of risk-adjusted mortality across 183 hospital trusts in England^^. It was 
therefore included as a predictive variable in the present study. However, no relationship 
was found between indicators of staffing level and five-year relative survival. It is of note 
that the indicators were not cancer specific but rather reflected general staffing at hospital 
trusts.
On the other hand, colorectal cancer patients were usually managed by general, 
rather than colorectal cancer-specific staff. Overall, the development of cancer-specific 
specialisation was not in place for a time frame referred in the thesis. Also, only limited 
number of hospital trusts (5 to 12, depending on standard) were in compliance with three 
‘colorectal nurse specialist qualification’ related standards in a peer review assessment in 
2001 (see Results chapter. Table 4.27). Compliance with these standards was not shown to 
be associated with five-year relative survival. In addition, no dataset for cancer-specific 
staffing was available for the study purposes.
Therefore, staffing level data which were available for the study could only be 
viewed as a proxy for true staffing. Since the Cancer Plan for England proposed increases 
in specialist cancer staff, both medical and nursing, as a major area of clinical 
improvement, it would be appropriate in future research to investigate the independent 
effect of staffing levels on colorectal cancer survival.
5.5.4 Volume
This study found no relationship between average annual volume of patients treated 
at NHS hospital trust and five-year relative survival. There is conflicting research evidence 
about the potential benefits of care provided by high-volume providers, specialists or in 
specialists units, compared with that provided by low-volume providers and non­
specialists. A systematic review of ‘improving outcome’ for colorectal cancer
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commissioned by the National Institute for Health and Clinical Excellence (NICE) showed 
a strong association of higher volume with better outcomes for rectal cancer, but little or no 
effect for colon cancer^^.
Generally, several studies in the literature emphasise that volume can be covariate 
for other factors more critical to patient care, including high volume hospitals may have 
more surgeons who specialise in specific procedures, more consistent processes for 
postoperative care^ "^^ ; better staffed intensive care units, and greater resources, in general, 
for dealing with postoperative complications^^^; physicians who use effective treatments, eg 
adjuvant chemotherapy, more often than their low-volume counterparts^^^’^ ^^ . However, 
many volume-outcome studies, including a study by Ko et al^ ^ ,^ indicated the issue of 
‘reverse causality’: one cannot be sure that hospitals get good results because they are high- 
volume, or whether hospitals with good results consequently become high-volume.
The current study used HES data to identify the average annual number of patients 
treated at the hospital trusts forl 997-2001. (It was not until 1997 that HES started assigning 
unique patient identifiers, which distinguish individual patients over different episodes of 
care or multiple admissions within a year, thus preventing their over-counting.) Moreover, 
in the present research, unlike many other reported studies, ‘volume’ refers not only to 
surgical patients (although they constituted majority) but to all colorectal cancer patients 
admitted to the hospital. This gave compatibility with the cancer registry survival data set, 
which included all cancer patients regardless the type of treatment received.
Another important factor is that volume (workload) cut-off points were arbitrary, 
and based on statistical factors (see Materials and Methods chapter). However, there is no 
consensus or agreed definitions on appropriate volumes or caseloads (hospital- and 
surgeon-specific) for colorectal cancer patients^^’^ .^ The only figure suggested in the 
literature was from a study by Hermanek & Hohenberger, who proposed monthly average 
of between one and two radical resections for colorectal cancer as a minimum^
The lack of association between hospital volume of patients and survival might 
partly be explained because admission rates to hospital trusts in London are above some 
‘critical’ minimum volume level, so that all of them ‘complied’ with a (lower) ‘volume 
standard’ (say, more than 100 patients per year). The average annual volume of patients for 
these trusts varied from 150 to 2525 patients a year (see Appendix 8,), while in majority of 
literature studies hospital volume ranged from 17 to 55 cases a year^^ '^^ °^'^^ .^
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5.5.5 Specialists
The study had no specific measure of individual specialist care, but the literature, 
mainly supports the belief that specialist care improves patient outcomes^^ '^^^ '^^^ '^^ '^ .^ 
Outcomes following specialist treatment appear to be independent of case-mix
Specialisation in relation to cancer surgery has been implemented widely in the 
management of breast cancer patients in England. In contrast, the move towards surgical 
site-specialisation in colorectal cancer has been slower and many colorectal cancer patients 
during the period of this study would have been operated on by general surgeons.
It is not clear what constitutes ‘sufficient’ experience for a colorectal specialist. 
Comparisons will depend on the frequency of the adverse event of interest. For example, to 
accurately assess inter-surgeon variation in peri-operative mortality, around 150 cases for 
each surgeon will be required^^" .^ The lack of formal accreditation means that there is no 
way of assessing the experience of a surgeon. A colorectal surgeon is (only) ‘expected’ to 
attend the MDT meeting, to be a member of the specialist association and to contribute to 
local and national audit of their colorectal cancer work^^ .^
Although this study could not investigate specialisation, the likely benefit o f patients being 
treated by specialists, as shown in the literature^^^’^ ^^ ’^ ^^ ’^ '^^ , suggests that this issue needs to 
be addressed in future research.
5.5.6 Waiting time
Meeting ‘two week wait’ target by hospital trusts in London was not found to be 
associated with five-year relative survival for colorectal cancer patients. There may be 
several reasons for this finding.
No primary study was identified to investigate the associations between waiting 
times and colorectal cancer survival. Analysis of this association was carried out within the 
framework of current study.
Various studies have described the so called ‘waiting time paradox’: patients with 
longer waiting times generally have less advanced disease and better survival^^^"^^ .^ The 
traditional view is that delay caused by organisational deficiencies has an adverse effect on 
the disease and this influences survival. As a possible explanation of these trends, it was
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suggested that patients with advanced disease were ‘fast-tracked’ by GPs and hospitals, and 
had shorter delays. Also, consultants may be able to differentiate patients at greater risk and 
to ensure faster diagnosis and treatment. On the other hand, due to severity of condition, 
survival of ‘fast-tracked’ patients was poor, affecting overall outcome among patients 
received prompt treatment within the target.
In addition, the ‘two week wait’ target does not necessarily reflect the process of 
care of cancer patients alone. The review of Cancer Waiting Times Statistics^^^ showed that 
the majority of patients urgently referred by GPs with suspected cancer do not have cancer. 
(See Appendix 10: for data from quarter 3 in 2005/2006, there were 141052 two-week wait 
referrals for all patients with suspected cancer, but in the same period only 17137 patients 
(12.15%) received treatment for cancer within the two month wait standard.) Moreover, a 
substantial proportion of all colorectal cancer patients are diagnosed by other pathways, not 
‘urgent’ GP referral. Thus, lack of association found in this study was expected from by 
other studies.
The Department of Health changed its targets for NHS hospital trusts from 95% 
achievement of two-week wait standard to 98% from 2004, since most hospitals had 
complied with the standard by that time. Also, from the quarter 4, 2004/2005 they began 
monitoring a one-month wait target from diagnosis to treatment, and a two-month wait 
target from GP urgent referral to treatment for all cancers (i.e. moving from delay in GP 
referral to delay in diagnosis and treatment). The impacts of these new measures on 
survival remain to be seen and should be ascertained in future research.
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CHAPTER 6
CONCLUSION
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6 CONCLUSION
6.1 Overview
There is a growing interest in defining and measuring health care outcomes, both to achieve 
intrinsic improvements in health care and also to demonstrate cost-effectiveness. These 
perspectives have stimulated new approaches to using routinely collected, 
administrative/clinical data for outcome research^^. Yet, even though the field of quality 
measurement is nearly 20 years old, experts disagree about how adequately the quality of 
care can be measured today "^^ .^ Although outcome measures may be used as evidence for 
quality of care, outcomes do not indicate directly how care might be improved^^^.
Donabedian’s model remains central in thinking about quality of health care^^'^^'^\ 
However, structure, process and outcome are not themselves attributes of quality. They are 
only attributes and measures from which one can infer that quality is good or not.
Inferences about quality examine the relation among the three dimensions, so that structure 
influences process and process influences outcomes. But this is a much simplified version 
of a much more complex reality, and it is somewhat arbitrary to say where “structure” ends 
and “process” begins.
One of the main limitations of research using routine data is the lack of information about 
important confounding factors (with the exception of age and sex). Case-mix adjustment 
has been shown to be important for comparisons of hospitals and specialists. In cancer care, 
stage is an important attribute for prognosis, but there is doubt about the reliability of the 
measurement of stage. Stage level increases with the amount of investigation (eg number of 
lymph nodes examined pathologically, scanning of distant organs), so that hospitals with 
similar patients may report different stage levels. For this reason, it is not necessarily 
helpful for health services research (in contrast with clinical studies) to compare hospital 
outcomes by stage, unless there are standardised definitions. Differences in recording of 
additional diagnoses may equally limit the use of co-morbidity as a prognostic factor.
Administrative datasets were not designed to assess quality of care or patients outcomes.
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They were developed to answer administrative questions. For this reason, they are probably 
most useful as screening tools that highlight areas in which quality should be investigated 
in greater depth^ *^ . However, with additional clinical data, either incorporated within the 
existing datasets or through the linkage to other sources of data, opportunities for asking 
questions about quality of care and looking at patient outcomes now exist.
• ‘Ideal’ dataset
‘Ideal’ datasets, to quote lezzoni^^, should contain adequate clinical information “generated 
not only by clinicians and electronic reporting systems (such as those in laboratories and 
pharmacies) but also by patients.” Additional sets of data, particularly those reflecting 
palliative care, screening activities and health behaviour (smoking; diet; physical exercise 
and so on), should be incorporated too, when available and appropriate, to enhance the 
analytical potential of datasets. Linking primary care and hospital datasets will enhance 
their capabilities to capture patient pathway including prevention, diagnosis, treatment, 
rehabilitation and patient education. Nationally approved codes should be used across the 
datasets to ensure feasibility of their linkage. There should be unified definitions of similar 
variables contained across the national datasets with explicit coding rules stated. Clinicians 
should participate in these efforts and ensure that ultimate coding schemes are clinically 
meaningful. Also, continuous validation at source (e.g. through audit or case-note studies) 
and external validations with other related data sources should be conducted to ensure their 
accuracy.
This issue is high on the current agenda for cancer information policy in England, and 
present study may assist in future developments. Particularly, NHS Connecting for 
Health^^^" initiative came into operation in April 2005 as an agency of Department of 
Health. It aims to combine information from different sources within the NHS into a single 
structure. Among the main priorities of this initiative is to link GP and hospital data sets 
and give patients access to their personal health information.
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• Main findings
This study has tested the hypothesis that hospital organisational factors contribute to 
survival at population level independently of individual patient factors. It also assessed the 
feasibility of using secondary data about the hospitals for these purposes.
Particularly, study shows that secondary data on various hospital level organisational 
determinants of cancer survival exist, although there is lack of some disease-specific 
indicators (e.g. cancer-specific staffing) which hinders more robust testing of possible 
explanatory associations. It was feasible to draw data together and analyse it. However, 
conclusion on statistical methods must include reservations due to limitations in temporal 
relationships, incomplete adjustments for confounding factors, and concerns over data 
accuracy. In general, literature shows that despite limitations, authors continue using 
routine data sets for explanatory purposes to draw tentative conclusions which need to be 
tested again in other settings, with indicated further research implications.
Several possible factors indicated in the literature have not proved to be supported by the 
study -  including hospital volume, delay (waiting-time) and staffing levels. On the other 
hand, two dimensions have proved to be statistically associated: teaching hospital status 
and compliance with a small number of cancer service standards, especially use of 
guidelines.
The Cancer Plan for England was created, in part, with the knowledge from Eurocare-1 that 
England appeared to have poorer survival, and -  along with significantly higher levels of 
NHS funding -  set about improving organisation (eg through multi-disciplinary teams), and 
practice (eg through waiting time targets). The Cancer Plan for England is currently under 
mid-term review. The present study raises the question which organisational interventions 
will in fact improve survival. Staffing at a general level was not associated with survival, 
nor waiting times, nor hospital volume, whereas academic hospital status, and some 
elements of cancer standards, appeared to be related. There are of course reservations from 
the design of this study, both in its cross-sectional associations rather than longitudinal 
relationships, and in the limits of investigating co-variants. However, most importantly, the 
study shows that research is able to investigate dimensions of the organisation of cancer 
services that are part of public policy. It would therefore be appropriate for further research
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to be commissioned which looks in greater detail at the issues identified by this feasibility 
study, and seeks to determine whether the investments and changes in cancer services over 
the past decade in England have been successful -  and thus to provide lessons for future 
practice.
6.2 Implications for future research
• This study shows that it is feasible to use national data which reflect dimensions of 
structure and process to monitor the impact of changing service provision.
However, it also demonstrates limited feasibility in terms of limitations of 
inferences while using routine databases for explanatory purposes. A larger number 
of hospitals would give greater power. New ways could also be used to adjust for 
case-mix, for example by linking HES data and cancer registry data at individual 
level.
• The present study used data in cross-sectional form at the start of implementation of 
the Cancer Plan for England. Further research could repeat this analysis using 
longitudinal data, relating changes in cancer survival at hospital level with changes 
in organisational characteristics. This would allow proper accounting of temporal 
relationships between compliance with standards and cancer survival.
• It would be useful to investigate the possibilities of using other methodological 
approaches designed to deal with hierarchical data (e.g. multilevel modelling) and 
allow calculating more current survival estimates (e.g. period analysis).
• Further investigations into variations in treatment, and implementation of MDT 
practice, provided in different hospitals and its effect on cancer survival would be 
desirable. More detailed treatment information, including adjuvant therapy, would 
enable outcomes to be assessed, fully accounting for treatment impact. Such data 
are becoming available through the national audit procedures, and would form an 
important opportunity for collaboration.
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Appendix 1
Table Al Distribution of DCO cases by hospital trust
H ospital trust
No. o f  
patients
No. o f  
deaths
R elative
Survival
(% )
DCO  cases
No. %
A 1443 760 39.49 56 3.74
B 856 470 42.41 25 2.84
C 506 255 41.75 12 2.32
D 664 346 41.61 24 3.49
E 337 169 46.23 17 4.80
F 308 180 35.63 4 1.28
G 614 315 46.72 5 0.81
H 638 367 37.06 27 4.06
I 505 271 31.27 55 9.82
J 420 233 43.29 5 1.18
K 298 154 40.19 4 1.32
L 403 206 45.11 10 2.42
M 657 339 43.24 11 1.65
N 605 316 47.13 21 3.35
O 378 211 34.74 12 3.08
P 287 172 37.65 31 9.75
Q 1173 525 55.44 24 2.00
R 559 295 42.98 7 1.24
S 538 287 41.25 11 2.00
T 561 272 51.32 16 2.77
U 632 335 44.14 17 2.62
V 364 171 45.90 18 4.71
w 443 245 39.78 12 2.64
X 596 256 50.14 5 0.83
Y 423 221 44.03 16 3.64
Z 397 194 46.64 6 1.49
AA 291 165 40.73 33 10.18
BE 569 329 43.04 14 2.40
based on analysis o f  the Tham es C ancer Registry data
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Appendix 2
Table A2 Relative frequencies of age group distribution by hospital trust in London
(1996-2001)*
Hospital
trust
Five-year 
reiative 
survival, %
Age groups, years
15-39 40-49 50-59 60-69 70-79 80-99
Q 55.44 2.81 4.60 13.30 25.49 29.07 24.72
T 51.32 2.67 3.21 14.62 22.46 34.94 22.10
X 50.14 6.54 7.89 20.47 26.17 27.35 11.58
N 47.13 1.49 4.79 8.26 26.12 33.55 25.79
G 46.72 1.63 2.44 10.10 20.20 36.16 29.48
Z 46.64 2.52 4.03 10.83 26.70 34.01 21.91
E 46.23 2.97 5.34 14.24 20.18 31.75 25.52
V 45.9 2.75 5.22 10.71 27.20 32.42 21.70
L 45.11 2.73 5.96 10.17 27.05 32.75 21.34
U 44.14 2.06 4.75 13.29 21.04 33.23 25.63
V 44.03 2.60 4.02 12.29 25.06 34.28 21.75
J 43.29 1.19 3.33 9.76 24.76 34.29 26.67
M 43.24 0.76 3.65 9.74 20.09 32.27 33.49
BB 43.04 1.93 3.51 10.37 19.86 33.57 30.76
R 42.98 1.25 3.76 9.30 24.69 37.03 23.97
B 42.41 1.99 2.57 10.63 21.96 32.24 30.61
C 41.75 2.37 6.72 13.04 26.68 34.19 17.00
D 41.61 1.05 2.86 9.79 24.10 36.75 25.45
S 41.25 0.56 2.97 10.59 24.35 35.69 25.84
AA 40.73 1.72 2.75 8.93 24.05 33.33 29.21
K 40.19 2.68 6.38 11.41 20.47 34.56 24.50
W 39.78 2.71 4.51 12.64 25.96 32.05 22.12
A 39.49 1.94 4.23 10.53 24.81 35.90 22.59
P 37.65 2.79 5.57 14.63 24.74 32.40 19.86
H 37.06 2.51 5.02 11.44 25.24 35.42 20.38
F 35.63 3.57 3.90 13.31 20.45 29.22 29.55
O 34.74 2.65 4.76 9.52 26.46 36.24 20.37
I 31.27 2.57 4.36 15.45 27.33 30.10 20.20
based on analysis o f  the Tham es C ancer Registry data
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Table A3 Relative frequencies of sex distribution by hospital trust in London (1996-
2001)*
Hospital trust Five-year relative  
survival, %
Sex
M ale Fem ale
Q 55.44 51.92 48.08
T 51.32 49.02 50.98
X 50.14 55.20 44.80
N 47.13 48.43 51.57
G 46.72 45.44 54.56
Z 46.64 51.13 48.87
E 46.23 51.34 48.66
V 45.9 56.59 43.41
L 45.11 52.61 47.39
U 44.14 53.64 46.36
Y 44.03 50.83 49.17
J 43.29 54.52 45.48
M 43.24 47.49 52.51
BB 43.04 52.72 47.28
R 42.98 52.59 47.41
B 42.41 51.29 48.71
C 41.75 58.70 41.30
D 41.61 49.55 50.45
s 41.25 51.30 48.70
AA 40.73 48.80 51.20
K 40.19 54.70 45.30
W 39.78 53.95 46.05
A 39.49 50.87 49.13
P 37.65 49.13 50.87
H 37.06 54.23 45.77
F 35.63 54.22 45.78
O 34.74 48.94 51.06
I 31.27 54.65 45.35
* based on analysis o f  the Tham es C ancer R egistry data
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Table A4 Relative frequencies of distribution by social deprivation (IMD 2000, income
quintile), by hospital trust in London (1996-2001)*
Hospital trust Five-year relative 
survival, %
IMD 2000, income quintile
1 2 3 4 5
Q 55.44 6.31 15.69 30.86 32.99 14.15
T 51.32 5.53 19.79 32.62 21.21 20.86
X 50.14 27.68 18.62 18.12 22.15 13.42
N 47.13 10.41 17.85 19.83 37.69 14.21
G 46.72 32.74 25.73 18.08 11.24 12.21
Z 46.64 3.78 13.35 7.56 14.61 60.71
E 46.23 19.88 19.88 16.62 35.91 7.72
V 45.9 2.75 16.48 17.86 18.13 44.78
L 45.11 1.24 5.71 1.49 24.57 67.00
U 44.14 10.13 17.09 28.96 32.59 11.23
Y 44.03 0.71 3.55 20.09 5.20 70.45
J 43.29 14.52 20.24 22.14 40.48 2.62
M 43.24 43.38 32.88 17.05 3.81 2.89
BB 43.04 2.46 11.60 17.22 37.79 30.93
R 42.98 3.04 7.33 16.64 14.85 58.14
B 42.41 8.06 25.70 30.72 24.65 10.86
C 41.75 0.99 3.36 4.94 6.92 83.79
D 41.61 51.66 6.78 17.47 18.83 5.27
S 41.25 22.30 32.71 17.29 16.36 11.34
AA 40.73 33.33 5.50 15.81 37.11 8.25
K 40.19 0.00 0.00 0.34 1.34 98.32
W 39.78 0.45 0.23 8.35 35.21 55.76
A 39.49 9.01 15.04 21.76 18.85 35.34
P 37.65 0.70 1.39 9.06 16.72 72.13
H 37.06 4.70 2.98 4.23 20.06 68.03
F 35.63 4.87 6.49 16.56 51.30 20.78
O 34.74 0.26 0.53 r  1,59 0.00 97.62
I 31.27 8.51 15.45 14.65 34.65 26.73
based on analysis o f  the Tham es C ancer R egistry data
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Table A5 Relative frequencies of tumour stage distribution by hospital trust in
London (1996-2001)*
Hospital trust Five-year relative 
survival, %
Tumour stage
1 II III IV Not
Known
Q 55,44 25.92% 21.40% 19.27% 21.99% 11.42%
T 51.32 18.36% 20.14% 18.54% 20.68% 22.28%
X 50.14 2.68% 7.21% 6.21% 5.54% 78.36%
N 47.13 23.97% 14.55% 22.98% 21.49% 17.02%
G 46.72 21.34% 28.01% 24.27% 22.31% 4.07%
Z 46.64 32.49% 5.04% 18.64% 18.39% 25.44%
E 46.23 11.28% 16.62% 14.84% 24.04% 33.23%
V 45.9 22.80% 21.43% 23.63% 21.43% 10.71%
L 45.11 13.15% 27.79% 17.62% 22.58% 18.86%
U 44.14 19.78% 25.47% 22.15% 21.84% 10.76%
Y 44.03 37.59% 12.06% 17.49% 20.80% 12.06%
J 43.29 30.48% 14.76% 20.48% 23.57% 10.71%
M 43.24 19.63% 26.79% 23.59% 21.31% 8.68%
BB 43.04 45.17% 5.27% 22.32% 23.37% 3.87%
R 42.98 28.44% 22.72% 23.08% 20.21% 5.55%
B 42.41 16.36% 23.36% 18.22% 21.96% 20.09%
C 41.75 11.07% 15.02% 9.49% 28.46% 35.97%
D 41.61 8.89% 18.07% 10.09% 21.39% 41.57%
S 41.25 8.36% 23.23% 9.85% 26.95% 31.60%
AA 40.73 14.78% 14.43% 22.68% 22.34% 25.77%
K 40.19 15.77% 6.71% 3.36% 29.53% 44.63%
W 39.78 24.83% 26.19% 19.19% 21.44% 8.35%
A 39.49 22.04% 19.89% 19.40% 21.62% 17.05%
P 37.65 12.89% 21.60% 21.25% 21.95% 22.30%
H 37.06 13.48% 26.80% 22.10% 21.16% 16.46%
F 35.63 13.64% 25.65% 17.86% 27.92% 14.94%
O 34.74 13.76% 6.88% 2.91% 33.33% 43.12%
I 31.27 14.06% 19.80% 22.77% 22.57% 20.79%
based on analysis o f  the Thames Cancer Registry data
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Table A6 Relative frequencies of type of treatment (surgery) distribution by hospital 
trust in London (1996-2001)*
Hospital
trust
Five-year 
relative 
survival, %
Type of treatment
Total 
removal of 
organ
Partial 
removal of 
organ
Tumour/lymph 
node removal 
or exclusion
Non-tumour
removing
surgery
Investigative
procedure
only
Not
Known
Q 55.44 17.73% 54.05% 7.08% 3.50% 10.23% 7.42%
T 51.32 22.28% 50.09% 8.02% 0.71% 10.16% 8.73%
X 50.14 4.70% 16.11% 1.85% 20.97% 1.34% 55.03%
N 47.13 13.55% 59.83% 4.96% 7.11% 6.61% 7.93%
G 46.72 17.10% 57.17% 4.89% 4.40% 10.10% 6.35%
Z 46.64 13.10% 51.64% 15.87% 0.76% 11.59% 7.05%
E 46.23 20.77% 47.18% 10.68% 5.04% 9.20% 7.12%
V 45.9 12.64% 56.59% 12.64% 2.20% 11.26% 4.67%
L 45.11 12.16% 55.33% 7.20% 2.98% 9.68% 12.66%
U 44.14 15.51% 50.95% 13.29% 2.06% 9.81% 8.39%
Y 44.03 16.55% 57.45% 11.82% 3.07% 4.96% 6.15%
J 43.29 20.71% 49.05% 5.48% 5.00% 12.62% 7.14%
M 43.24 19.03% 57.38% 5.63% 3.96% 6.70% 7.31%
BB 43.04 18.80% 52.55% 8.44% 6.50% 5.98% 7.73%
R 42.98 19.32% 50.63% 9.84% 1.43% 8.05% 10.73%
B 42.41 16.71% 58.18% 6.31% 2.57% 5.96% 10.28%
C 41.75 24.51% 39.92% 12.06% 1.19% 11.46% 10.87%
D 41.61 18.98% 43.37% 8.13% 2.56% 10.09% 16.87%
S 41.25 17.10% 51.12% 9.67% 1.30% 8.36% 12.45%
AA 40.73 14.78% 49.48% 9.28% 1.37% 8.25% 16.84%
K 40.19 28.19% 38.93% 10.40% 2.01% 10.40% 10.07%
W
39.78 17.61% 45.37% 13.09% 1.81% 9.26% 12.87%
A 39.49 21.21% 51.91% 8.11% 4.16% 7.00% 7.62%
P
37.65 21.25% 47.39% 3.83% 5.23% 4.18% 18.12%
H
37.06 15.67% 48.28% 8.93% 3.13% 9.87% 14.11%
F
35.63 20.45% 45.78% 5.52% 3.57% 8.77% 15.91%
O 34.74 32.80% 35.98% 10.05% 1.59% 13.23% 6.35%
I
31.27 15.64% 45.94% 11.49% 1.78% 9.70% 15.45%
based on analysis o f  the Thames Cancer R registry data
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Appendix 7
Table A7 Medical, ward and radiology staffing level for hospital trusts in London 
(2000/2001-2001/2002 financial years)*
Hospital
trust
M edical 
W TE per 
1000 
adm issions
Consultant 
W TE per 
1000 
adm issions
M edicine  
consultant 
W TE per  
1000  
adm issions
A naesthetist 
consultant 
W TE per 
1000 
adm issions
Pathology  
consultant 
W TE per 
1000 
adm issions
R adiology  
consultant 
W TE per  
1000 
adm issions
R adiographers 
per 1000 FCEs
C linical 
nurse  
specialists  
W TE per  
1000 
adm issions
A 5.17 1.73 1.55 0.77 1.00 1.76 0.78 0.77
B 6.01 2.12 2.11 0.85 1.88 2.04 0.71 0.39
C 8.83 2.54 1.83 1.47 3.06 2.13 1.12 N/A
D N/A N/A N/A N/A N/A N/A 0.69 N/A
E 7.54 2.49 1.88 1.00 0.00 1.90 0.86 0.70
F 5.58 1.79 1.42 0.94 1.53 1.46 0.99 0.93
G 7.33 2.49 1.63 0.75 3.17 2.27 1.09 0.50
H 8.41 3.18 2.17 1.65 2.08 2.83 0.89 0.57
I 7.47 2.63 2.05 1.35 3.48 2.57 0.78 0.37
J 5.97 1.92 1.68 0.89 1.47 2.06 0.78 0.06
K 7.09 2.06 2.55 1.64 1.22 1.22 0.94 0.54
L 9.22 3.58 2.92 1.94 3.37 2.42 1.00 0.73
M 7.45 2.91 1.63 1.27 3.21 3.31 0.90 0.23
N 5.95 2.16 2.33 0.95 2.36 2.05 0.69 0.77
O 5.22 1.75 2.30 1.12 1.18 0.37 0.74 0.58
P 6.40 2.04 1.60 1.01 2.92 2.46 0.71 0.87
Q N/A 2.45 2.27 0.89 1.78 2.44 0.75 N/A
R N/A 1.94 1.60 0.78 2.47 1.76 0.98 0.51
S 4.96 1.63 1.58 0.98 1.66 0.03 0.64 0.59
T N/A N/A N /A N/A N/A N/A 1.24 0.32
U 9.56 3.25 2.73 1.48 3.18 2.80 0.66 0.48
V 8.54 3.18 2.07 1.30 3.60 2.28 0.67 0.96
w 6.04 2.45 1.95 1.06 3.50 1.56 0.70 0.82
X 6.51 2.33 0.85 2.65 3.23 6.50 0.95 2.31
Y 6.52 2.26 2.34 1.31 2.00 2.17 N/A 0.65
Z N/A N/A N /A N/A N/A N/A 1.48 0.50
AA 8.21 2.62 1.59 1.03 3.02 2.59 0.95 0.74
BB 5.53 2.11 2.08 0.82 1.84 1.02 0.74 N/A
' based on analysis o f  Acute Hospital Portfolio
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Table A8 Average annual volume of patients per hospital trust in London 
(1997/1998-2001/2002 financial years)*
Hospital
Trust
No. of patients per year Average annual 
number of 
patients
1997/98 1998/99 1999/00 2000/01 2001/02
A 1474 1463 1498 1463 1556 1491
B 644 623 663 747 333 602
c 1159 1098 1025 1068 1098 1090
D N/A N/A N /A N/A N/A N/A
E 177 191 176 237 446 245
F 242 237 225 283 281 254
G 574 539 N/A 744 650 627
H 1189 1203 1215 1190 1229 1205
I 1582 1413 1458 1489 1613 1511
J 234 263 296 281 358 286
K 124 117 163 170 176 150
L 353 322 396 372 366 362
M 256 244 380 411 403 339
N 413 368 481 389 368 404
O 348 301 320 292 305 313
P 864 823 828 720 725 792
Q 770 742 606 219 478 563
R 387 441 477 415 N/A 430
S 275 297 352 351 348 325
T 425 478 518 500 500 484
U 1039 925 839 882 777 892
V 1469 737 573 590 511 776
w 273 308 333 271 239 285
X 2558 2457 2342 2502 2768 2525
Y 416 371 357 362 363 374
Z 900 814 836 834 803 837
AA 311 307 267 255 281 284
BB 549 592 620 593 613 593
* based on analysis o f  HES dataset
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Temporal trends in colorectal cancer survival in London
The recent ONS reports on trends in survival for eight common cancers in England 
present data on colon cancer survival rates for adult patients resident in each of the 
government office regions and strategic health authorities in England (including London), 
who were diagnosed over different time periods during 1994-1999 and followed up to the 
end of 2001-2004^^^''. Table A9.1 below indicates one- and five-year relative survival rates 
with 95% confidence intervals.
Table A9.1 One-year and five-year relative survival estimates (England and London) 
for colon cancer patients, by year of diagnosis and follow-up (based on ONS 
reports)**'
Y ear of diagnosis 
and follow-up (fu)
M en
W om en
O ne-year relative  
survival
Five-year relative 
survival
O ne-year relative  
survival
Five-year relative  
survival
Place % 95%  C l % 95%  C l % 95%  C l % 95%  C l
1994-96; 
fu 31/12/2001* England 66.2 65.6 - 66.9 43.6 4 2 .7 -4 4 .4 64.3 63.6 -6 5 .0 44.6 43.8 -4 5 .4
London 68.9 6 6 .8 -7 1 .1 43.6 4 0 .9 -4 6 .3 66.0 6 3 .9 -6 8 .1 45.2 4 2 .7 -4 7 .8
1995-97; 
fu 31/12/ 2002** England 66.2 64.8 -6 7 .5 43.0 4 1 .3 -4 4 .7 66.2 64.9 - 67.5 44.9 4 3 .4 -4 6 .5
London 68.0 63.8 -7 2 .2 4 1 3 36.1 -4 6 .5 67.2 6 3 .3 -7 1 .2 44.5 39.6 -4 9 .4
1996-98;
fu 31/12/2003*** England 6 7 J 66.0 - 68.6 46.8 45.1 -4 8 .5 66.9 65.6 - 68.1 47.5 4 6 .0 -4 9 .0
London 68.5 64.4 - 72.6 44.9 39.6 - 50.2 68.3 64.5 -7 2 .0 48.1 43.4 -5 2 .8
1997-99;
fu 31/12/2004**** England 67.8 66.5 - 69.0 4 8 3 46.6 - 50.0 67.3 66.0 - 68.5 48.8 47.3 - 50.4
London 67.1 63.1 -71 .1 45.1 39.9 - 50.2 67.3 6 3 .6 -7 1 .0 47.3 4 2 .6 -5 2 .0
*http://ww w .statistics.gov.uk/dow nIoads/them e_health/SurvivalRatesbySH A 200 lD ata.xls 
**http://ww w .statistics.gov.uk/dow n]oads/them e_health/SurvivalRatesbySH A 2002D ata.xls 
***http://ww w .statistics.gov.ukydownloads/them e_health/SurvivalRratesbySH A 2003 Data.xls 
♦ ♦♦♦http://w w w .statistics.gov.uk/dow nloads/them e_health/SurvivalRatesbySH A 2004D ata.xls
Caution is required in the interpretation of any apparent changes in the rates over 
consecutive time periods since they overlap for two years. For example, 1995-97 period 
includes two years (1996 and 1997) from the previous period 1994-96 and so on. However, 
if we compare survival of patients diagnosed in 1994-96 vs. 1997-99, the following trends 
may be noticed:
1. There appear to be significant differences in survival nationally, with both one-year
’‘’‘’‘''ONS. Cancer Survival in England by Strategic Health Authority. 
Source: http://www.statistics.gov.uk/statbase/Product.asp?vlnk=l 1991
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and five-year relative survival estimates improved for patients diagnosed in 1997- 
1999 as compared to patients diagnosed in 1994-1996 years.
2. In contrast to national figures, survival rates for London improved to the lesser 
extent and were apparent particularly for five-year survival. However, there were no 
significant changes in survival over time (1994-96 vs. 1997-99) for London.
3. There were no significant differences in survival rates between men and women 
across the time periods, for England and London.
Similar analyses, based on TCR data available for the study, did not show 
significant time trend in London survival over time, for example, between two-year relative 
survival for 1996-98 vs. 1999-2000 (see Table A9.2). There was no significant difference in 
survival by sex (see Table 4.15); therefore, the Table A9.2 below presents combined 
survival (male and female).
Table A9.2 One-year and two-year relative survival estimates for colorectal cancer 
patients in London, by year of diagnosis (based on TCR data available for the study)
Year of 
diagnosis
One-year relative survival Two-year relative survival
Relative 
survival (%)
95% Confidence 
Interval %) 95% Cl
1996 72.74 70.73 74.63 62.02 59.81 64.15
1997 69.51 67.53 71.40 58.31 56.17 60.39
1998 69.53 67.57 71.39 59.23 57.11 61.28
1999 68.53 66.54 70.43 58.33 56.2 60.40
2000 70.77 68.88 72.57 - - -
1996-1998 70.53 69.39 71.63 59.79 58.56 61.00
1997-1999 69.19 68.06 70.29 58.63 57.41 59.83
1998-2000 69.64 68.53 70.72 58.56 57.31 59.78
1999-2000 69.69 68.33 71.01 58.11 56.55 59.63
However, for small area cancer survival statistics (London vs. England), caution is 
required in the interpretation both of the survival rates themselves and particularly of any 
apparent changes in the rates over time. The survival rates, even when based on cases 
accumulated over a three or two-year period, therefore have considerable uncertainty, as 
indicated by relatively wide confidence intervals.
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Appendix 10
Table AlO. The relationship between two week’ and ‘two month’ waiting time 
standards for all cancers*
Time period Total number of 
two week referrals 
within the quarter
Patients who were treated for cancer 
within the quarter under 
two month standard
Total number Percentage (out of 
two week referrals)
Quarter 4, 
2005/2006
142055 18401 12.95
Quarter 3, 
2005/2006
141052 17137 12.15
Quarter 2, 
2005/2006
145137 16028 11.04
Quarter 1, 
2005/2006
142153 14299 10.06
Quarter 4, 
2004/2005
117942 12114 10.27
* based on analysis o f  Cancer W aiting Tim es Statistics
(source: http://\vww.oerfonnance.doh .gov .uk/cancerwaitS’'2006/q 1/archive.htm ll
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Appendix 11
A cute  H o spita l  P o r t f o l io
Data Quality Assessment^""'
GENERAL ASPECTS 
Background information
The Acute Hospital Portfolio (AH?) is a collection of ongoing audit reviews (not cancer- 
specific) that are undertaken at acute and specialist hospital trusts by former Audit 
Commission (currently Healthcare Commission). They focus on key service areas or 
resources within the hospital trust that are of concern to trust managers and patients.
The following national reviews have been published (or being undertaken) by Audit 
Commission/Healthcare Commission (indicated years are ‘financial’ years -  of April to
3C* of March):
1. Accident and Emergency 2000/01 ; 2004/05
2. Admissions Management 2005/06
3. Bed Management 2002/03
4. Catering 2000/01
5. Day Surgery 2000/01 ; 2004/05
6. Diagnostic Services 2005/06
7. Facilities Management 2003/04
8. Information and Records 2003/04
9. Medical Staffing 2001/02
10. Medicines Management 2001/02; 2005/06
11. Operating Theatres 2002/03
12. Outpatients 2002/03
13. Pathology 2003/04
14. Procurement and Supply 2001/02
15. Radiology 2001/02
Based on Directory o f  Clinical Databases (DoCDat) form at 
(http://www. lshtm.ac.uk/docdat/page.php? t=index).
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16. Therapy and Dietetics 2003/04
17. Waiting for Elective Admission 2002/03
18. Ward Staffing 2000/01; 2004/05
Source: former Audit Commission (currently Healthcare Commission) 
http://www.healthcarecommission.oru.uk/lnformatioiiForServiceProviders/GuidanceForNH 
S/Guidance/fs/en?CONTENT lD-4006400&chk-2NeKOO 
and
http://www.healthcarecommission.org.uk/InfoiTnationForServiceProviders/ReviewsAndIns 
pections/AcutePortfolio/fs/enl :
Reference population
Common circumstance that determines inclusion in the database:
All NHS acute hospital trusts are covered by the dataset.
Geographical area covered by the database:
England and Wales.
Time period covered by the database:
2000/2001 - ongoing, depending on topic (see Background information). The data of the 
earliest period of AHP (2000/2001 -2001/2002 financial years) were used in this study, 
since it was the most comparable with other datasets in relation to time period covered.
Level of aggregation:
Hospital
DATA SET 
Content
Number of individuals or episodes of care included in the database:
The intention of the dataset is to include data on patients, staff, resources, services and 
activities of all NHS acute hospital trusts in England and Wales and to reflect treatment of 
all patients in relevant financial years.
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Data collection questionnaire:
According to the Audit Commission, wherever possible, data were taken from routine 
national sources and standard definitions are applied. However, many areas of the portfolio 
are not covered by existing data, so the Audit Commission conducted national surveys for 
each topic at all relevant acute hospital trusts in England and Wales by providing electronic 
forms for trusts to complete. In some cases specially written computer software was also 
provided to assist hospital trusts.
Data collection forms for selected topics (medical staffing 2001/2002; radiology 
2001/2002; ward staffing 2000/2001) have not been published and not available on-line. 
Data collection forms/tools or questionnaires are available for more recently reviewed 
topics.
Data linkage 
Are nationally approved codes used for identifying the subject, clinician or 
institution?
Nationally approved codes are used to identify each hospital.
To which other databases is linkage routinely undertaken?
None known
OUTPUTS 
Analysis 
Can ad hockad hoc analyses be performed for health care providers?
• Locally (“the health care provider who collects the data locally is able to analyse 
their data even though their data are also sent to the centralised database to be 
analysed with the data collected from other health care providers”) -  no;
• Centrally (Local health care providers can obtain ad hoc analyses of their own data 
from the central database custodian) -  yes. Healthcare Commission provides CD 
version of audit review data to individual trusts. The CD uses Audit Commission’s 
software tool “Compare”. Also, on-line query form is available for all AHP queries: 
http://www.healthcarecommission.oru.uk/lntbnnationForServiceProviders/Rcviews 
Andlnspections/AcutePortfolio/QuervForm/fs/en
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Audit reports 
How frequently are multi-centre audit reports produced?
National overview reports are available for each topic completed
(http://www.healthcarecoinmission.org.uk/NationalFindings/NationalThemedRcports/Aciit 
eAndSDecialist/AcuteAndSpecialistReports/fs/en?CQNTENT ID^40QQ247&chk=aJZ6hPT 
The intention is to audit the same topic each four years.
How frequently are provider-specific audit reports produced?
Provider specific reports for audited topics are produced each four years, as soon as audit 
reviews for these topics are completed, (see previous item and Analysis)
Publications 
Bibliography
Healthcare Commission provides no references to any studies that have used these data. 
However, national overview reports are available for each topic completed 
(http.7/www.healthcarecommission.org.uk/NationalFindings/NationarThemedReports/Acut 
eAndSpecialist/AcuteAndSpecialistReports/fs/en?CQNTENT ID=4QQQ247&chk=aJZ6hP).
The following article which was produced using AC/HC data has been identified:
1. Fittall B. Can we measure how changes in the nursing workforce affect patient care? 
(2004) Jowrna/ o f Nursing Management 12, 397-402.
MANAGEMENT 
Support for database
Is the database approved by any clinical or professional associations?
No.
Who is involved in the management of the database?
Doctors; statisticians; epidemiologists; IT specialists
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Source of funding:
Acute Hospital Portfolio transferred from the Audit Commission to the Healthcare 
Commission on of April 2004 under the Health and Social Care (Community Health and 
Standards) Act 2003.
DATA QUALITY 
Coverage
Extent to which the eligible population is representative of the country:
All NHS acute hospital trusts in England are covered by the dataset.
Completeness of recruitment of eligible population:
Not all datasets within the AHP contained data for all 28 hospital trusts included in the 
study. Table A l l  specifies the number of hospital trusts for which information was 
available for each indicator considered.
Table A ll. Number of hospital trusts for which data were available for each indicator 
considered
Variable No. of hospital trusts
Radiology
Radiographers per 1000 FCEs 27
Radiology consultant WTE per 1000 admissions 25
Medical staffing
Consultant WTE per 1000 admissions 25
Medicine consultant WTE per 1000 admissions 25
Anaesthetist consultant WTE per 1000 admissions 25
Pathology consultant WTE per 1000 admissions 25
Medical WTE per 1000 admissions 23
Ward staffing
Clinical nurse specialist WTE per 1000 FCEs 24
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Variables included in the database
There are numerous variables available in Acute Hospital Portfolio for each specific topic.
Only indicators, which reflect medical, radiology or ward staffing level, were considered 
during this study. Here is the list of all examined variables:
medical per 1000 admissions;
consultant WTE per 1000 admissions; 
medicine consultant WTE per 1000 admissions; 
anaesthetist consultant WTE per 1000 admissions; 
pathology consultant WTE per 1000 admissions; 
radiology consultant WTE per 1000 admissions; 
radiographers per 1000 FCE^^ '^'"'s; 
clinical nurse specialists per 1000 FCEs.
This selection has been made based on relevance, completeness and following discussions 
with a number of healthcare professionals and researchers associated with the “Measures of 
Quality for the Improvements of Cancer Services” study^^ '^ .^
Completeness of data (% variables at least 95% complete):
1) Medical Staffing -  4 variables had 11% missing values (data on 3 hospital trusts 
were missing); 1 variable had 18% missing values (data on 5 hospital trusts were 
missing).
2) Radiology -  1 variable had 4% missing values (data on 1 hospital trust were 
missing); 1 variable had 11% missing values (data on 3 hospital trusts were 
missing).
In this topic, ‘missing’ includes also hospital trusts which do not provide radiology 
services.
3) Ward Staffing -  1 variable had 14% missing values (data on 4 hospital trusts were 
missing).
(see Table A l l )
' Whole time equivalent (WTE)
" Finished consultant episode (FCE)
h t tp ; / /w w w .u c[ ,ac ,u C p u b l ic : i iea l th /m e a s i i r in g % 2 0 ca n c er% 2 0 s
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Accuracy
Use of explicit definitions for variables:
The definitions of most of variables are provided in national overview reports or published 
guides to indicators.
Use of explicit rules for deciding how variables are recorded:
Data manuals (guide to indicators) are available for the following topics:
• medical staffing
fhttp://www.healthcarecommission.oru.uk/assetRoot/04/00/25/48/04002548.pdfl
• radiology
(http://www.healthcarecommission.org.uk/assetRoot/04/00/25/47/04002547.pdfl 
No published data manual has been identified for ward staffing topic.
Extent to which data are validated:
No published information has been identified as to whether data have been validated. Our 
internal analyses show some inconsistencies between data sets within the Acute Hospital 
Portfolio as well as between Acute Hospital Portfolio and external sources, namely 
Hospital Episode Statistics and Hospital Activity Statistics.
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A ppendix 12
H o spital  E piso de  St a t ist ic s
Data Quality Assessmenf^
GENERAL ASPECTS 
Background information
The Hospital Episode Statistics database (HES) contains information on all admitted 
patients treated in NHS hospitals in England. Each record contains a variety of 
administrative, clinical and patient information describing the care and treatment a patient 
received while in hospital.
The data is captured from hospital patient administration systems, and HES now collects 12 
million records per year from all hospital trusts in England.
HES publishes standard tables of analyses of NHS admitted patient care by diagnosis, 
operation. Healthcare Resource Group, consultant specialty, hospital trust and Health 
Authority on their website. Users can also request specialised analyses to be performed on 
their behalf by the HES team.
HES is used by the NHS, Government and many other organisations and individuals who 
have an interest in health and healthcare administration.
Source: NHS Health and Social Care Information Service; Department of Health 
http://www.dh.gov.uk/PublicationsAndStatistics/Statistics/HospitalEpisodeStatistics/fs/en
Reference population
Common circumstance that determines inclusion in the database:
HES contain data on inpatient and day cases admitted to NHS hospitals in England. It 
includes private patients treated in NHS hospitals, patients who were resident outside of
Based on Directory o f Clinical Databases (DoCDat) assessments 
(http://wM'\\'.lshtni.ac.ul<j'docdai'records.php'.'l records&ici I IBS).
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England and care delivered by treatment centres (including those in the independent sector) 
funded by the NHS^''.
Geographical area covered by the database:
England.
Time period covered by the database:
April 1989 - ongoing. The data from 1997/1998 to 2001/2002 financial years were used in 
this study, a time period comparable with other datasets.
Level of aggregation:
Patient 
DATA SET
Content
Number of individuals or episodes of care included in the database:
The intention of the dataset is to include data on all in-patients at NHS hospital trusts in 
England.
Data collection questionnaire:
There is no questionnaire for this database.
Data linkage
Are nationally approved codes used for identifying the subject, clinician or 
institution?
Nationally approved codes are used to identify each hospital. Special patient identifiers 
were introduced in 1997, to link different episodes of care or multiple admissions within a 
year, thus preventing their over-counting.
To which other databases is linkage routinely undertaken?
None known.
http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=l 937&categoryID=456
2 2 4
OUTPUTS
Analysis 
Can ad hockad hoc analyses be performed for health care providers?
• Locally (“the health care provider who collects the data locally is able to analyse 
their data even though their data are also sent to the centralised database to be 
analysed with the data collected from other health care providers”) -  yes;
• Centrally (Local health care providers can obtain ad hoc analyses of their own data 
from the central database custodian) -  yes.
Audit reports 
How frequently are multi-centre audit reports produced?
Never.
How frequently are provider-specific audit reports produced?
Annually.
Publications 
Bibliography:
There are numerous references identified to studies that have used HES data with regard to
different pathologies and for different purposes.
Some of the main references are listed below:
1. Aylin P, Alves B, Cook A, Bennett J, Bottle A, Best N, Catena B, Elliott P.
Analysis of Hospital Episode Statistics for the Bristol Royal Infirmary Inquiry. 
Division Primary Care & Population Health Sciences, Imperial College School of 
Medicine, St. Mary’s Campus. London: Crown Copyright 1999.
2. Dixon J, Sanderson C, Elliott P, Walls P, Jones J, Petticrew M. Assessment of the 
reproducibility of clinical coding in routinely collected hospital activity data: a 
study in two hospitals. Journal o f Public Health Medicine 1998; 20:63-69.
3. Jarman B., Gault S., Alves B, Hider A, Dolan S, Cook A, Hurwitz B, lezzoni LI. 
Explaining differences in English hospital death rates using routinely collected data. 
BMJ 1999;318:1515-1520.
4. Lakhani A, Coles J, Eayres D, Spence C, Rachet B. Creative use of existing clinical 
and health outcomes data to assess NHS performance in England: Part 1 -  
performance indicators closely linked to clinical care. 5M J2005; 330:1426-1431.
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5. Lakhani A, Coles J, Eayres D, Spence C, Sanderson C. Creative use of existing 
clinical and health outcomes data to assess NHS performance in England: Part 2 
more challenging aspects of monitoring. 5M J2005; 330:1486-1492.
6. Pollock AM, Vickers N. Trends in colorectal cancer care in southern England, 
1989-1993: using HES data to inform cancer services reviews. Journal o f  
Epidemiology and Community Health 1998; 52(7):433-438.
7. Williams JB & Mann RY. Hospital Episode Statistics: time for clinicians to get 
involved? Clinical Medicine 2002; 2:34-37.
MANAGEMENT 
Support for database
Is the database approved by any clinical or professional associations?
No
Who is involved in the management of the database?
Doctors; statisticians; epidemiologists; IT specialists
Source of funding:
Department of Health.
DATA QUALITY 
Coverage
Extent to which the eligible population is representative of the country:
Total population of country included (patients treated in NHS hospitals).
Completeness of recruitment of eligible population:
Out of 28 hospital trusts included in the study, only data for colorectal cancer patients 
treated at Bromley Hospitals NHS Trust were not available in HES dataset.
Variables included in the database:
There are numerous variables in HES dataset reflecting patient and provider identifiers; 
administrative information; condition; intervention and outcome. Due to confidentiality and
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protection of patients’ privacy regulations, it was not possible to receive data with the level 
of identifiers to allow linkage with the Thames Cancer Registry dataset. For this reason, the 
data on comorbidity of patients were not accounted for in the study.
For study purposes, only average annual number of colorectal cancer patients for 27 
hospital trusts during 1997-2001 were used.
Completeness of data (% variables at least 95% complete):
On national level, from 80% to 97% of variables are at least 95% complete in the HES 
dataset (National Data Quality Indicators, 2002).
‘Average annual hospital volume of patients’ had 4% missing values (data on 1 hospital 
trust were missing).
Accuracy 
Use of explicit defînitions for variables:
All or almost all variables (>97%) have clear definitions. Definitions of variables are 
available in HES Data Dictionary
(http://www.Derfbrmance.doh.2 ov.uk/hes/dictionary/index.html)
Use of explicit rules for deciding how variables are recorded:
All or almost all variables (>97%) have clear rules on how to code them in the database 
(HES Data Dictionary).
Extent to which data are validated:
Range and consistency checks (continuous auto-cleaning followed by validation). There is 
no rigorous validation at source; however, the NHS Information Authority conducts 
periodic external audits.
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Appendix 13
C ancer  W a itin g  T im es
Data Quality Assessmenf
GENERAL ASPECTS 
Background information
Cancer Waiting Times contain data on the waiting time of patients with suspected cancer 
and those subsequently diagnosed with cancer at NHS hospital trusts in England. Data are 
submitted quarterly by hospital trusts.
Cancer Waiting Times Statistics monitors the following waiting time targets:
• ‘Two week wait’ from urgent GP referral to first outpatient appointment for all 
patients with suspected cancer.
• ‘One month wait’ from urgent GP referral to treatment for children’s cancers, 
testicular cancers and acute leukaemia.
• ‘One month wait’ from diagnosis to treatment for breast cancer.
• ‘Two month wait’ from GP referral to treatment for breast cancer.
• ‘One month wait’ from diagnosis to treatment for all cancers.
• ‘Two month wait’ from GP referral to treatment for all cancers.
It is impossible to differentiate cancer sites under ‘lower gastrointestinal cancer’ though it 
is assumed to reasonably reflect waiting times for colorectal cancer.
Only two week cancer waits were used in this study. It was the only target monitored in 
relation to lower gastrointestinal cancer patients in 2001/ -  2002 financial year, a time 
period comparable with other datasets.
Based on Directory o f Clinical Databases (DoCDat) form at 
(http://www.lshtm.ac. uk/docdat/page.php?t=index).
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Source: Cancer Action Team; Department of Health.
http://wvvvv.perfoiTnance.doh.gov.uk/cancemaits/
Reference population
Common circumstance that determines inclusion in the database:
All urgent GP referrals of patients with suspected cancer seen by a specialist
Geographical area covered by the database:
England
Time period covered by the database:
Data submitted quarterly, from the quarter of 2001/2002 financial year -  ongoing. The 
data of the earliest period (2001/-2002 financial year) were used in this study, since it was 
the most comparable with other datasets in relation to time period covered.
Level of aggregation:
Patients’ records are aggregated at NHS hospital trust level. Data are available also at 
Strategic Health Authority level.
DATA SET 
Content
Number of individuals or episodes of care included in the database:
The intention of the dataset is to include all urgent GP referrals of suspected cancer 
patients.
Data collection questionnaire:
There is no questionnaire for this database.
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Data linkage
Are nationally approved codes used for identifying the subject, clinician or 
institution?
Nationally approved codes are used to identify each NHS hospital trust.
To vyhich other databases is linkage routinely undertaken?
None known.
OUTPUTS
Analvsis
Can ad hockad hoc analyses be performed for health care providers?
• Locally (“the health care provider who collects the data locally is able to analyse 
their data even though their data are also sent to the centralised database to be 
analysed with the data collected from other health care providers”) -  yes;
• Centrally (Local health care providers can obtain ad hoc analyses of their own data 
from the central database custodian) -  yes.
Audit reports
How frequently are multi-centre audit reports produced?
The Department of Health issues statistical reports each quarter.
The National Audit Office^'"' and Audit Commission '^*'^ have produced audit reports on
accuracy and management of NHS waiting time statistics:
How frequently are provider-specific audit reports produced?
No published information is identified.
National Audit Office. Inappropriate adjustments to NHS waiting lists. London: The Stationary Office, 
December 2001.
Audit Commission. Waiting list accuracy. Assessing the accuracy o f  waiting list information in NHS 
hospitals in England. London: 2003.
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Publications
Bibliography
No references have been identified to any studies that have used these data.
MANAGEMENT 
Support for database
Is the database approved by any clinical or professional associations?
No.
Who is involved in the management of the database?
Doctors; statisticians; epidemiologists; IT specialists
Source of funding:
Department of Health.
DATA QUALITY 
Coverage
Extent to which the eligible population is representative of the country:
All urgent GP referrals of patients with suspected cancer are included in the dataset. 
However, the dataset does not include cancer patients with non-urgent GP referrals and 
those who admitted to the hospital without GP referral.
Completeness of recruitment of eligible population:
All 28 hospital trusts included in this study, were covered in the dataset. It is difficult to 
determine to what extent the recruitment of eligible population is complete, since it depends 
on reporting from each NHS Trust.
Variables included in the database:
Total referrals seen during the quarter, and the number of patients whose waiting times are 
within specific time periods (days) of the decision to refer by their GP, are the main
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variables included in the dataset. There are also variables indicating cancer type, hospital 
trust and Strategic Health Authority (Health Authority for 2001/2002).
For study purposes, quarterly data have been summed into annual data.
Completeness of data (% variables at least 95% complete):
Data for all 28 hospital trusts included in the study are complete.
Accuracy 
Use of explicit definitions for variables:
Clear definitions of all variables are available on-line
('http://www.performance.doh.gov.uk/cancerwaits/) and in published Health Service 
Circulars (HSC 1998/242’ HSC 1999/084; HSC 1999/205; HSC 2001/012; HSC 
2002/005).
Use of explicit rules for deciding how variables are recorded:
All variables have clear rules on how to code them in the dataset 
(http://www.dh.gov.uk/assetRoot/04/01/90/66/04019066.xls and
http://www.dh.gov.uk/PolicvAndGuidance/HealthAndSocialCareTopics/Cancer/CancerAi1i 
cle/fs/en?CONTENT ID=4001800&chk=dpRNWQ). (see also previous item)
Extent to which data are validated:
No published information has been identified as to whether data have been validated.
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A ppendix 14
C a n c e r  S e r v ic e s  P e e r  R e v ie w  
Data Quality Assessmenf
g e n e r a l  a s p e c t s
Background information
The Manual of Cancer Services Standards published by Department of Health in December 
2000 sets out a number of quality measures (standards) in relation to the commissioning of 
cancer services.
At the beginning of 2001 every cancer unit and centre was intended to assess itself against 
these standards to measure own performance. This was then followed up with a peer review 
visit. The visits were carried out by teams of health care professionals and managers, all of 
whom are involved in the day-to-day delivery of cancer care, together with patient 
representatives. The main purpose of this peer review visits was to validate the self- 
assessment, so identifying where standards were or were not being met.
The standards look at the infra-structure and process of care rather than clinical outcomes.
The following ten topics have been considered during peer review visits:
• Patient centred care;
• Specialist multi-disciplinary teams (MDT);
• Diagnostic services;
• Provision of non-surgical oncology to cancer units;
• Radiotherapy;
• Chemotherapy;
• Specialist palliative care services;
• Education, training and continuing professional development;
• Communication between primary, secondary and tertiary sectors;
Based on Directory o f Clinical Databases (DoCDat) format 
(http://www.lshtm.ac.uk/docdat/page.php?t=index).
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• Cancer services organisation and management.
Standards for specialist MDT are specified separately for breast, colorectal, lung and 
gynaecological cancers. No data are available for urological cancers since urology was not 
included in the 2001 programme.
Second round of peer review assessments is in process now, using the revised version of 
the Manual of Cancer Services Standards published by Department of Health in 2004^*'". 
Source: NHS Cancer Action Team, Department of Health.
http://www.dh.gov.ulc/PublicationsAndStatistics/Publications/PublicationsPolicvAndGuida 
nce/PublicationsPolicvAndGuidanceArticle/fs/en?CONTENT ID=4002999&chk=/BiOBs
Reference population 
Common circumstance that determines inclusion in the database:
All cancer units and centres.
Geographical area covered by the database:
England
Time period covered by the database:
2001
Level of aggregation:
Cancer units and centres.
xlvi
h ttp://WWW.dh.gov .Ilk/Publications A n d S t a tis tic s /P u b lic a tion s -'P u b lic a t ionsf* o]i cyA  n dG  u i daji c e/ Pub l ic  a t i on s P 
olicyAndGuidanceAfticle/fs/enYCONTHNT ID=409QÜ81 &chk-hq2Sgu
2 3 4
DATA SET 
Content
Number of individuals or episodes of care included in the database:
The intention of the dataset is to include all cancer units and centres in England.
Data collection questionnaire:
There is no questionnaire for this database.
Data linkage
Are nationally approved codes used for identifying the subject, clinician or 
institution?
Cancer units and centres are identified by nationally approved organisational codes. 
Available look-up table was used to link organisational codes to nationally approved NHS 
hospital trust codes.
To which other databases is linkage routinely undertaken?
None known.
OUTPUTS
Analvsis
Can ad hockad hoc analyses be performed for health care providers?
• Locally (“the health care provider who collects the data locally is able to analyse 
their data even though their data are also sent to the centralised database to be 
analysed with the data collected from other health care providers”) — no;
• Centrally (Local health care providers can obtain ad hoc analyses of their own data 
from the central database custodian) -  yes.
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Audit reports
How frequently are multi-centre audit reports produced?
National overview report’"''"' (one-off) has been produced after 2001 peer review.
Second round of peer review assessments is currently in the process.
How frequently are provider-specific audit reports produced?
It is assumed that final report (one-off) to the hospital trust, Strategic Health Authority and 
Cancer Network has been prepared by the peer review team chair and agreed with the 
hospital trust. However, no published information has been identified.
Publications
Bibliography
No references have been identified to any studies that have used these data.
Professor Scrivens and colleagues conducted the evaluation of the whole process of 2001 
peer review and published report’"''^ "'.
MANAGEMENT 
Support for database
Is the database approved by any clinical or professional associations?
No.
Who is involved in the management of the database?
Doctors; statisticians; epidemiologists; IT specialists
Source of funding:
Department of Health, Cancer Action Team.
^''"Department of Health. Peer Review o f  Cancer Services. A National Overview. 2002.
E. Scrivens, L. Coleman, D. Levy. K. Von Degenberg, K. Wilde, H. Barlow, J. Luthert. Evaluation o f  
National Peer Review 2001. CASU:2002
2 3 6
DATA QUALITY 
Coverage
Extent to which the eligible population is representative of the country:
Total population of country included. Six regions used the final version of the cancer 
services standards (Manual of Cancer Services Standards, 2000). Eastern Region used the 
draft version and Trent used "Trent Standards". These are very similar to the final version 
of the standards but are not mappable one to one with the standards. Hence, the dataset 
includes individual standard data for each Trust in the 6 regions and summary data for 
Trent and Eastern regions.
Completeness of recruitment of eligible population:
All cancer unites and centres in England are covered by the dataset.
Out of 28 hospital trusts included in the study, data for 3 hospital trusts have not been 
considered for the analysis of associations of compliance with cancer standards and 
survival, due to differences in structure of hospitals between the Thames Cancer Registry 
and Cancer Services Peer Review datasets.
Variables included in the database:
Variables represent cancer standards for each topic specified within the “Manual of Cancer 
Services Standards” (Department of Health, 2001).
All 35 colorectal cancer-specific MDT standards were selected for analysis in this study. 
Compliance with each standard was considered present or absent.
Completeness of data (% variables at least 95% complete):
The data on compliance with standards for 25 hospital trusts (out of total 28 hospital trusts) 
were available for study purposed. This means that the information was missing for 11% of 
hospital trusts.
Accuracv
Use of explicit definitions for variables:
Clear definitions of all variable are available in the “Manual of Cancer Services Standards” 
(Department of Health, 2001), accessible on-line at:
2 3 7
http://www.dh.iiov.uk/PublicationsAndStatistics/Publications/PublicationsPolicvAndGuida 
nce/PublicationsPolicvAndGuidanceArticlc/fs/en?CQNTF.NT lD = 4002999& chk= /B iQ B s
Use of explicit rules for deciding how variables are recorded:
No published information (e.g. data manual) has been identified. However, the “Manual of 
Cancer Services Standards” (Department of Health, 2001) sets out for each standard the 
information that would demonstrate that the standards have been complied with.
Extent to which data are validated:
No published information has been identified as to whether data have been validated.
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A ppendix 15
T h a m es C a n cer  R eg istr y
Data Quality Assessmenf^"^
g e n e r a l  a s p e c t s
Background information
Cancer registration has been conducted in parts of the UK since 1929, with national 
coverage since 1960-s.
The Thames Cancer Registry (TCR) is one of 12 population based cancer registries in the 
UK and covers the residential population of London, Surrey, Sussex and Kent. The registry 
collects information about new cases of cancer and uses this to produce statistics about 
cancer incidence, prevalence, survival and mortality.
A subset of the data collected by the regional cancer registries is collated centrally by the 
National Cancer Intelligence Centre at the Office for National Statistics (ONS), to provide 
national figures on cancer incidence and survival on a regular basis.
Source: Thames Cancer Registry (TCR). http://www.thames-cancer-reg.org.uk/
Reference population
Common circumstance that determines inclusion in the database:
Diagnosis of cancer (colorectal cancer ICD-10: C18-2l').
Geographical area covered by the database:
Based on Directory o f Clinical Databases (DoCDat) format 
(http://www. lshtm.ac.uk/docdat/page.php? t^index).
International Classification o f Diseases, Tenth Revision (h t tp ' . / \v \v \v 3 .w h o . in t / icd /cu rr
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London, Surrey, Sussex and Kent.
Time period covered by the database:
1960 -  ongoing. Patients diagnosed in 1996-2001 and followed up until the end of 2001 
were considered for the study.
Level of aggregation:
Patient
DATA SET 
Content
Number of individuals or episodes of care included in the database:
The intention of the dataset is to include data on all cancer patients in the region (London, 
Surrey, Sussex and Kent).
Data collection questionnaire:
There is no questionnaire for this database.
Data linkage
Are nationally approved codes used for identifying the subject, clinician or 
institution?
Individual patients are identified within the system by unique codes so that separate data 
elements such as diagnosis and death can be accurately linked, but data that are released for 
analysis do not contain personal identifiers. Nationally approved codes are used to identify 
hospitals. Available look-up table was used to link individual hospital codes to nationally 
approved NHS hospital trust codes.
To which other databases is linkage routinely undertaken?
The National Health Service Central Register
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OUTPUTS 
Analvsis 
Can ad hoc analyses be performed for health care providers?
• Locally (“the health care provider who collects the data locally is able to analyse 
their data even though their data are also sent to the centralised database to be 
analysed with the data collected from other health care providers”) -  yes;
• Centrally (Local health care providers can obtain ad hoc analyses of their own data 
from the central database custodian) -  yes.
Audit reports 
How frequently are multi-centre audit reports produced?
Never.
How frequently are provider-specific audit reports produced?
Never.
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MANAGEMENT
Support for database
Is the database approved by any clinical or professional associations?
Yes -  the UK Association of Cancer Registries
Who is involved in the management of the database?
Doctors; statisticians; epidemiologists; IT specialists
Source of funding:
The NHS funds the regional cancer registries and the Department of Health pays the ONS
to process the data and to operate the National Cancer Registry.
DATA QUALITY
Coverage
Extent to which the eligible population is representative of the country:
Total population of the covered region included.
Completeness of recruitment of eligible population:
2 4 2
The database includes 90-97% of the eligible population.
Absolute levels of case ascertainment are very difficult to obtain as there is no independent 
source with which to compare. The level of ascertainment can be judged by the proportion 
of cases which are registered through death certificates only (DCO).
The study had a relatively low percentage of DCO cases (548 patients - 3%), which were 
excluded from the analysis.
Variables included in the database:
The following main variables from the TCR dataset have been considered for survival 
analysis in this study: age; sex; Index of Multiple Deprivation 2000 (income domain) 
quintile; tumour stage; hospital of first attendance/treatment; type of treatment/surgery; date 
of diagnosis; days to end of follow-up; vital status at the end of follow-up.
Completeness of data (% variables at least 95% complete):
All variables considered for survival analysis were complete, except for the tumour stage 
(20.9% missing values) and the type of treatment/surgery (11.6% missing values).
Accuracy 
Use of explicit definitions for variables:
All or almost all variables (>97%) have clear definitions, either within the WHO’s 
International Classification of Diseases for Oncology or within other source documents 
agreed between the Department of Health and the UK Association of Cancer Registries.
Use of explicit rules for deciding how variables are recorded:
All or almost all variables (>97%) have clear rules on how to code them in the database, 
(see previous item)
Extent to which data are validated:
Range and consistency checks plus external validation using an alternative source.
Regional registries are required to audit a sample of their cases, however in reality this is 
done sporadically and differently between registers. Proposals for a standard audit 
programme are currently being developed.
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